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Char;rcteriz;rtion and Modulation of Imrmme Responses in Mice b a DNA-based Vaccine 
DNA-based vaccines represent a novel method of * * "on that has been demonatrated to 
induce immune responses in animals against a variety of plasmid encoded antigens and following a 
d e r  of different methods of vaccine delivery. 
We characterized the imrmme response to DNA-based vaccines encoding intmellular, 
membrane anchored (cell associated) and extracellular (secreted) forms of glycoprotein D CgD), an 
antigen fi-om the viral envelope of the bovine herpesvirus4 (BW-I). hhmuscular injection of mice 
with plasmids encoding secreted or cell associated forma of this antigen led to seroconveraion and a 
predominance of splenic IFN y . Mice receiving plasmids encoding cell associated or secreted 
antigens displayed a predominance of I& and IgG, , respectively. m e  predominant serum isotype 
correlated with the cytokine and antibody isotype profiles within the drahing lymph node. 
We demonshated modulation of inmnme responses in mice following co-delivery of plasmids 
encoding a secreted fom of gD and each of eight diffefenf mrPine cytokinee @r 1 a, IL-12, IIA, IL-6, 
IL-10, GM-CSF, IFN y , TNF a). Plasmids encoding GM-CSF, TNF a, IG4 and IL-6 demonstrated 
the capacity to enhance s e m  IgG titers and seroconversion e&iency. Plasmids encoding IFN y end 
TNF a increased levels of serum a in mice. Varying the dose of plasmids enrodlog CiM-CSF 
enhanced (10 pg) or suppressed (50 pg) serum antibody levels and induced significant increases in 
IL-4 levels in the spleen and draining lymph nodes. High doses of GM-CSF (50 irg) increased the 
levels of serum IgCi, dter boosting. Co-administration of plasmids encoding IFN y either reduced 
(10 pg) or enhanced (50 pg) serurn antibody levels and elevated mean serum IgGp levels. 
Finally, we investigated the potential for plasmids encoding the secreted form of gD to elicit 
immune responses in passively inmume mice. We demonatrated that a single inhamuacder 
. . 
ummrmzahon of passively immune C3H.HeN or C57BU6 mice with plasmids encoding the secreted 
form of BHV-1 gD resulted in the development of both cell-mediated and humoral W t y .  
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ABSTRACT 
DNA-based vaccines represent a novel method of immunization that has been 
demonstrated to induce immune responses in animals, using a variety of antigens and 
methods of vaccine delivery. More recently, modulation of immune responses to DNA 
vaccines has been studied through codelivery of plasmids encoding a number of different 
murine cytokines. Moa recently scientists have assessed the abiliy of these novel 
vaccines to overcome certain problems associated with immunization of passively 
immune young animals. 
We characterized the immune response to several DNA-based vaccines encoding 
intracellular, extracellular and membrane anchored forms of glycoprotein D (gD), an 
immunodominant antigen, f7om the viral envelope of the bovine herpesvirus- 1 (BHV- 1 ). 
BHV- 1 is an economically important respiratory pathogen of cattle which is responsible 
for infectious bovine rhinomcheitus, genital infection, abortion and is also the 
immunosuppressive primary pathogen of the shipping fever complex We noted that the 
kinetics of @-specific senun antibody development was delayed if the antigen was 
expressed inside the cell (cytosolic) as compared to expression outside the cell (plasma 
membrane anchored or semeted) It was also noted that most mice immunized with 
plasmids encoding secreted, cell surface or cytosolic, versions of gD displayed 
significant levels of anti-@ antibody, in sera, at 5 and 1/2 months post immunization. 
Indeed, some mice showed maintenance, or increases, in serum ELISA titers at 5 and 1/2 
months post immunization. Intramuscular injection with plasmids encoding secreted or 
cell associated forms of BHV-1 gD resulted in a predominance of splenic EN y 
consistent with a Th- 1 type of immune response. Surprisingly, despite the involvement of 
IFN y in the isotype switch to IgG, only mice receiving plasmids encoding the cell 
associated (plasma membrane anchored and cytosolic) displayed a predominance of this 
isotype. Mice immunized with plasmids encoding the secreted form of gD displayed a 
predominance of serum IgG,. Using cyokine and antiiody forming cell (AFC) 
ELISPOT, we demonstrated that the predominant serum isotype correlated with the 
cytokine and AFC isotype profile within the draining iliac lymph node. 
The humoral and cellular immune responses in C3WHeN mice following co- 
delivery of plasmids encoding a secreted form of BHV-1 gD, and plasmids encoding one 
of eight different murine cytokines (IL- 1 a, E- 12, IL-4, IL-6, IL- 1 0, GM-CSF, y , 
lNF a), were analyzed. Initially a subopimal, single dose of plasmid encoding antigen 
was co-administered with a 10 pg dose of each of the cytokine expressing plasrnids. Data 
from this experiment demonstrated that co-administration of plasmid encoding GM-CSF 
enhanced not only early mean serum titers but also the seroconversion efficacy of 
immunized mice. Plasmids encoding murine TNF a, IL-4 and IL-6 also enhanced the 
magnitude of serum IgG titers but with differing kinetics. Co-administration of plasmids 
encoding IFN y and TNF a increased in the levels of serum IgG, in some, but not all, 
immunized mice. In a follow-up experiment where an optimal, fixed, dose of piasmid 
expressing BHV-1 SgD was co-administered with two different doses of plasmids 
encoding GM-CSF or IFN y, we noted that varying the dose of either of these plasmids 
had a substantial impact on the immunological outcome. Moderate doses of GM-CSF 
reproducibly enhanced early mean titers. High doses of GM-CSF resulted in a 
suppression of humoral responses, however, boosting with high doses of this cytokine 
resulted in an ememely potent memory response that resulted in very high serum titers 
and a surprising increase in the levels of senun IgG,. Assessment of cytokine secretion, 
within draining lymph nodes and the spleen, showed that co-administration of plasmids 
encoding GM-CSF induced significant increases in IL-4 secretion afier boosting. Co- 
administration of plasmids encoding IFN y resulted in the reduction of antibody 
responses, at moderate doses, that persisted regardless of boosting. Conversely, mice 
immunized with high doses of this cytokine showed enhanced mean serum antibody titers 
and benefited from boosting. Mice immunized with both moderate and high doses of 
plasmids encoding E N  y displayed elevations in mean s e w  IgG,. 
Finally, we chose to investigate the potential for plasmids encoding the secreted 
form of gD to elicit immune responses in passively immune mice following 
intramuscular immunization. In these experiments we passively immunized 6-7 week 
old female C3WHeN or C57BU6 mice with hyperimmune antisera raised against BHV- 
1 recombinant, truncated (secreted), gD immediately prior to immunization with plasmid 
encoded antigen. These studies demonstrated that a single immunization of passively 
immune mice with plasmids encoding the secreted f o m  of BHV-1 gD resulted in the 
development of both cell mediated immunity and antibody responses. We also showed 
that co-administration of plasmids encoding GM-CSF at 25 pg! mouse had a detrimental 
effect on antibody levels and semconversion efficacy in passively immune mice. 
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1.1 DNA-based vaccines 
Immunization of animals with naked nucleic acid encoding antigens under the 
control ofa variety of gene regulatory elements has been described as: polynucleotide 
immhation, DNA-based vaccination, somatic transgene vaccination, genetic 
vaccination and nucleic-acid vaccination (Gerloni et al., 1997; Robinson, 2 997). 
Regardless of the terminology, and despite the need for technical correctness, most 
researchers have senled on DNA-based, or simply DNA vaccines to descnbe this novel 
method of immunization. DNA-based immunization was fim described in 1992 despite 
the fact that the evidence for delivery, uptake and expression had been described much 
earlier (Chattergoon et al., 1997). Since that time detractors have described DNA-based 
vaccination as "Biological cold fusion" , while proponents have termed this unique form 
of immunization as the "Third Revolution in Vaccinology" (Waine and McManus, 
1995). DNA-based vaccination is, without question, we11 beyond the less than flattering 
comparison to "Cold Fusion". To date, well over four hundred publications have appeared 
in respected scientific journals since the first publication coined the phrase "Genetic 
immunization", in 1992 (Tang et al., 1992). The inherent simplicity of the technology is 
unquestionably revolutionary and it is this simplicity that has, in part, driven detractors to 
distraction. Certainly the simple eloquence of DNA vaccine technology is in stark 
contrast to the inherently complex forms of vaccine construction such as attenuated and 
attenuated recombinant pathogens, recombinant subunit vaccines and adjuvants research. 
Despite the technical simplicity of DNA-based vaccines, it was over 30 years fiom the 
time researchen fim demonstrated immune responses following injection of naked DNA 
to the first published description of "genetic immunization" (Atanasiu, 1962; Tang et al.. 
1992). That simple leap of logic from in vivo introduction of naked genetic material, to 
immunogen synthesis and immune response was as surprising as it was profound. 
1.1.1 Injection Grade Plasmid Preparation 
From a purely technical standpoint, systemic immunization of animals with naked 
nucleic acid is eloquent in its simplicity. Plasmid DNA containing any of a variety of 
eukaryotic gene regulatory sequences, in ?he appropriate context of a gene, or genes, 
encoding antigen, are injected intramuscularly ( i m )  or intradermalIy (i.d.). Purification 
of amplified plasmid is typically carried out using cation exchange affinity columns with 
or without removal of endotoxin (Davis et al., 1996). Traditional techniques such as 
cesium chloride (CsCl) centrifugation may also be used, however, injection of quality 
DNA typically requires a double CsCl cenaifbgation usually followed by dialysis. This 
centrifugation and dialysis procedure is time consuming, hazardous and results in 
substantial plasmid loss. Despite the limitations of CsCl purification, some researchers 
have chosen to move away fiom column purification protocols and back to density 
gradient purification claiming enhancement of immunization effectiveness and 
experimental reproducibility (David Emery, personal communication). At the present 
time issues regarding plasmid preparation protocols and correlation to immunization 
efficacy remain unresolved and may simply reflect differences in such things as plasmid 
sequences, bacterial host cell types and/or growth media. Undoubtedly, as interest in 
immunosdmulato~y sequences (ISS's) encoded within bacterially derived DNA, as well 
as, inclusion of immune modulatory genes grows, researchers are moving towards a 
greater degree of standardization of plasmid purification protocols. This move will 
ensure that data reproduction and accurate interlaboratory data comparisons are made 
possible and reliable. 
1.1.2 Delivery of DNA Vaccines 
Regardless of purification protocol differences, injection-grade supercoiled 
plasmid DNA may be stored for long periods of time or resuspended immediately in 
sterile saline or phosphate buffered saline (PBS). intrarnuscuiar or inaadermal delivery 
may be canied out using standard 0.3-0.5 mL sterile syringes and small gauge 
hypodermic needles to inject the vaccines. There are several other methods described for 
delivery of plasmid based vaccines that include: ballistic delivery (Tang et al., 1992; 
Pertmer et al., 1 999, cationic liposomal or microsphere encapsulation (Huang and 
Wang, 1989; O'Hagan et at., 1993; Keller et al., 1996; Gregoriadis et al., 1997; Jones et 
al., 1997), and use of bacterial or host cell carriers (Gerloni et al., 1997; Manickan et al., 
1997; Sizemore et al., 1997). Ballistic delivery of DNA-based vaccines involves CQ- 
precipitation of plasmid DNA with gold or tungsten microparticles (0.95 - 2.6 p) such 
that DNA adsorbs to the surface of the beads. Beads are then "fired" into epidermal 
Maces  resulting in in vivo transfedon of a variety of dermal cell types including 
keratinocytes, fibroblasts and Langerhans cells (Raz et al., 1994). Aerosol or droplet 
instillation of naked DNA on nucosal surfaces, in the absence of any facilitators, has also 
elicited immune responses. Mucosal and transdermal (Li and Hofkun, 1995) delivery of 
DNA vaccines may be facilitated by incorporating DNA-based vaccines into a variety of 
cationic liposomal preparations or biodegradable microspheres (Alpar et al., 1997; 
Barnfield er al., 1997). Finally, attenuated bacterial vectors, such as Shigella flaneri, 
which nonnally infect via intestinal mucosa and also penetrate and persist within host 
cells, have been specifically mutated such that lysis occurs within host cells. This 
intracellular lysis releases any plasmid DNA carried by these bacteria into the cytoplasm 
of the host cell which then sets the stage for subsequent translocation to the nucleus of 
cells. A number of intracellular pathogens including Listeria and Salmonella sp. infect via 
mucosal routes and penetrate host cells. These bacteria provide a mechanism to immunize 
against the delivery vehicle, as well as, a potentially efficient method of immunizing 
against a variety of antigens encoded within plasmid DNAs used to aansfom these 
bacteria. All of these methods have been demonstrated to deliver intact plasmid DNA to 
sites of interest with expression of encoded reporter genes or imrnunogens. Ultimately the 
purpose of these facilitated delivery systems is to carry, protect and enhance cellular 
uptake of encapsulated DNA sequences. 
12 Serum Khetics and Uptake Mechanisms 
From the few phannacokinetic studies done we know that intravenous (i-v.) injected 
plasmid DNA (naked or packaged in liposornes) has a serum (extracellular) half-life of 
-3- 10 minutes and that the majority of injected DNA is degraded by serum nucleases and 
cleared from the body through the kidneys (Kawabata et al., 1995). It is also known that 
i.v. injected DNA tends to distribute to selected tissues such as the liver, spleen. and 
skeletal muscle and that mscie associated inmcellular DNA appears to persist the 
longest in vivo (Lew et al., 1995). We have demonstrated that im injected DNA travels 
&om the injection site to the draining lymph nodes within minutes of injection (see 
section 3.3.5). It is not known what percentage of, or indeed if any, DNA that enters the 
draining lymph node actually passes out of the node and spreads systemically. Despite 
the polymerase chain reaction VCR) evidence, showing efflux of DNA from injection 
sites we do not, at the moment, h o w  if this DNA is cell associated (intracellular or cell 
surface) or free in the senrm. However, we can safely predict that the vast majority of 
injected DNA is rapidly degraded and Likely cleared through the kidneys. 
When Wolff et al. (1992) first demonstrated in vivo transient transfection of 
myocytes it was proposed that these cells were unique in their ability to take up plasmid 
DNA. This was felt to occur as a result of the substantial network of T-tubules that 
penetrated deeply into myocytes. It was also postulated, based primarily on electron 
microscopic studies, that uptake may be facilitated by non clathrincoated pits called 
caveolae (Anderson et al., 1992; Wolff et al., 1992; Danko and Wolff, 1994). However, 
in both instances no discussion was presented as to how a relatively large, poiyanionic 
and hydrophilic molecule, could successfully penemte the charged lipid bihyer into the 
Largely anionic cell cytoplasm. Further explanations for this myaery were not 
immediately forthcoming and, indeed with the demonstration that nonmyocytic cells 
such as keratinocytes, fibroblasts, and epithelial Langerhans cells were also able to take 
up naked plasmid DNA the answer seemed an even greater mystery than earlier (Raz et 
al., 1994; Condon et al., 1996; Casares et al., 1997). Indeed there has been little research, 
in the context of DNA-based vaccines, to understand how piasmid DNA is perceived at 
the cell surface let alone translocated into the cytoplasmic compartment and then to the 
nucleus. In the absence of direct data we are left to rely on several unrelated studies that 
allow us to theorize on several additional possible mechanisms of plasmid DNA uptake. 
Naked DNA uptake by cells, in vivo, may be occurring by either a nonspecific 
method akin to a phagocytic or pinocytotic process, or by a specific receptor-mediated 
mechanism Cenainly phagocytic uptake of DNA is possible and it has been 
demonstrated that cytoplasmic access can occur through "leaky" phagosomal membranes 
within the cytoplasm O(ovacsovics-bankow ski and Rock, 1 995). Receptor mediated 
uptake is also plausible although the specific mechanism by which specifically bound 
plasmid DNA is translocated into the cytoplasm is still unknown (Bennett et al., 1985). 
DNA-binding cell surface receptors include: the macrophage scavenger receptors, which 
are capable of binding a variety of molecules including polynbonucleotides, such as, 
polyO and poly(G), and a 30 kd surface receptor, first identified on cancerous cells, 
found to bind 4500 bp fragments of genomic DNA (Krieger et al., 1985; Bemet et al., 
1988; Kimura et al., 1994). This receptor appears to be very specific and also appears to 
be restricted to such populations as antigen presenting cells, B-cells and T-cells. There is 
also preliminary evidence that polypyla te  sequences may faciiitate receptor mediated 
uptake. This receptor complex has been shown to be internalized from the cell surface 
and there is evidence that some of this internalized DNA is degraded. 
Packaging and protection of plasmid based vaccines within cationic liposomes, 
cochleates, dendrimee or ballistic delivery otherwise may seem to make funher research 
into mechanisms of naked DNA redundant, however, a clear understanding of the 
modality of uptake and aanslocation may result in the reduction of the need for 
cytofectins and ultimately enhance the cost effectiveness of this novel form of 
immunization. A parameter that is uniquely important in the development of efficacious 
and cost effective vaccines for the food animals industry. 
1.3 Mechanism of Antigen Presentation 
Despite the fact that im. injection has been the most prevalent route of delivery for 
DNA-based vaccines the details regarding mechanism of immunity are, at lean 
hypothetically, more clearly understood with dermal and intradamal delivery of DNA 
Inidally researchers were lead to believe that im. delivery was the most efficacious mode 
of delivery due the presence of unique T-tubular network which presumably allowed 
penetration of the injected DNA deep within the cells and conceivably facilitated 
cytoplasmic access of injected DNA. Certainly im. injected, plasmid encoded, reporter 
genes such as p -galactosidase clearly demonstrated that myocytes were effectively 
tx-ansfected and, depending on the protocol and construct, could be transfected, at least 
transiently, with efficiencies approaching 30% (Hartikka e t  al., 1 997). Despite the 
demonstration that MHC molecules could be upregulated on rnyoblasts, and to a lesser 
extent myocytes, and that these cells were capable of producing the cytokine interleukin 
0 - 1  5, it was shown that these cells were incapable of synthesis of important 
costimulatory molecules such as B7 or CD40 ligand. This informadon, in conjuntion 
with the inability of myocytes to traffic to draining lymph nodes led researchers to predict 
that transfected antigen producing myocytes were highly unlikely candidates to be 
directly involved in priming and expansion of antigen-specific T and B-cell receptor 
repertoire. Indeed it has been demonstrated recently by several authors that myocytes 
transfected with plasmids "hand-off' antigen to professional antigen presenting cells such 
as dendritic cells or macrophages. An important experiment confirmed suspicions that 
myocytes transfected in vivo were indirectly involved in T-cell priming and that direct in 
vivo msfection of professional antigen presenting cells was not an absolute requirement 
for priming responses (Wlmer et al., 1996~). Ulmer et al. (1996) injected rnyoblasts of 
H-2k haplotype, transfeaed in vim with plasrnid encoded Influenza v i m  nucieoprotein 
antigen, into F1 hybrid mice derived from a parental cross of H-2* and H-Zd haplotypes, 
and found CD8' cytotoxic T-cell (CTL) responses developed to both haplotypes. Similar 
studies were carried out by others confirmed the theory that the transfected myocyte was 
primarily a source of antigen that could be accessed through the n o d  release of 
secreted protein or release of cell associated antigen through, antigen "leakiness", 
overproduction related cytotoxicity, or through antigen-specific CTL activity (Corr et al., 
1996; Iwasaki et al., 1997). While this theory is still plausible and may explain the 
longevity of humoral and cell mediated immune (0 responses associated with DNA- 
based vaccination it has come under fire recently (Feltquate and Robinson, 1997). 
We have demonstrated, using PCR, that within minutes after an im. injection of 
plasmid encoded antigen the gene sequence could be detected within the draining lymph 
node (see section 3.3.5). However, no one, to dare, has demonmated the presence of 
plasmid DNA within draining lymph nodes 20 hours or more after i.m injection, which 
suggests that inaaceiluiar localization within this compartment is minimal. Also, "Van 
Gogh" experiments. in which tissues, including muscles, receiving plasmids have been 
amputated at various time points following injection suggest that excision of DNA 
immunized muscle within 1 minute of DNA delivery, had no effect on the initial 
immune response (Torres et al., 1997). This work suggests that msfection of myocytes 
is irrelevant to the developing immune response and that critical trmsfection of cells 
distal (lymphatics and draining lymph node) to the injection site or possibly the 
extremely rapid exit of transfeaed resident interstitial dendritic cells must occur. The 
Iatter explanation seems unlikely in that it assumes that unfacilitated transfection (or at 
least a stable receptor mediated pre-uptake association with cells) is an ememely rapid 
occurrence and that maturational and/or mobilization signalling must occur almost 
simultaneously with DNA-binding. There remains controversy associated with these 
studies. For example, some studies have demonstrated that excision of skin sites within 
minutes of ballistic delivery of plasmid DNA had little impact on the developing 
immune response (Taubes, 1997). These initial observations contradict more recent 
information and leaves considerable ambiguity with regard to plausible explanations for 
the mechanisms of immune response to naked DNA delivered im or i.d. (Torres et al., 
1997). Thus, from a mechanistic standpoint the contriiution of transfected myocytes, or 
any nonprofessional antigen presenting cell at the injection site, to the immune character 
is very much in question. While it was not surprising that myocytes do not play a direct 
role in priming naive T and B-cells it will be surprising if they are found to play no role 
whatsoever in some aspect of the immune response. Perhaps longer term srudies will 
demonstrate that myocytes, by virtue of a relatively long period of plasmid encoded gene 
expression (2 30-60 days) or "bolus" antigen release following antigen-specific CTL 
activity do contribute to the durability of the immune response by providing a reservoir of 
antigen that serves to sustain B and T-cell responses (Bachman et al., 1994; Bachman et 
al., 1996; Neuberger, 1997; Robinson and Torres, 1997). 
The demonstration that a multiplicity of cell types that include: keratinocytes, 
fibroblasts and cells with Langerhans cell morphology, were able to take up, in the 
absence of any cytofectins, i.d injected plasmid DNA and express an encoded reporter 
gene was perhaps, pivotal, in ailowing a greater understanding of the mechanistic 
possibilities of immune responses to DNA-based vaccines (Fynan et al., 1993; Raz et al., 
1994). This work, in the context of maturation and mobilization studies on peripheral 
dendritic cells, allowed the prediction that injection site ~ s f e c t i o n  of Langerhans cells 
and subsequent matufation and migration to draining lymph nodes, was a likely 
mechanism for priming of T and B-cell responses (Austyn, 1 996; Lutz et al., 1 996). 
Several recent articles have established that in vino and in vivo transfected Langerhans 
cells are able to localize within the draining lymph node and are of critical importance in 
the initiation and expansion of the developing immune response (Condon et al., 1996; 
Manickan et al., 1997). Thus research into dermakpidermal delivery allowed 
investigators pursuing i m  delivery of DNA vaccines to develop a more accurate picture 
of the underlying mechanism of immunity following immunization with plasmid DNA. 
Apart from the issue of the role the transfected myocytes contribute to the overall 
immune character, there remains a significant question that revolves around the 
possibility that a lymph node resident population of relevant professional antigen 
presenting cells, or for that matter antigen producing cells such as fibroblasts, endothelial 
cells or mornal cells, are transfected by the "wave" of antigen encoding DNA that 
washes into the node following injection. If this occurs then one must ask what, if any, 
role these node resident cells play in the overall immune response. Certainly the literature 
suggests that many interdigitating, and possibly follicular dendritic cells, within the 
lymph node represent a mature population that have arrived via afferent lymphatics 
(murine models)(Steinman et al., 1997). Presumably, mature antigen presenting cells 
within the paracortical regions would, in the absence of an efficient endogenous to 
exogenous antigen processing pathway, present plasmid encoded antigen primarily in the 
context of MHC I. If this is the case then distally aansfeaed professional antigen 
presenting cells would preferentially expand the CD8' CTL population. Certainly 
expansion of CTL populations is an important feature of DNA-based vaccines. 
However, one might predict that dendritic cells tmsfected at the site of injection, 
expressing cell surface or secreted antigen, would, upon migration to the draining lymph 
node, drive the priming and expansion of CD4+ T helper population and ultimateiy B- 
cell responses. The successful and efficient priming of naive lymphocytes would require 
presentation of antigen derived epitopes in the context of class II MHC and, depending on 
the rate of plasma membrane turnover (cell surface antigen) or maintenance of antigen 
uptake and processing (secreted antigen) functions. 
In an attempt to acquire a clearer undemanding of the cells involved in induction of 
the immune response following immunization with naked DNA encoding antigen, ir is 
important to separate the immune response into priming and anamnestic responses. In 
this contea it is a relatively simple task to predict that phagocytically active epidermal 
Langerhans cells, acquiring antigen either through direct msfection from introduced 
DNA, or indirectly through phagocytosis of antigen produced locally by transfected 
keratinocytes or fibroblasts, are key components initiating the immune responses in naive 
animals. This model predicts a requirement for access to the exogenous pathway of 
antigen processing and presentation of antigen derived T-cell epitopes via class II MHC 
molecules either through highly efficient phagocyti c mechanisms or, following direct 
trans fection, an endogenous to exogenous antigen processing crossover. Support for this 
mechanistic prediction is substantial , indeed recent studies utilizing Langerhans cells 
transfected in vimo and in vivo with plasmid expressing the marker gene for Green 
Fluorescent Protein (GFP) have clearly shown trafficking of msfected Langerhans 
cells to the paracortical regions of the draining lymph node (Condon et al., 1996). Of 
course the priming T-cell response must have the initial involvement of an immature 
population of dendritic cells that possess the capacity to take up and process large 
amounts of material, particularly if the genets) within the plasmid encode secreted 
antigen. Alternatively interdigitating dendritic cells, although hypothetically exhibiting 
greatly diminished phagocytic capacity, upon msfection with plasmid encoding 
membrane anchored antigens may result in significant MHC II loading and subsequenr 
CD4-T-cell priming as a result of normal cellular %ousekeeping4' and membrane 
turnover (Guery and Adorini, 1995). Furthermore predicted p r i m  naive B-cell 
interaction with antigen may occur within the paracortical region if membrane anchored 
antigen is being produced by transfected interdigitating dendritic cells. However, the 
possibility for B-cell receptor engagement of soluble antigen (secreted or intmcellular) 
may occur prior to enay into the lymph node and is not necessarily restricted to the 
paracortical zone. While histological and immunocytochemicd information abounds 
with regard to skin immunology and resident cell populations, this information is less 
evident in myocytic tissues such as skeletal muscle. Although an interstitial population of 
dendritic cells has been identified within cardiac muscle it is unknown if a similar 
population occurs within skeletal muscle. Despite this paucity of infomation, 
predictions can be made regarding the mechanism of immune priming based on what is 
known to occur following im. introduction of plasmid encoded genes. First, myocytes 
are transfected relatively efficaciously following i m  injetion (Wolff et al., 1990; Wolff 
et al., 199 1; Hartikka et al., 1996). Muscles injected with plasmid encoding the reporter 
gene P-galactosidase clearly show considerable ability to express this protein to a very 
high degree following uptake and nuclear localization of plasmid. Second, myocytes are, 
immunologically, incapable of priming T-cell responses directly and must "hand-off' 
antigen to professional antigen presenting cells in order to initiate the immune response 
(Hohlfeld and Engel, 1994; Ulmer et al., 19%; Torres et d., 1997). Third, this priming 
population of professional antigen presenting cells are Likely dendiitic-like cells because 
studies utilizing in vino msfected antigen presenting cells subsequently introduced into 
naive animals described immunity only if the aansfeaed cells were dendritic cells and 
not macrophages (Manickan et al., 1997). More recently, it was demonstrated that in vzvo 
transfmtion of splenic B-ceils with plasmid encoding a heavy chain immunogJobulin 
displaying a B-cell epitope within the complementarity determining region 3 resulted in 
the development of a significant humoral response (Gerloni et al., 1997). These 
researchers Limited expression to B-cells by utilizing immunoglobulin promoter enhancer 
elements and demonsmted that mansgene integration into the B-cell genome occurred 
with a high frequency (Xiong et at., 1997). Thus it would appear that transfected B-cells 
are capable of contributing to the ensuing immune response, although it is unknown at 
this time why coligation of B-cell receptors and Fcy RIIB 1 do not inhibit the humoral - - 
response (D'Ambrosio et al., 1995). Fourth, a wave of injected piasmid DNA washes 
into the draining lymph node within minutes of injection supporting the possibility that 
extramuscular transfection may occur. Finally, recent studies involving "Van Go&" 
experiments, in which the injected muscle bundle was excised within minutes of 
injection, had little impact on immunological p e g  or the early anamnestic response. 
This find piece of evidence is very compelling and suggests that a population of skeietal 
muscle resident dendritic cells are, even if they exist, of questionable relevance to the 
developing immune response. Furthennore it also suggests that myocytic injection site 
recruitment of immature dendritic cells would be of questionable use, even if it did occur, 
to the development of the priming immune response. Therefore we must conclude that the 
relatively high doses of im injected DNA required to induce immunity are needed to 
effectively ~ s f e c t  critical immune surveillance cells distal to the site of injection 
(within draining secondary lymphoid tissues). 
As stated previously, a variety of cell types can be transfected in vivo in the 
absence of any uptake-facilitating cytofectins. However, given that antigen presenting 
cell acquisition of antigen occurs indirectly (Ulmer et al., 1996c) and that n o d  
resident and recent immigrant dendritic cells, in the course of normal maturation, undergo 
significant phagocytic downregulation one might predict that transfecdon of virtually any 
cell type (including afferent lymphatic endothelid cells. subcapsular lining macrophages 
or fibroblastic reticular cells) would require the presence of an immature, phagocytically 
active population of dendritic cells. While it has been demonstrated that Bcells and 
macrophages have the capacity to prime naive T-cells, these antigen presenting cells are 
generally less efficient than dendritic cells in this regard (Ziegier and Unanue, 198 1 ; 
Romani et al., 1989; Steinman, 199 1; Cassell and Schwartz, 1994; Guery et al., 1996). 
This may, in part, be a result of the normal architectural constraints within the lymph 
node that are designed to bring together T-cells (and possibly naive B-cells) in the context 
of interstitial dendritic cells within the paraconical comdors (Steinman et al., 1997). The 
larger doses typically utilized with DNA-based vaccines injected i.m or i.d. may reflect 
the diminished efficacy of macrophage or B-ceU priming of T-cells and the need to 
transfect antigen presenting cells, including degdritic cells, at some threshold level of 
efficacy. In light of recent data desmiing the potent immunostimulating, or adjuvant, 
capacity of bacterially derived DNA (Pisetsky, 1996a) it would not seem unreasonable to 
hypothesize that recruitment of immature dendritic cells to the distal afferent lymphatic, 
subcapsular sinus or cortical regions of the draining lymph and subsequent uptake and 
processing of antigen expressed by resident nonprofessional antigen presenting cells. For 
the moment it appears Likely that transfection of cell populations distal to the i.m 
injection site occurs, however, the exact role these populations play in development and 
maintenance of immune responses remains unclear. 
1.4 Adjuvancy Effects of Bacterially Derived DNA 
Recently, bacterially derived DNA (genomic and exmc hromosomal) has been 
descnied as a member of bacterial, innate immune, activating substances that include: 
lipopolyssacharide (LPS), techoic acid or peptidogiycans (Pardoll and Beckerleg, 1995; 
Krieg, 1996; Pisetsky, 1 M a ;  Pisetsky, 1 996b; K l i m  et al., 1997; Sparwasser et al., 
1997). The intrinsic adjuvant capacity of bacteria had been descnied as early as 1984 
(Tokunaga et al., 1984), however, it is only within the last four to five years, coincidental 
with the first publications describing immune responses to DNA-based vaccines, that 
details of nucleic acid adjwant effect have emerged (Sato et al., 1996; Sun et al., 1997). 
At present three distinct elements of immunostimulatory sequences QSSs) have been 
determined and/or postulated to play pivotal roles in the activation of the innate immune 
response, as well as, deviation of immunity towards a Th 1 type phenotype. First, 
eukaryotes and plants exhi%it what is termed "CpG suppression" and is characterized by a 
20 fold lower than expected occurrence of the CpG dinucleotide pairs within genome 
nucleotide sequences. Conversely, bacterial, certain viral and some nonvertebrate DNA 
sequences have been demonstrated to exhibit the expected number of CpG dinucleotide 
pairs within the coding and noncoding regions (Yamamoto et al., 1992). Second, the 
CpG motifs that do occur in eukaryotic DNA are all methylated at the cytosine nucleotide 
whereas the equivalent motif within bacterial chromosomal or extrachromosomal DNA is 
hypomethylated (Bird, 1987; Hergersberg, 199 1; Pisetsky, l996a). Finally, 5' and 3' DNA 
sequences immediately adjacent to the CpG motifs can determine both, efficacy of the 
target cell association of the DNA fragment and stimulatory capacity of the core 
sequence. Ctmently it is believed thar a PuPu-CpG-PyPy hexamer is the most efEcacious 
stimulatory hexamer, although this data was originally obtained by assessing 
blastogenesis and IgM production in DBAD and C3H4IeJ mice (Krieg et al., 1995; Sato 
et al., 1996). It has also been demonstrated that short synthetic 5'-NPu-CpG-PSI-3' 
oligonucleotides with no additional flanking sequences are also stimulatory but only 
when prepackaged in cationic iiposomes prior to delivery to murine splenocytes 
(Sonehara et al., 1996). It has also been demonstrated that flanking sequences outside of 
this hexamer core must include a guanine rich region to ensure binding, and subsequently 
uptake, by target cells (Kirnura et al., 1994). These observations suggest that the 
hexameric ISSs must penetrate the cytosol of target cells to elicit responses. The exact 
mechanism of DNA association and uptake and cytoplasmic delivery is unknown, 
however, there is evidence that the potential quadmplex polyanionic structure, that arises 
due to the polyguanylate sequence domains, binds with high m i t y  to the polycationic 
regions of the collagen-like domain of macrophage scavenger receptor I (Kimura et al., 
1994). It has been suggested that upon entry into the cytosol, CpG motifs bind to the 
CAMP responsive element binding protein (Sonehara et al., 1996). Indeed, addition of the 
CAW agonist forskolin results in the inhibition of ISS induced upregulation of IM y. 
The responses of professional antigen presenting cells, T-cells and NK cells following 
stimulation with hexameric ISS's are wide ranging and profound and includes: 
blastogenesis, IgM secretion and upregulation of cytokine expression and secretion. 
Cytokines induced by ISSs include: m a ,  IFN a, and P, IFN y, IL-6, IL-12 and IL- 
18 (Elalpern et al., 1996; Klinman et al., 1996; Yi et al., 1996b: Roman et al., 1997; 
Spanuasser et al., 1997). All but one of these cytokines have been shown to be derived 
from ISSs stimulated macrophages, while B-cells appear to be the major source of IL-6 
and some IL-12. Inbred mouse strains including BALBk, C3WHeN, C3WHeJ (LPS 
insensitive), CBA, C57BU6 and SCID Beige, representing a variety of generic and 
immunologic backgrounds, have been demonstrated to respond to ISS sequences 
displaying the 5'-PuPu-CpG-PyPy-3 ' motif (Spanvasser et al., 1 997). It has been clearly 
shown that inclusion of these CpG motifs in plasmid encoded vaccines can, not only 
ensure the success of the immune responses to the plasmid encoded antigen , but also 
specifically drive the immune response towards the Thl phenowe (Raz et al., 1996; Sato 
et al., 1996; Carson and Raz, 1997; Chu et al., 1997; Roman et al., 1997). Theoretically, 
direct induction of IM a and P, IL-12, IL-18, TNF a, in conjunction with indirect NK 
cell derived IFN y, could deviate the ensuing immune response, to a plasmid-encoded 
antigen, to the Thl phenotype and/or enhance the serum levels of IgG, (Snapper and 
Paul, 1987). It has been demonstrated for one protein antigen and a commercially 
available subunit human influenza vaccine delivered i d ,  that codelivery of 50 pg of 
ISSs containing plasmid not only increases total IgG serum levels, but also leads to 
increases in serum IgG,, splenic IFY y and inhibition of serum IgE in BALB/c mice 
(Roman et al., 1997). Surprisingly, Roman et-al. (1997) also demonstrated that 
secondary immunization with a DNA-based vaccine could redirect a pre-existing , Ag- 
specific, Th2 response toward a Th 1 type immune response. It has been established that 
some cytokines, characteristically associated with early innate immune responses a - 1 2 ,  
IL-18, EN a and P) are all inducers of IFN y and promote the development of Th 1 
lymphocytes (Roman et al., 1997). Thus the ability of the innate immune system to 
instruct the adaptive immune response, to not only mount an immune response, but to 
also polarize immunity is potentially useful when protecting against pathogens which 
require this type of immunity for cjearance (Mosmann and Sad, 1996). 
It must be pointed out that virtually all studies on ISSs of bacterial origin, or 
synthetic oligodeoxynucleotides (ODNs), have taken place in mice. Caution, as always, 
should be exercised when attempting to extrapolate, from ISS data gathered in mice, to 
other species. For example, the defined, highly efficacious, ISS 5'-PuPu-CpG-PyPy-3" 
motif described for mice may require unique, alternate flanking sequences to induce 
immune stimulation in other species. Indeed it has been shown that binding properties of 
scavenger receptors can differ from species to species (Kneger et al., 1985). For that 
matter ruminant species, which exhibit a huge gastrointestinal microbial load, may have 
evolved an innate response that, through necessity, is tolerant, or at least insensitive, to 
putative ISSs. There is no doubt that ISSs exhibit the potential to play an intriguing role 
in ensuring rapid immune responses are evoked against invading pathogens by 
upregulating many aspects of the innate and, consequently, adaptive immune responses. 
It may even be possible that this "third genetic code" may define the pre-eminent example 
of initial early distinction between self and nonself (prokaryote and eukaryote) that drives 
the decision to mount an adaptive response (Janeway, 1992; Matzinger, 1994; Pisetsky. 
199%). 
1.5 Immune Response To DNA-based Vaccines 
1.5.1 Intramuscular 
There are a gowing number of publications describing immune responses to 
DNA-based vaccines delivered to mucosal surfaces as naked DNA, encapsulated within 
cationic Liposomes, or associated with poly (DL-lactide-co-glycolide) microparticles. 
However, the next section will focus predominantly on immune responses to DNA 
delivered i-m., i d  and ballistically. Table 1.1 shows a compilation of immune outcomes 
to a variety of DNA-based vaccines delivered im. in mice. This is by no means a 
complete list of references describing immune responses to plasmid encoded antigen 
injected intramuscularly. However, it is a relatively comprehensive collection of citations 
which describe data that includes serum IgG isotype and/or splenic or lymph node 
cytokine profiles in immune mice. This data confirms that mice immunized i m  with 
plasmid encoded antigen typically, but not exclusively, respond with a Thl type immune 
response, characterized by a predominance of IFNy, in stimulated splenocytes, and of 
senun I&. Table 1 .1 also shows that there are a significant number of articles that 



describe splenic cytokine profiles that do not support the predominance of IgG, occurring 
in the serum (Mor et al., 1995; Mancini et al., 1996; Lewis et al., 1997; Sallberg et al., 
1997) . Indeed there is at least one article that shows not only a predominance of sewn 
IgG, but also levels of IL-4 that exceed those of IEN y in immune splenocytes (Waisrnan 
et al., 1996). These exceptions to the rule of "im delivery of plasmid encoded antigens = 
Th l -type of immune response", clearly illustrate that parameters such as antigen, strain of 
mouse, compartment in which the antigen occurs (Cardoso et ai., 1996; Lewis et al., 
1997) affect the immunological outcome. They also suggest that dming of analysis, 
presence or absence of secondary immunizations, source of immune cells for ELISPOT 
(spleen verms draining lymph node versus bone marrow), inclusion or exclusion of an in 
vizro stimulation step and use of ELISPOT or bioassay techniques should be considered 
when assessing and interpreting immunological outcomes. 
There is growing evidence that i.& delivered DNA is the more efficacious mode of 
immunization when using DNA-based vaccines. However, there is also recent evidence 
that incorporation of plasmids encoding antigen(s) within cationic lipids formulated with 
neutral Lipids to foxm CLDC enhances humoral and T helper cell responses following ism 
delivery (Gregoriadis et al., 1997). Innovations such as these will continue to push the 
dose and efficacy bouodaries until DNA-based vaccines become legitimate alternatives to 
a variety of conventional vaccines. 
1.5.2 Intradermal. 
Intradermally injected, and ballistically delivered, DNA-based vaccines target the 
immunologically rich dermal and epidermal tissues of the skin. These regions of the 
murine skin are comprised of a varied population of cell types and include: keratinocytes, 
endothelid cells, fibroblasts, dendritic epidermal T-cells (y6 T-cells) and Langerhan cells 
(Williams and Kupper, 1996). Assumptions are that the epidermal Langerhans cells, with 
their critical capacity to take up and process antigen, followed by mobilization to regional 
lymph nodes and subsequent presentation to naive T-cells, are necessary and sufficient 
for immunity following DNA delivery to the h. Although epidermal Langerhs  cells 
account for only 1 % of skin cells, the m a c e  area available to this relatively small 
population of these vital cells is in the range of 25% of rhe epidermal slrrface area (Abbas 
et aL, 1997). One must also consider the microenvironmental milieu, in the context of 
injection or ballistic delivery muma and DNA adjuvancy effects. Kera~ocytes ,
endothelid cek,  y 6 T-cells, fibroblasts and mast cells are all capable of responding to 
trauma or inflammatory molecules by upregulating expression of a variety of cytohnes 
@,-la and p, IL-3, L-6, IL-7, IL-10, IL-12, I .-15 and TNF a), chemokines (E-8, MIP 2, 
IF-1 0 and RANTES), histocompatibility antigens (MHC I and II), and costimulatory 
molecules (B7-2), (Bos and Kapsenberg, 1993; Gemtsen and Bloor, 1993; Schroder, 
1995; Tigelaa. and Lewis, 1995; Williams and Kupper, 1996). This microenvironmental 
milieu may contribute, in a very significant manner, to the resulting immune character 
depending on the method of delivery and "adjuvant dose" of DNA. In this way method of 
delivery and immunological outcome must be considered in the context of the route (skin 
versus muscle) of delivery. 
To date there has been some controversy as to whether i.d. injected DNA elicits a 
predominantly Thl/IgG, response or a Th2AgG, response (Barry and Johnston, 1997; 
Feltquate et al., 1997). Of the few published articles describing splenic cytokine profiles 
and serum IgG isotypes there appears to be a split in the immune outcome with antigen, 
mouse strain, and possibly variations in DNA adjuvancy (dose), playing a greater role 
than the method, or route, of administration (Table 1.2). Splenic cytokine responses 
typically suggest that the predominant T helper response is of the Thl phenotype, 
although, once again caution must be exercised against over-interpreting this information 
in the absence of draining lymph node or peripheral blood lymphocyte (PBL) CD4' T-cell 
cytokine profiles. Typically, potent CTL responses are also achieved following i.d. 
injection of DNA-based vaccines (Raz et al., 1994). However, none of the authors cited in 
Table 1.2 assessed this parameter of the immune response. 
As seen with i.m delivered DNA vaccines there does not appear to be a "hard and 
fast" rule that describes the anticipated serological outcomes to i.d. injected DNA-based 
vaccines. There does appear to be a tendency towards diminished levels of serum IgG, 
as compared to im. injected plasmids of the same dose, and this, in conjunction with the 
suggestive increases in serum IgG, , supports arguments that the immunological 
composition of target sites (route) determines to some extent the immune character 
following delivery of plasmid encoded antigen. Feltquate et. al. (1997), have recently 
argued that the method (gene gun versus injection) of DNA delivery is solely responsible 
for the immunological outcome and that the target site cellular composition is essentially 
irrelevant to the resulting immune character. This data is compelling and it will be of 
considerable interest and importance to see if this hypothesis holds up with a variety of 
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antigens and larger selection of mouse haplotypes or in outbred species. 
1.5.3 Banistic, 
Ballistic delivery of DNA-based vaccines involves adsorption of small amounts 
(typically 1.0 pg or less) of plasmid to gold particles and acceleration of the coated 
paxticles into the epidermal layer and d d  tissues (Haynes et al., 1996). Ori,%ally 
mylar discs, with DNA+gold particles on one surface, were accelerated onto a stop screen 
which retained the mylar disc while allowing the gold particles+DNA to continue through 
the screen and into the skin surface. More recently DNA+ gold particles have been coated 
on the internal surface of Teflon tubing (Pertmer et al., 1996). One end of the coated rube 
is placed on the pressure nozzle of the device used to provide propulsion to the particles 
while the other is placed against the skin surface to be "immunized". Pressurized gas, 
typically helium, is utilized to accelerate the particles from the sides of the tubing . - and 
into the skin. This method of particle delivery minimizes the side spray of the vaccine. 
Obviously a significant drawback of mylar disc delivery is the potential for waste of 
vaccine, as well as , the distinct possibility of immunizing, not only vaccinees, but also 
workers delivering vaccines. Serological responses to ballistically delivered DNA appear 
to show less variation in isotype than observed in mice immunized i.d. or i.m (Pertmer et 
al., 1996; Feltquate et ai., 1997). However the current numbers of published articles 
describing serum antibody isotype and lymph node/spleen/bone marrow B-cell and 
cytokine profiles is small (Table 1.3) and will demand considerably more studies before 
any dogmatic statements may be made regarding predilection toward one Th-type or 
another. Inclusion or exclusion of secondary immunizations is an important 
consideration when assessing cytokine or serum isotype data following ballistic 
immunization with plasmids encoding antigen. Indeed it has been shown that splenic 
cytokine profiles may show either a predominance of IL-4 or a FN y and go on to 
demonstrate that boosting increases the splenic levels of I L I  with diminished levels of 
E N  y (Pertmer et al., 1996). Conversely, Feltquate et. ai. (1 997) demonmated that a 
splenic Th2 cytokine profile, and accompanying high levels of serum IgG, , was not 
altered by subsequent booster immunizations with i.d. or i n  delivered vaccine. In other 
words, the priming Th2 response could not be deviated towards the expected Thl 
response (with increased levels of IgG,) when delivering DNA via i.d. or i.m routes. 
One might predict that the initial Th2-type response is a direct result of the greatly 
diminished dose of hypomethylated CpG motif mediated adjuvancy as a result of the dose 
Limits associated with ballistically delivered DNA. Furthennore, one might argue that the 
trauma experienced by keratinocytes, fibroblasts, Langerhans cells and endothelial cells 
may create a unique local cytokine and chemohe profile that deviates the developing 
cognate immune response towards a Th2-type response. However, the contribution of 
this imagined cellular trauma and postulated inflammatory response may be minims1 
when one considers that transdennal delivery of liposome packaged recombinant antigen 
leads to potent Th2 immune responses with virmally exclusive production of serum IgG, 
(personal communication, Dr. M. Baa-Estrada). This immune response to transdermally 
delivered antigen is restricted to the local draining lymph node aod argues that delivery 
site trauma plays little, or no, role in the ensuing immune character. It also suggests that a 
"preset" immune response within lymph nodes draining skin drives the response toward a 
potent Th2flgG: immunity, in the absence of an immune polarizing adjuvant such as LPS 
or hypomethylated CpG motifs (Everson et al., 1996; Raz et al., 1996). It would appear 
that dose, in t e r n  of diminished adjwancy, and perhaps immune compartmentalization 
within the immediate draining lymph microenvironment, may be primarily responsible 
for the Th.2-type character of the immune response to ballistically delivered plasmid 
encoded antigen. Thus, the compelling argument that Feltquate e t  al. (1 997) have made 
that the method of DNA delivery determines the immunological outcome must be 
considered in the context of DNA dose as it affects adjuvancy and immune compartment 
restriction. Furthermore, the cytokine ichemokine profiles in W o ,  ex vivo and in sim 
following i.d. and ballistic delivexy of DKA vaccines must be assessed to ascertain what 
roles, if any, the route, site or method of DNA delivery has on the developing immune 
response. 
1.6 Mucosal and Epidermal Delivery 
1.6.1 Unfacilitated Mucosal Delivery 
Administration of DNA-based vaccines to mucosal and skin sites represents an 
exciting extension to more conventional systemic immunization studies currently 
underway (Ulmer et al., 1996). Surprisingly, mucosal delivery of naked DNA, without 
the aid of any cytofectins, results in substantial levels of transfection locally and distally 
to the inoculation site (Fynan et al., 1993; Etchart et al., 1997; Kuklin et aL, 1997). Fynan 

et. al. (1993) demonstrated a 75% survival rate against lethal Influenza virus in mice 
immunized intranasally (i.n.) with 100 pg of a plasmid encoding a hemagglutinin 
glycoprotein (subtype Hl). While mucosal levels of IgA were not assessed it was clearly 
shown that in.  immunization primed for systemic IgG responses. Kuklin et. al. (1997) 
immunized BALB/c mice three times with 100 pg of plasmid encoding glycoprotein B 
from Herpes Simplex virus (HSV)-1, and demonstrated expression of gB in the lungs and 
cervical lymph nodes. While these mice developed delayed type hypersensitivity 
responses and moderate to high levels of IgA in the vagina and feces, they were not 
protected following inmvaginal challenge. Co-administration of 2 pg of cholera toxin (a 
potent adjuvant) with the DNA vaccine si@cantiy increased the levels of @-specific 
IgA occurring at the vaginal mucosa, and offered some protection against a low dose 
HSV-1 vaginal challenge. Thus the potential of using DNA vaccines at mucosal surfaces 
has been established. However, researchers recognize the need to investigate 
methodologies whereby naked DNA may be delivered with greater efficiency to relevant 
cells associated with mucosal surfaces. Encapsulation of naked DNA within cationic 
liposomes or microspheres may be two approaches currently available that would enhance 
delivery of DNA to cells of the mucosa and associated lymphoid tissues. 
1 h.2 Liposome Facilitated Delivery 
It has been demonstrated that packaging naked DNA vaccines in cationic 
liposomes or microparticIes can greatly increase the efficiency of delivery to certain 
mucosal &aces (Puyal et al., 1995; Wheeler et al., 1996; Ban et al., 1997; Etchart et al., 
1997; Gregoriadis et al., 1997; Klavinskis et al., 1997; Wang et al., 1997). Despite 
preliminary evidence suggesting delivery limitations of liposomes, it now seems apparent 
that modification of existing cationic and neutral lipids, in conjunction with extensive 
testing of various combinations of these lipids, can greatly enhance delivery and 
expression of genes encoded within plasmids. It has been demonstrated that novel 
cationic lipids such as GAP-DLRIE, and existing cationic lipids such as DOTIM or 
DOTAP formulated with neutral lipids (DOPE or cholesterol) can enhance in vivo uptake 
and expression of i.n. or i.v. administered cationic liposomes:DNA complexes (CLDC's) 
1,000 to 2,000 fold (Wheeler et al., 1996; Liu et al., 1997; Templeton et al., 1997). 
Immune responses to liposome encapsulated DNA-based vaccines are broad and include 
distal mucosal antibody and CTL activity, as well as, significant serum levels of 1-6 and 
systemic CD8+ CTL activity (Gao-et aL, 1995; Etchart et al., 1997). These advances in 
lipid structural modification and formulation, in conjunction with a greater understanding 
of how the three dimensional structure of cochleates, multilamellar (MLVs), and 
unilamellar (lTLVs), vesicles alter effectiveness of gene delivery, and the potential for 
targeting to specific cell types predict a significant increase in the success and use of 
DNA-based immunization (Gould-Fogerite and Mannino, 1 996). 
1.63 Microsphere Facilitated Delivery 
Encapsulation or adsorption of plasmids encoding reporter genes or antigens 
within, or on the surface of, biodegradable microparticles such as poly@L-lactide-co- 
glycolide) specifically target and can elicit antigen-specific mucosal IgA responses, as 
well as, serum IgG titers (Alpar et al., 1997; Jones et al., 1997). Mice immunized with 
DNA complexed to microparticles displayed antigen-specific IgA responses at, and distal 
to, the oral and gamic rnucosal administration site. Oral imrunization also stimulated 
good serum IgM and IgG titers. Alpar et. al. (1997) demonstrated that i.n. administration 
of DNA adsorbed to biodegradable pseudo-polyaminoacid microspheres {poly (DTH 
carbonate)) induced good systemic IgG responses that equalled, or exceeded, antibody 
responses to LipofectinE encapsulated DNA despite using 4-8 times less DNA. 
1.6.4 Adenovirus Facilitated Delivery 
Co-internalization of replication deficient adenovirus with plasmids encoding 
genes can increase reporter gene expression in cultured cell lines with efficiencies equal 
to those achieved with cationic lipid mediated transfection (Yoshimura et al., 1993). 
Adenovirus facilitated uptake of plasmids encoding gene sequences occurs as a result of 
receptor mediated binding of virus to ubiquitously expressed receptors on host cells and 
subsequent endosomolytic activity of viral capsid proteins during acidification of the 
endosomal compartment (Allgood et al., 1997). Adenovirus mediated escape from the 
endosomal vesicles leads to the relatively efficient release of other macromolecules 
within the endosome. A number of modifications to the co-inoculation protocol have 
been utilized that include: cationic polymer facilitated association of plasmids to 
adenovirus, cationic lipid and iigand based enhancement of adenovirus vectored plasmid 
DNA complex uptake (Wagner et ai., 1992; Ferkol et al., 1995; Fasbender et d., 1997; 
Schwarzenberger et al., 1997). Covalent or noncovalent linkage of cationic polymers, 
prebound to plasmid DNA, to adenovirus to augment uptake of genes of interest have 
been reported (AUgood et al., 1997). Typically the cationic polymers have a very high 
&ty for the polyanionic phosphate groups of DNA and are typicaily poly-L-lysine or 
polyethylenimine (Baker and Cotten, 1997). It has been hypothesized that poly-L-lysine 
sequences may facilitate nuclear targeting of associated DNA sequences (Ferkol et al., 
1 995). Although receptors for adenovirus are relatively ubiquitous on host cells, 
researchers have found that in viva transfection of airway mucosa proceeds poorly due to 
inefficient binding of adenoviruses to the apical surface of epithelial cells (Ferkol et al., 
1995). One approach utilized to rectify deficiencies in mucosal epithelial delivery 
included formulating recombinant adenovirus vectors, expressing P-galactosi dase, with 
polycationic Lipids such a s  LipofectamineE, GL-67 or a combination of GL-67/DOPE 
(dioleoylphosphatidyl-ethmoMe)(Fasbenr et al., 1997). Although recombinant viral 
vectors were utilized in this case it is conceivable thar polylysine/adenovirus/DNA 
conglomerates may be compiexed with polycationic lipids to facilitate augmented 
mucosal delivery, and uptake, of plasmids expressing foreign antigens or immune 
modulating genes. A second approach utilized to circumvent problems associated with 
mucosal delivery of plasmids encoding genes involved covalent linkage of Fab 
fragments, directed against the IgA receptor at the basolateral s e a c e  of epithelial cells, 
to poly-L-lysine and subsequent condensation with plasmid encoding genes of interest 
(Ferkol et al., 1995). Intravenous introduction of the ligand/poly-L-lysine/DNA 
complexes leads to specific targeting of plasmids encoding genes to the airway 
epithelium. Although adenoviruses were not a component of these Fab/poly-1ysineDNA 
complexes they have been utilized as ligand-adenovim-poly-L-lysine complexes and do 
appear to facilitate receptor mediated augmentation of plasmid delivery to the cytoplasm 
of specific cell types (Curie1 et at., 1991). 
1.6.5 Future Prospects 
The funue of liposomal and microsphere facilitated DNA-based immunization 
appears to lie in the ability to increase the senun or mucosal half-life of encapsulated 
DNA and to increase the efficiency of delivery to the cytoplasm of cells. These delivery 
vehicles also possess the potential to target specific cells of the immune system more 
effectively than naked DNA alone (Eldridge et al., 1989; O'Hagan et al., 1993) . There is 
also preliminary evidence that specific cell targeting may be further enhanced through 
inclusion of appropriate Ligands in the outer lipid envelope of liposomai vesicles (Fuyal 
et al., 1995). It is unknown whether targeting will offer any advantages at this point or if 
this is a possibility with biodegradable rnicrospheres. 
1.6.6 Transdermal 
The potential exists to immunize animals through topical application of DNA 
vaccines to the epidermis. The potential of this concept was fim demonstrated in 1995 
when researchers showed that reporter genes, packaged in liposomes, were transfected 
into hair follicular cells with high efficiency (Li and Hofhm,  1995). Although there was 
little evidence for transfedon outside of hair follicles, ttansfection of cells within the 
base of the hair bulb was clearly evident. Transfection of this cell population, in 
conjunction with the vasCUIarization and likelihood of lymphatic drainage of the dermal 
papillar region allows one to hypothesize that plasmid encoded antigen would quickly 
gain access to secondary lymphoid tissue. The recent advances in transdermal delivery of 
drugs and proteins clearly suggests that these advances will be transferred to transdermal 
delivery of plasmids as well. 
1.7 Cytokine Modulation of Immunity to DNA-based Vaccines 
Of constant concern to immunologists involved in vaccine development is to ensure 
that vaccination results in an immune response that bea protects animals or humans 
against a given pathogen or disease (Mosmann and Sad, 1996). In order to accomplish 
this we must: be able to polarize CD4' T helper cells towards Th2 or Thl phenotypes, 
ensure that the magnitude of humoral immunity, when required, is adequate, and finally 
elicit CD8+ T-cell mediated cytotoxicity when protection from infection requires this arm 
of immunity. DNA-based vaccines currentiy display the potential to polarize immune 
responses depending on several parameters, including: form of antigen, method and route 
of delivery, and dose of plasmid injected (Cardoso et d., 1996; Pertmer et al., 1996; Sato 
et al., 1996; Feltquate et al., 1997; Lewis et al., 1997; Roman et al., 1997). A further 
advantage of DNA-based vaccines is the relative ease with which imrnunomoddadng 
cytokines can be co-administered as plasmid encoded gene(s) (Xiang and Ercl, 1995). 
The advantages of this approach include: low cost, simplicity of codelivery, elimination 
of the need for multiple dosing of recombinant cytokines with short serum half-lives, and 
avoidance of toxicities and regulatory issues plaguing many current adjuvants (Hughes et 
aI., 1992; Gupta et al., 1993). Disadvantages of this approach revolve around issues of 
sustained expression and the potential toxicities (Cohen, 1995) associated with potentially 
long term responses, as well as the need to identify, isolate, and assess cytokines of 
importance in target species. 
Co-administration of plasmid-encoded cytokines is achieved by delivering a 
mixture of two separate plasmids, one of which encodes the antigen and one which 
encodes the cytokine, or by delivering a single bi- or polycistronic vector with internal 
ribosomal enw sites s C ! ~ = M ~  genes representing antigen and cytokine (Clarke et al., 
1997). Cytokines may also be delivered as molecular chimaeras comprised of antigen 
and cytokine usually separated by a domain presewing spacer region (Syrengelas et al., 
1996; Maecker et al., 1997). Too date a variety of cytokines and growth factors have been 
co-administered with plasmid encoded antigen and include: GM-CSF, IL- 12, IL-2, IL4, 
IL-6, IL-7, IL-1 cr and P (Table 1.4). Data included in Table 1.4 is not meant to be 
complete, however, infoxmation included summarizes a relatively comprehensive list of 
publications that have included data describing serum isotype, splenic cytokine profiles 
and CTL data. 
Mice immunized with plasmids encoding antigens and plasmids encoding GM- 
CSF show substantial augmentation of serum IgG titer, seroconversion efficiency, 
enhanced cell mediated responses that include blastogenesis and CTL. The mechanisms 
involved in these responses appear to involve: enhancement of antigen immunogenicity 
(Iwasaki et al., 1997), significant upregulation of IL-4 in spleens and draining lymph 
nodes (unpublished data) and the enhancement and maintenance of antigen capture and 
processing functions of local, or possibly recruited, dendritic cell populations (SalIusto 
and Lanzavecchia, 1994; Lutz et al., 1996). Dose, and the presence or absence of 
secondary irnmllnizations, of plasmids encoding GM-CSF can have very significant, and 
surprising effects on the immune outcome to antigen co-administered with this cpokine. 
We were able to demonmate that a single dose (50 pg) of plasmids encoding GM-CSF, 
co-delivered with a plasmid encoding a secreted version of bovine herpesvirus (BHV)- 1 
glycoprotein D (which normally gave us very high serum titers of IgG,), resulted in 
suppression of the humorai response (see section 43.4). However, post-boos titers 
reflected a potent anamnestic humoral response and a significant trend towards increased 
serum IgG, (see section 4.3.5). Conversely, moderate doses (10 pg) of plasmids 
encoding GM-CSF showed serum Ig isotypes that were predominantly IgG, regardless of 
whether mice received secondary immunizations. In some instances co-administration of 
plasmids encoding GM-CSF enhanced antigen-specific cytotoxic immunity. Geissler et. 
al. (1 997) and Iwasaki et. al. (1 997) were able to demonstrate enhancement of T-cell 
mediated cytotoxicity to Hepatitis C virus p2 1 core antigen and Influenza virus 
nucleoprotein respectively, when plasmids encoding these antigens were co-administered 
with plasmids encoding GM-CSF. 
Co-administered plasmids encoding the p35 and p40 subunits of IL- 12 could also 
enhance T-cell mediated cytotoxicity responses, confer protection against challenge, and 
deviate immunity towards a Thl-type response (Inme et aL, 1996; Iwasaki et al., 1997; 
Kim et al., 1997; Tsuji et al., 1997). A decrease in serum IgG levels and splenic, 
antigen-specific, IL-4 levels were consistent with an increase in cells of the Th h y p e  
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IFN y is known to be involved in deviation of the immune response towards the 
Th l phenotype and the Ig switch to a IgG, isotype (a surrogate marker for Th 1 
responses), (Snapper and Mond, 1993). Early published work suggested that co-delivery 
of plasmids encoding IFN y resulted in suppression of both humoral and cell mediated 
immune responses (Xiang and Ertl, 1995). We also found clear evidence for a suppressive 
humoral effect following co-administration of 10 pg this cytokine (Lewis et al., 1997). 
However, we also noted that co-administration of plasmids encoding 1 ' -  y resulted in 
increases in relative amounts of IgG, , although this increase was not consistent in all 
mice. Finally, we observed that following co-administration of 50 pg doses of IFN y, 
with plasmids encoding a secreted form of BHV-1 gD, the suppressive humoral effect 
disappeared while the tendency toward increased levels of serum IgG, was maintained 
(see sections 4.3.4 and 4.3.5). Interestingly, we found that co-administration of plasmids 
encoding TNF a, with plasmids encoding a secreted form of BHV- 1 gD increased the 
magnitude of the serum IgG response at 2 weeks and elicited increases in the mean 
serum IgG, levels (Lewis et al., 1997). Despite the tendency towards higher ievels of 
serum IgG, we have not been able to demonme  consistent isotype switching in 
individual animals using a dose range of plasmids encoding IM y (2 -50 
pg),(unpublished data). Recently, the issue of isotype contribution to protection was 
raised by Bachmann et. al. ( 1997), who, using a murine lymphochoriomeningitis virus 
( L o  model, concluded that beyond a threshold level of serum antibody, isotype 
becomes irrelevant Although this article is worth noting, it does not diminish the 
potential importance of efficient complement fixing isotypes, such as murine IgG,, in 
other disease models (Zshizaka et al., 1995), or the protective advantages a predominance 
of complement fixing isotypes may offer in poor vaccine responders in olnbred 
populations. Thus, it will be of considerable interest to assess other cytokines, such as: 
ENS cr and P and IL- 18. known to play roles in deviating the immune responses towards 
a Th 1 -type phenorype and potentially modulate the serum antibody profile, as well as, 
facilitate the development of cytotoxic CD8' T-cell responses (Roman et al., 1997). 
Co-administration of plasmids encoding iL-2 or IL-4 with plasmids encoding 
antigens, have been demonstrated to enhance humoral and cell-mediated responses (Raz 
et al., 1993; Chow et al., 1997; Geissler et al., 1997). Mice imrmlnized with plasmids 
encoding IL-2 and antigen display increases in senun IgG levels, increased 
seroconversion efficacy, and increased protection following challenge (Irvine et al., 
1996). Plasmids encoding IL-2 also appear to enhance: T-cell blastogenesis, cytotoxic T- 
cell levels, both IFN y and L-4 cytohne expression levels within splenic T-cell 
populations, and increase delayed rype hypersensitivity reactions (Raz et al., 1993; Chow 
et al., 1997; Geissler et al., 1997). We were not able to show any augmentation of 
immunity following co-administration of IL-2 with a suboptimal dose of plasmids 
encoding a secreted f o m  of BHV-1 gD. However, we assessed humoral responses only, 
to a single, moderate, dose of IL-2, that may not have been optimized for C3H/HeN mice 
(Lewis et al., 1997). Mice immunized with plasmids encoding IL-4 displayed increases in 
serum IgG in seropositive animals, increases in IgG, and seroconversion efficiency (Raz 
et al., 1993; Geissler et al., 1997). Mice receiving plasmid encoded IL-4 also displayed a 
substantial increases in splenic T-cell blastogenic responses following in v - o  
stimulation with antigen. We were able to demonstrate increases in mean serum IgG tilers 
using a 10 pg dose of plasmids encoding IL-4 co-administered with plasmids encoding a 
secreted form of BHV- I gD (Lewis et al., 1997). 
Several other cytokines including: IL-1 a and P, IL-6 and IL-7 have shown a 
varying impact on the immune responses in mice immunized with DNA-based vaccines 
(see Table 1.4). It would appear, at first glance, that these cytokines are not worth 
pursuing as vaccine modulators, however, it must be pointed out that in many instances 
responses to a dose range of these plasmids encoding cytokines have not been carried out. 
In these cases, and with cytokines that do show modulatory effects, dose range impact on 
immunological outcome must be assessed before any generalizations may be made. 
Indeed, dose range with each antigen , particularly if the expression compartment varies 
(intracellular, extracellular etc) in a variety of different murine hap lotypic backgrounds, 
as well as target species, must be canied out before researchers can begin to appreciate 
the possibilities for immune augmentation or deviation through co-administration of 
plasmid encoded cytokines. 
Finally, several recent articles have assessed immunity to DNA-based vaccines 
encoding antigen:cytokine fusion proteins (Syrengelas et al., 1996; Maecker et al., 1997). 
Syrengelas e t  al. (1996), demonstrated that i m  delivery of plasmids encoding a B-cell 
lymphoma idiotype:GM-CSF fusion protein resulted in significant increases in serum 
IgG, levels that coincided with moderate increases in serum IgG,. In traded  delivery of 
this plasmid resulted in suppression of serum IgG,, as compared to plasmid encoding B- 
cell lymphoma idiotype only. Maecker et. al. (1993, created plasmids encoding fusions 
between ovalbumin (OVA) and: GM-CSF, IFN y, IL-2, IL-4 IL- 12 and a nine amino acid 
fragment of IL- 1 P known to possess adjuvant activity. Serum antibody levels were 
minimal with all constructs except for the 0VA:IL-4 chimaera. Immunization with 
plasmids encoding 0VA:IL-1 P and 0VA:IL-12 fbsions appeared to deviate splenic 
cytokine responses towards a Thl phenotype and appeared to elicit the strongest T-cell 
mediated cytotoxic responses. In light of the molecular intricacies involved in creating 
and expressing stable chimeric proteins, this preliminary data, while novel, must be 
compared directly to simpler immunization models where modulatory proteins are co- 
administered as separate plasmids or co-expressed from the same plasmid that encodes 
antigen. 
1.8 Safety 
1.8.1 Autoaggression and Autoimmunity 
Several safety issues predominate when addressing possible deleterious outcomes 
to the use of DNA-based vaccines. These issues include: the potential for chronic 
autoaggression and subsequent development of epitope spreading and the development of 
anti-DNA antibodies or a Lupus-like syndrome. We have the technology, at least in 
mouse models, to achieve 2530% in vivo transfection efficiencies following i.m 
immunization (Hartikka et al., 1996). Several recent articles demonstrating the existence 
of CTL activity within the muscle mass (Davis et al., 1997; Yokoyama et al., 1997), 
clearly ihstrate the potential for siguficant levels of immune mediated myositis and 
potentially the development of a true autoimmune disorder through epitope spreading 
(Vanderlugt and Miller, 1996). While the development of autoimmunity through epitope 
spreading remains a possibility there has been at least one published instance where 
assessment of imm-miry towards the self antigen myosin failed to detect any evidence 
autoimmune responses following i m. DNA immunization (Mor et al., 1 997). 
Sytemic lupus erythematosus (SLE) is an autoimmune disorder characterized by 
substantial levels of serum IgG that are typically reactive to double stranded mammalian 
DNA (Gilkeson et al., 1989; Steinberg et d., 1990). Gikeson et. al. (1989) demonstrated 
that immunization of normal mice with bacterially derived (Escherichia cob) DNA, 
complexed to methylated bovine serum albumin (mBSA) in Freunds complete adjuvant 
(CFA) elicits very high levels of anti-bacterial DNA antibodies . However, these mice 
showed no evidence of crossreactivity with mammalian (calf thymus) &DNA. More 
recently it was demonstrated that immunization of BALB/c mice with single stranded 
DNA complexed with mBSA in CFA also induced significant renal pathology (Gilkeson 
et al., 1993). Most recently, crossreactive anti-mammalian &DNA antibodies developed 
in preautoimmune NZB/NZW mice immunized with bacterial DNA in mBSA and CFA 
(Gikeson et al., 1995). Thus it is possible, using heavily adjuvanted bacterial DNA, to 
elicit anti-DNA antibodies. However, responses require formulation with potent 
adjuvants, appear to be crossreactive only in susceptible mains of mice and renal injury 
appears to require ssDNA of bacterial origin as the immunizing antigen. There remains 
the possibility that the potent immunostimulatory sequences encoded within injected 
plasmids may provide sufEcient costimulatory signalling to activate B-cells 
simultaneously recognizing plasmid DNA through engagement at the B-cell receptor 
(Kneg et al., 1998). Certainly it has been clearly demonstrated that immunostimulatory 
sequences within plasmid DNA can induce proliferation, MHC class II antigen 
expression, costimulatory signal upregulation and immunoglobulin syutbesis in naive B- 
cells. 
Although it is still early, there has been no evidence for the sustained development of 
anti-DNA aati'bodies in animals immunized with naked DNA-based vaccines (Mor et al., 
1997). There has been some suggestion of a transient, predominantly IgM, antibody 
response. However, this response did not develop into a clinically relevant problem 
Researchers investigating the potential of DNA-based vaccines to cause a Lupus-like 
syndrome have focussed on assessment of humoral responses to DNA. Recent 
information indicates that autoimmune antibodies characteristic of this disorder are not 
directed solely againa nucleic acids (Speciale, 1993). In over 95% of persons with 
systemic lupus erythernatosus (SLE) antibodies were found againa a 30 kDa cell surface 
protein that binds cell membrane DNA (Bennett et al., 1987; Bemet et al., 1988). The 
role these anti-DNA receptor antibodies play in the development or maintenance of SLE 
is unknown too date. Indeed, these antibodies may simply be a diagnostic indicator for an 
increased risk of development of SLE or may be involved in the conversion of the 
transient, T-cell independent, igM response to a T-cell dependent response. In either case, 
it will be important to screen for seroconversion to this neoantigenic complex (plasmid 
DNA:30 kDa receptor) when studying the potential for development of autoimmune 
disorders resembling systemic lupus erythernatosus following immunizations with DNA- 
based vaccines. 
1.8.2 Integration 
Integration of injected plasmid DNA into host genomic sequences remains an 
issue of contention between researchers and regulatory agencies (Robertson, 1994). 
Initially, when it was felt that the myocytes were unique in the ability to take up plasmid 
DNA and translocate it to the nucleus, the argument was made that the absence of mitotic 
activity in myocytes would virtually eliminate the likelihood of hazardous mutational 
integration occurring (Wolff et al., 1992; Danko and Wolff, 1994). Of course the frequent 
use of myotoxic agents such as cardiotoxin, or bupivicaine, to upregulate myoblastic 
mitotic activity diminished the importance of this argument. Similarly, the demonsnation 
that uptake and nuclear localization can occur in a variety of cell types, and that injected 
DNA does not remain immediately adjacent to the injection site has raised the possibility 
of genomic integration once again ((Raz et al., 1994; Condon et al., 1996; Torres et al., 
1997). More recently, using i m  injection of plasmids at doses of 100 pg per quadriceps, 
researchers were unable to demonstrate any evidence of integration in the genomic DNA 
hawested from 11 tissues (Nichols et al., 1995). Indeed these authors calculated that a 
mutation event arising fiom random integration of plasmid DNA into a host gene is 1.3 x 
10-g/cell. However, mutational events do not necessarily require integration into a host 
cell gene to result in a deleterious outcome, and with a spontaneous random integration 
ftequency calculated at 2 x lod, one may assume that the mutational frequency might 
actually be higher than the 1.3 x 10-g/cell value given. To the authors credit, they 
envisioned a "worst case scenario" and assumed each "gene" was comprised of 1.0 x 106 
base pairs, an excessive length that would allow for integration into intron, regulatory or 
other sequences not immediately adjacent to the coding region of the "gene". Indeed, the 
value these authors anived at may actually be artificially high. 
Integration into the genomic DNA of stem cells, particularly those of the 
reproductive organs, have been areas of concern, pam'cuiarly in Light of growing interest 
in liposomal or microsphere mediated delivery and the circumvention of many of the 
uptake Limitations that occur when delivering naked DNA.. However, liposome packaged, 
i.v. administered, plasmid DNA has been demonstrated to partition poorly to the testes or 
ovaries of mice (Lew et al., 1995). This evidence, although speculative, to some extent, 
suggests that the injection of DNA as a systemic or mucosai vaccine in animals and 
humans does not provide great risk to recipients. Conversely, there is recent evidence 
demonstrating unequivocally that integration can occur following intrasplenic or oral 
administration of naked plasmid DNA (Gerloni et al., 1997; Schubbert et al., 1997). 
Cenainly this may be an &air assessment of the integration potential of DXA vaccines 
because it has been demonstrated that the Ig heavy chain switch region of B-cells are high 
frequency insertional sites for transfected DNA (Baar and Shulman, 1 995). However, 
these results suggest that integration is a very real possibility and, more importantly, 
describe a procedure where high frequencies of integration can occur. This data will allow 
researchers to begin to determine what the integration potential is for a given plasmid 
delivered in a specific manner and perhaps provide the tools and information to establish 
assessment criteria that will determine the true risk of genomic integration into relevant 
and irrelevant host cells. It would be unfortunate to have to assess the integration 
potential of DNA-based vaccines on a plasmid by plasmid basis as sequences within 
DNA-based vaccines are altered to accommodate changes in regulatory elements or new 
antigens. This "overkil~" approach for determining risk assessment of DNA-based 
vaccines would be unfortunate and, in all likelihood, unnecessary, particularly in Light of 
the fact that a nonprescription form of genomic DNA (from salmon sperm) has been 
taken by injection, topical administration and orally by people for decades without any 
apparent adverse effects (Whalen and Davis, 1995). Indeed the oral doses of this DNA- 
based supplement are 1000-100,000 fold greater (125-250 mg) than doses injected into 
mice . Of course there remains bdamental differences between intrinsically 
immunosuppressive eukaryotic DNA and, profoundly immunostimulatory bacterial DNA 
that must not be overlooked Indeed, shon Linear bgments of self DNA have been 
identified that are normally bound to the outer cell membrane of antigen presenting cells 
(Lemer et al., 1971). The exact function of this cell surface population of nucleic acid is 
unknown, however, it is possible these sequences serve to suppress effector T-cell 
functions that may be directed against antigen presenting cells presenting antigen in the 
context of major histocompatibility antigens (Russell and Golub, 1978). This information, 
in the context of mucosd bacterial loads and the resulting exposure of host tissues to 
both genomic and extrachromosornal DNA, suggests that risks of deleterious mutation 
events, due to integration of nonself DNA, at mucosal surfaces is minimal. F i d y ,  for 
the fwd animal industry the question of integration may be moot, given the time that 
these animals would be exposed to any potential deleterious effects resulting from a 
integration/mutation event following DNA imrmmization. 
1.9 Future Directions 
1.9.1 Mechanistic Studies 
Poor understanding of the exact mechanism of immune induction by DNA-based 
vaccines necessitates the need for identification of relevant cell populations involved in 
immune responses and determination if naked DNA uptake by cells is a receptor 
mediated phenomenon. Identification of critical cell populations and an uptake 
mechanism will potentially allow scientists to direct plasmids encoding antigens or 
immunomodulatory genes to cell populations in a more efficient and specific manner. 
Immunostimulatory sequences, or hypomethylated CpG motifs have a profound 
impact on the immune outcome to DNA vaccines and should prove to be a very 
interesting area of study. There are several issues with regard to imrnuno*ulatory 
sequences that remain to be resolved and include the question of adjacent High-G 
sequences and their putative involvement in surface receptor binding and uptake. One 
may predict that motifs such as the High-G sequences may be playing a fundamental role 
in facilitating uptake of injected plasmid DNA, not only for adjuvant effects but also for 
translocation to the nucleus. Identification and mutation of these could possibly enhance 
narural transfeaion efficiency, targeting to specific APC populations as well as more 
efficacious adjuvant effects. 
1.9.2 Target Species 
Table 1.5 nunmarizes delivay, dose, immunological and challenge outcomes for 
a variecy of target species. Generally speaking, the preliminary data summarized in 
Table 1.5 suggests that there is a very real potential for DNA-based vaccines to offer 
protection against diseases in outbred populations of veterinary importance. Efficacy of 
DNA vaccines has been a concern particularly when faced with "scale-up" to species. 
such as cattle, that are 2,000 times heavier at birth than the typical adult laboratory 
mouse. 
Immunization of cattle with plasmids encoding the bovine herpesvirus 1 
glycoprotein D (BHV-1 gD) required substantial doses of DNA with multiple boosting 
when administered i.m (Cox et d., 1993). Resulting serum antibody titers were 
relatively low when vaccine was delivered by this route although moderate levels of 
protection did occur . Subsequently it was demonstrated that i.d. administration of 
plasmid encoding a secreted version of BHV-1 gD (tgD) in the ear of cattle elicited 
moderate doses of serum antibody and offered greater levels of protection than 
immunization with plasmids encoding the membrane anchored authentic version of BHV- 
1 gD (van h e n  Littel-van den Hurk et al., 1998). Additionally, immunization in the 
dermis of the ear in these cattle focusses immune responses within the parotid lymph 
node which also drains the external nares and eyes in cattle (Sisson and Grossman, 1963). 
Localizing immunity within this lymph node will Likely contribute to the level of local 
protective immunity at the appropriate mucosal route of e n w  for BHV- 1 (Gao et al., 
1995). In this instance it appears that choice of route and method of immunization had a 




profound impact on the immunological outcome. Although there is the suggestion that 
delivery to dermal tissue results in greater immunological efficacy, the potential for 
deiivery to im. tissues must not be ignored. Indeed it has been demonstrated that DNA 
immunization of different muscle groups within mice can result in substantial differences 
in the rnagoirude of the immune responses (Yokoyama et al., 1997). It is also important 
to recognize that humoral immunity (levels of serum antibodies) are not always a good 
indicator of protection against a given disease. Intramuscular immunization of calves with 
plasmids encoding protective antigens fiom the parasite T. annulata failed to elicit 
detectable serum antibodies and yet provided significant levels of protection in 66% of 
animals following lethal challenge (d'oliveira et al., 1997). Similarly, dogs immunized 
with plasmids encoding canine pawovirus antigens did not demonstrate any antibody but 
were still protected from parvovirus infection (Schultz, R., personal communication). 
In two instances there was either no evidence of protection (Monteil et al., 1996) 
or disease progression was actually exacerbated following immunization (Richardson et 
al., 1997). In one instance one day old neonatal pigs fiom nonimmune mothers were 
immunized i .m. with plasmids encoding glycoprotein D from Pseudorabies virus and 
failed to develop detectable levels of serum antibodies (Monteil et al., 1996). In this case 
immaturity of the neonatal immune system was likely a complicating factor. 
Immunization of young cats with plasmids encoding the Feline Immunodeficiency virus 
envelope protein resulted in enhancement of the early stages of infection (Richardson et 
ai., 1997). In this instance, the authors felt that low serum antibody titers or low affinity 
antibodies may have played a role in dissemination of chdlenge virus, or that antigen, 
superantigen, or plasmid derived immunostimulatory sequence mediated activation of T- 
or B-cells that may have augmented early levels of viral replication. 
Preliminary data supports the potential for efficacy of DNA-based vaccines in 
target species. Enhancement of DNA vaccine efficacy in these species will necessitate a 
closer look at: the method of immunization, targeting of appropriate immunization sites, 
the appropriateness of antigen, expression cassette choice, and identification of the most 
effective cellular compartment in which antigen expression occurs. Co-administration of 
plasmids encoding cytokines is an area that has been largely unexplored in target species, 
as has enhancement of plasmid uptake by micropam'cle, adenoviral or liposomal 
facilitated delivery. These methods, and others, offer mechanisms whereby immune 
responses to DNA-based vaccines, in target species, can be made more efficacious and 
practical. 
1.9.3 Neonatal Vaccines 
Resence of maternal antibody in the sera of neonates specifically inhibits the 
development of humoral responses in vaccinated animals (Ravetc h, 1 997). Conventional 
neonatal vaccination typically involves multiple highdose immunization regimes 
designed to minimize the time between waning passive immunity and development of 
active immunity during which young animals are susceptible to disease (MacDonald, 
1992). For many species of food animals this approach may not be cost effective, or 
achievable, within current management practices. 
Use of DNA-based vaccines may allow certain advantages over existing licensed 
conventional vaccines when vaccinadng neonatal animals of immune mothers. Fim 
longevity of expression of these vaccines may facilitate a more efficacious method of 
immunization such that all animals in a litter, or herd develop active titers as quickly as 
possible after suppressive maternal derived serum titers are no longer protective (Wolff 
et al., 1992). Second, DNA-based vaccines almost invariably induce potent CTL. and 
frequently Th 1 -type immune responses and may prove to be an alternative , significantly 
advantageous, objective in neonatal animals. 
At this point it is presumptuous to assume that longevity of expression afforded by 
DNA-based vaccines will outpexfom existing or candidate adjuvants currently available 
(Dalsgaard et al., 1990; Cox and Coulter, 1997; Davis et al., 1997; Yokoyama et al., 
1997) . This may cenainly be the case when protection to a given pathogen requires a 
potent neutralizing antibody response. Consideration must also be given to the issue of 
immunostimulatory sequences within DNA-based vaccines and the contriibution these 
sequences are expected to make to the immune response (Roman et al., 1997). Certainly 
passively acquired maternal antibodies may serve to functionally separate the benefits of 
the adjuvant effect of CpG motifs within delivered plasmids and the rime point at which 
antigen interacts with naive Btells without the simultaneous, inhibitory, co-ligation of 
the FcyRIIB 1 receptor. This concept is further complicated when using neonatal mice as 
models for investigating this phenomenon due to recent evidence that the naivete of the 
immune system in this species is such that high zone tolerance, or a profound deviation 
towards a Th2-phenotype, is the outcome to standard adult doses of vaccine (Fomhuber 
et aL, 1996; Ridge et al., 1996). Indeed, at Least one recent article demonstrated B and T- 
cell tolerance in neonatal mice following an im. (gluteal) immunization with a low dose 
(10 pg) plasmid encoding the circumsporozoite protein (Mor et al., 1996). These 
problems, and others, will challenge the ability of any vaccine to elicit suong B-cell 
mediated immunity in passively immune neonatal animals. Fortunately, DNA-based 
vaccines have the unique capacity to activate the cell-mediated and cytotoxic arms of the 
immune response and indeed, may be a more appropriate and achievable goal with many 
pathogens. Obviously, the presence of a primed expanded CTL population would convey 
a significant degree of protection to a variety of pathogens (Mosmann and Sad, 1996). 
Furthemore a primed population of Th cells would narrow the window of susceptibility 
to disease by shortening the time to anamnedc immune responses. To date, no published 
article has described the development of humoral i m m ~ t y  in neonate models. However, 
clear evidence of CD4' T-cell priming and development of CD8' cytotoxic T-cells has 
been described p o t  et al., 1996; Hassett et al., 1997; Wang et ai., 1997). Obviously 
duration of antigen expression is also a determining factor and will depend, to a large 
extent, on the species studied, antigenicity, method and route of immunization. This 
aspea of DNA-based vaccines and the growing awareness that plasmid uptake and 
expression is occurring within critical lymphoid compartments distal to the site of 
vaccination make the largely unexplored area of DNA-vaccine applications to neonatal 
immunity an exciting area of research. 
1.9.4 Identification and Manipulation of Novel Antigens 
In 1995 a group of researchers described a technique, temed expression library 
immunization which provided new possibilities for rapid, yet exhaustive, identification of 
protective immunogens from a variety of pathogens (Barry et al., 1995). They created an 
expression library that represented many of the antigens from the lung pathogen 
Mycoplama pulmonis and immunization of mice with these expression Libraries elicited 
immune responses. While this approach established that specific identification of antigens 
was not necessarily required for creation of a protective immune response, it did provide 
the basis for an unconventional, yet highly efficient, procedure to screen entire genomes 
of pathogens for protective epitopes. Researchers involved in these studies have 
projected that expression library creation and initial screen for immmogens would take 
between 6 and 12 months for most pathogens (Taubes, 1997). Indeed, they have currently 
accomplished this task for several bacteria inciuding M. pulmonas and Mycobactenm 
ruberrulosis (Taubes, 1997). There are several potential caveats inherent in this 
technique that include: antigenic competition and partial protein expression resulting in 
the loss of conformational epitopes (LTLmer and Liu, 1996). 
Ultimately DNA-based vaccines are faced with many of the problems that have 
historically plagued immunologists involved in conventional vaccine development 
Perhaps the most relevant problem involves poor antigenicity. Ultimately if a given 
antigen tends to elicit poor immune responses as a conventional vaccine it may also work 
poorly as a DNA-based vaccine. This Leaves researchers with no choice but to spend 
money, time and effort in dissecting the structural and functional characteristics of the 
antigen such that an informed, logical approach can be developed to enhance the 
antigenicity of the protein in question. 
Bovine, human and murine rotavirus VP7 antigen is a case in point. This antigen 
has been notoriously difficult to elicit immune responses against despite evidence that 
protective responses directed against VP7 are protective (Andrew et al., 1990; Hermann 
et ai., 1996). Researchers have utilized a variety of different approaches to enhance the 
immunogenicity to these antigens with varying degrees of success. We have demonstrated 
that plasmids encoding bovine rotavirus VP7, delivered by a variety of different routes 
and methods, fails to elicit either humoral or cell-mediated immunity (unpublished data). 
Attempts to enhance the immunogenicity by altering the cellular cornpar&nent in which 
VP7 normally occun and by the addition of transmembrane anchoring domains from 
BHV-1 enhanced in vino expression but failed to elicit immune responses following 
immunization. Co-administration of plasmids encoding GM-CSF and IL-4 also failed to 
facilitate immunity to this antigen (unpublished data). Finally, fusion of VP7 to multiple 
copies of C3d fragment, shown to be a potent adjuvant for B-cell response, did nothing to 
enhance immune responses to VP7 despite evidence showing increased expression in 
vitro and greater stability of expression product (Dempsey et al., 1996). We are faced 
with the necessity to dissect this antigen in an effort to determine if peptide sequences 
exist that specifically inhibit the responses to this antigen (Ijaz et al., 199 1 ; Volchkov et 
al., 1 992; Hengel and Koszinow ski, 1997). Fortunately, DNA-based vaccine technology 
provides the methodology to significantly shorten the time and cost required for 
preliminary testing of VW subhgments. In this instance the obvious value of 
expression library immunization for the rapid identification of a strong imrnunogen, and 
the strength of the DNA-based vaccine approach to rapidly screen candidate isolates 
becomes self-evident. 
1.10 Summary 
Therapeutic and prophylactic DNA vaccine clinical trials for a variety of 
pathogens and cancers are underway (Chattergoon et al., 1997; Taubes, 1997) . The speed 
with which initiation of these trials occurred is no less than astounding; clinical trials for 
an HN gp 160 DNA-based vaccine were underway within 36 months of the first 
description of "genetic immunization" (Tang et al., 1992) ,and within 24 months of the 
fim published article descniing im delivery of a DNA vaccine (Ulmer et al., 1993). 
Despite the relative fervou. with which clinical uials have progressed., it can be 
safely stated that DNA-based vaccines will not be an immunological "Silver-bullet". In 
this reboard, it was satisfjmg to see a recent publication entitled "DKA Vaccines-A 
Modem Gimmick or a Boon to Vaccinology?" (Manickan et al., 1997). There is no 
doubt, that this technology is well beyond the phenomenology phase of study. Research 
niches and models have been established and will allow the nuly difficult questions of 
mechanism and application to target species to progress. These two aspects of future 
studies are inaicately intenwoven and will ultimately determine the necessiq for 
mechanistic understanding and the evolution of target species studies. The basic science 
of DNA vaccines has yet to be clearly defined and will ultimately determine the success 
or failure of this technology to find a place in the immunological arsenal against disease. 
In an recent commentary article by Ronald Kennedy (1997) in which he discusses 
and introduces a research article describing protection against heterologous challenge 
with W - 1  in chimpanzees he begins his article by stating, "As someone who has been in 
the trenches of AIDS vaccine research for over a decade and who, together with 
collaborators, has attempted a number of different vaccine approaches that have not 
panned out, I have a relatively pessimistic view of new AIDS vaccine approaches". 
Kennedy goes on to describe a DNA-based, multigene vaccine approach and the 
subsequent development of neuaalizing titers and potent CTL activity in immunized 
chimpanzees (Boyer et d., 1997). Dr. Kennedy closes his commentary by stating,"The 
most exciting aspect of this repon is the experimental challenge studies. .. . . . . . .Viraemia 
was extremely transient and present at low levels during a single time point. These 
animals remained seronegative ... for one year afier challenge", " Overall, these 
observations engender some excitement " (Kennedy, 1997). While this may seem less 
than a rousing cheer for DNA-based vaccine technology it is a refreshingly hopefbl 
outlook for a pathogen that experience has taught us humility. It has also been suggested 
that DNA-based vaccine technology may find its me worth as a novel alternate hope for 
development of vaccines for diseases that conventional vaccines have been unsuccessful 
in controlling (Manickan et al., 1997). A difficult task for any vaccine let alone a novel 
technology. DNA-based vaccine technology represents a powerful and novel enny into 
the field of immunological control of disease. The spin-off research has also been 
dramatic and includes: the rediscovery of potency of bacterially derived DNA sequences 
(Gilkeson et ai., 1989) , and availability of a methodology that allows ememely rapid 
assessment and dissection of both antigens and immunity. The full utility of this 
technology has not yet been realized and yet the broad potential is clearly evident. Fume 
investigations of this technology must not be hindered by impatience, misunderstanding, 
lack of funding or failure of an informed collective and collaborative effort. 
DNA-based vaccines represent a recent, and novel, technological advancement in 
the field of vaccine development. These vaccines have been demonstrated to deviate 
immune responses in a manner dependent on: method or route of delivery, type of antigen 
encoded and identity of co-administered immunomodulatory molecules. .Mice and cattle 
develop humoral and cell-mediated immunity to plasmids encoding g lycoproteins B, C 
and D from bovine herpesvirus (BHV)-I, an economically important pathogen in cattle. 
However, details regarding the character of the immune responses to these plasmid 
encoded antigens are limited. Furthermore, the full utility of DNA-based vaccine 
technology to modulate immunity by co-administration of plasmids encoding cytokine(s) 
and antigens has only recently begun to be explored. During his graduate program, Dr. 
Graham Cox initiated studies on DNA-based vaccines using several plasmid encoded 
antigens from BHV- I. This was one of the early reports that plasmid based vaccines 
could induce immunity in animals. Despite this compelling evidence this novel vaccine 
technology has been greeted with skepticism by many involved in vaccine development 
and immunity. We hypothesize that immune responses to DNA-based vaccines represent 
a very real immunological phenomenon. The studies in this thesis are directed toward the 
characterization of immune responses in mice to DNA vaccines with the following 
specific aims: 
(i) Create plasmids that efficiently express plasma membrane anchored, secreted 
and intracellular versions of BHV- 1 gD. 
(ii) Immunize C3WHeN mice im with each of these DNA vaccines and 
determine the efficacy and character of immune responses. 
(iii) Create expression plasmids encoding each of eight different murine cytokines 
@-la, IL-2, IL-4, IL-6, IL-10, GM-CSF, IFN y, TNF a). 
(iv) Characterize immune responses in C3WHeN mice following co-delivery of 
plasmids encoding these cytokines with plasmids encoding a secreted form of 
BHV-1 gD. 
(v) Characterize the immune responses in passively immune mice (C3WHeN and 
C57BU6), following immunization with DNA and conventional vaccine 
formulations. 
3.0  MAC^ OF ,L\TIGEX COMPARTME,UTALUTIOX ON THE bfMUh'E ~ S P O S S E  IS
C3H/HeN MICE RECEIVISG DNA-BASED VACC~XS 
3.1 Introduction 
Bovine herpesvirus - 1 is a member of the subfamily Alphaherpesvirinae and is the 
causative agent of infectious bovine rhinotracheitis (IBR) and infectious pustular 
vulvovaginitis (IPV) (Roirman et al., 198 1; van Drunen Littel-van den Hurk et al., 
1993a). BHV- 1 has also been described as a component of the etiology of certain 
conjunctival infections, abortions, meningoencephalitic diseases and infectious 
balanoposthitis (Gibbs and Rweyemamu, 1977; Wyler et al., 1989). Finally, it has been 
suggested that BHV-1 may be the primary viral agent involved in the development of 
secondary opportunistic bacterial infections leading to "shipping fever" in cattle (Y ates, 
1982; Tikoo et al., 1995). Of the 13 proteins associated with the viral lipid envelope 
glycoproteins B (gB), C (gC) D (gD) are consistently recognized by convalescent sera 
from BHV-1 infected animals (Collins et al., 1985; van Drunen Littel-van den Hurk and 
Babiuk, 1986). Immunization of cattle with each of these individual glycoproteins, 
formulated with a conventional adjuvant, Leads to protective immune responses that 
include: neutdizing serum antibodies and cell-mediated immunity (CMI) (Babiuk et al., 
1987; Hutchings et al., 1990; van Drunen Littel-van den Hurk et al., 1993b; Tikoo et al., 
1995). -tion of cattle with gD typically results in humoral responses of the 
greatest magnitude and most consistent CMI (Babiuk et al., 1987; van h e n  Linel-van 
den Hurk et al., 1993b). Also, gD has been demonstrated to efficiently induce CMI and 
humoral immune responses in C57BU6 (H-2b) mice following immunization in a novel 
water-in4 adjuvant (Baca-Estrada et al., 1 996). Finally, it was previously 
demonstrated that a DNA-based vaccine, encoding the authentic, membrane anchored 
versions of gB, gC and gD, efficiently induced humorai immune responses in BALB/c 
(H-Zd) mice and cattle (gD only) (Cox et al., 1993). 
DNA immunization, also termed Polynucleotide, Nucleic acid or Genetic 
immunization, represents an exciting, novel approach to eliciting protective immune 
responses in animals (Tang et al., 1992; Domelly et al., 1993; Ed and Xiang, 1996; 
Hassen and Lindsay Whitton, 1996; ULmer et al., l996a). This "third revolution" in 
vaccinology involves the introduction of naked , bacterially derived, p lasmid DNA 
carrying eukaryotic gene regulatory elements driving the expression of genes encoding 
antigens (Waine and McManus, 1995). Delivery of these DNA-based vaccines involves 
direct injection-of plasmid DNA solubilized in saline or ballistic delivery of gold or 
tungsten microparticles coated with DNA (Haynes et al., 1996). Injection of DNA is 
typically intramuscular or intradermd ( i n  or i d ,  respectively), while a "gene ,w" 
delivers DNA directly to epidermal or hadermal sites. More recently, DNA encoding 
antigens or reporter genes have been delivered topically (epidermis) and mucosally 
(respiratory) in a number of species (Smiling et al., 1 992; Li and Hoffman, 1995; 
Wheeler et al., 1996). The mechanism whereby these naked DNA-based vaccines lead to 
highly efficacious immune responses is slowly being unravelled, however, somatic cell 
uptake of DNA, followed by expression of encoded antigen is a fundamental feature of 
DNA-based immunization (Raz et al., 1994; Condon et al., 1996; Corr et al., 1996; L h e r  
et al., 1996~). Antigen presentation by transiently transfected, professional antigen 
presenting cells (APC), or indirect presentation following acquisition of antigen from 
nonprofessional APC by professional APC, is a crucial component of the process (Raz et 
al., 1994; Condon et al,, 1996; Corr et al., 1996; Ulrner et al., 1996~). Recently, it has 
been demonstrated that bacterially derived DNAs exhibit a potent adjuvant effect that is a 
function of hypomethylated CpG motifs (Rsetsky, 1 996a; Pisetsky, 1997a). Regardless 
of the mechanistic hurdles remaining it is evident in light of the significant numbers and 
diversity of pathogens that have been immunized against and animal species that have 
been immunized that this method of immunization shows considerable promise. 
Another significant feature of DNA-based vaccines is the unique ability to activate 
both humoral and cell-mediated immune responses in vaccinated animals. It has also 
been stated that not only does the CMI manifest as potent CD8'facilitated cytolytic 
activity but the predominant C W  T helper (Th) subset is comprised of interferon 
y secreting Th 1 cells (LTLmer et al., 1996a). T helper cells have been classified into 
several major groups that include: Thl, Th2 and Th3 (Mosmann et al., 1986; Chen et al., 
1994). Th l cells are characterized by secretion of interleukin @,)-2, EN-y and tumour 
necrosis factor 0 - P .  Th2 cells are characterized by secretion of interleukins 4,5, 6 
and 10, while Th3 cells are proposed to be a suppressor population expressing 
transforming growth factor (TGF)-P, IL-10 and IL-4 . DNA-based vaccines have been 
suggested to be of greater benefit &an many conventional vaccine formulations because 
they induce a predominantly Th 1 - m e  of immune response that would be a more 
appropriate protective immune response against a variety of pathogens (Fresno et al., 
1997). 
Of course humoral immunity also plays a significant role in prevention of pathology 
and it has been shown that in many instances IgG, is a predominant isotype following 
immunization with DNA-based vaccines (Uher et al., 1996a). It has also been 
demonstrated that the Th 1 cytokne IFN-y is an important B-cell switch factor for the 
indudon of antigen-specific IgG, secreting B-cells and that many viral infections in 
mice result in a predominance of the isotype IgG, (Snapper and Paul, 1987; Coutelier et 
al., 1988; Coutelier et al., 199 1). Conversely, IgG, and particularly IgE antibody 
production occurs, at least in part, due to the presence of the Th2 cytokine IL-4 (Snapper 
and Paul, 1987). Of come  a variety of other factors, including: mouse strain, dose of 
antigen, type of pathogen, route of infection~imrnunization, vaccine fornulatons, antigen 
form (soluble or modified) and early induction of IL-6 can all have an impact on the 
specific character of the developing immune repertoire (Parish and Liew, 1971; Bretscher 
et al., 1992; Audibert and Lise, 1993; Yang et al., 1993; Aramaki et al., 1995; Guery et 
al., 1996; Co fbm and von der Weid, 1997). 
In an effort to further characterize the immune repertoire to a DNA-based vaccine we 
immunized C3WHeN @-29 mice with plasmids encoding several deletion mutants of 
BHV-1 gD. We characterized antigen-specific sewn IgG kinetics and duration, as well 
as predominant IgG isotypes. We also quantified the levels of antigen-specific Thl and 
Th2 cytokines in spleens and draining lymph nodes at various time points post 
immunization. Olrr initial data showed that C3WHeN mice receiving plasmids encoding 
cell-associated forms (cytosolic or plasma membrane anchored) developed senun isotype 
profiles that were predominantly IgG, with an almost exclusive production of the Th 1 
cytokine IFN-y following antigen restimulation of splenocytes in vim. We also 
observed that mice immunized with a plasmid encoding the secreted form of BHV- I gD 
displayed a predominance of IgG, in senun despite the presence of antigen-specific IFN-y 
secreting splenocytes. In an effort to understand the relationship between splenic Th 1 
profiles and a serum isotype that reflected the influence of I L 4  we determined the 
antigen-specific levels of IL-4, IFN-y and IgG isotype secrehhg B-cells from the iliac 
lymph node. This node is the primary draining node of the deep tissues of the quadriceps 
muscle mass. The data showed that draining lymph node cytokine and antigen-specific 
antibody isotype profiles more accurately reflect the predominant serum isotype of 
C3HMeN mice immunized with cell-associated or secreted forms of the BKV-I gD 
antigen. The relevance of these observations are discussed in the context of manipulating 
immune responses by connolling the intra or extracellular location of the antigen when it 
is fim seen by the immune system. 
3.2 Materials and Methods 
3 -2.1 Plasmid Construction 
AU restriction enzymes and DNA modifjmg enzymes, as well as markers and 
74 
plasmids, were purchased from Pharmacia (Pharmacia Biotech., Quebec) or New England 
Bioiabs (NEB Ltd., Mississauga, Ontario) unless indicated othenvise. Expression 
cassettes utilizing promoter/enhancer regions from MCMV (Murine Cytomegalovirus) 
and RSV-LTR (Rous Sarcoma Virus -Long Terminal Repeat) were constructed (see 
Table 3.1 ). These regulatory elements were placed in the high copy pSL3O 1 T" 
(Invitrogen, San Diego, CA) to generate the expression plasmids pMCEL.Nu1 and 
PSLRSV.Nu1 (Fig. la). Briefly, pMCEL plasmids were constructed by ablating the 
existing PstI and EcoRI sites within the superlinker region of pSL3 0 1 and reintroduction 
of PstI and EcoRI sites, through blunt end linker ligation (PstI linker CCTGCAGG; 
EcoRI linker pGGAATTCC), at the EcoRV and HpaI sites, respectively. Vector 
pSLPm-77 was created by ligating the EcoRI-PsrI fragment containing the MCMV 
enhancer/promoter From pEnhIU&lini into PstI-EcoRI digested pSLPNEN-77 to create 
pSLPbEN-77-MCE (Keil et al., 1987; Messerle et al., 1992). The expression cassettes 
pMCEL.AgD and pMCEL.SgD were generated by ligating the BumHI-PstI fragment from 
a pSL301 vector containing the SV40 polyadenylation site BamHI-Bgm fragment and the 
Bgm fragments of the 1300-bp fuil length BHV-I giycoprotein D (A@) and the 1300-bp 
gene encoding the secreted (SgD) form of gD (Fig. 3.1, A and B). Cleavage of this 
construct at the BamHI site and shifted PsrI site allowed movement of the entire gD 
sequence and short polyadenylation signal into PstI-BamHI digested pSLPNEN-77-MCE 
to create pMCEL.AgD and pMCEL.SgD. A pMCEL.Nu1 plasmid was created by 
dropping the AgD gene from pMCEL.AgD and religating the plasmids at the Bgm site. 
The pAL.AgD and pAL.SgD plasmids were generated by ligation of the BamHI-Ssp1 
Table 3.1 Vectors and plasmids utilized in this study 
- - - 
Plasmids Relevant characteristics (references) 
pSUO I Tm .................... high copy number cloning plasnid with superlinker region ( Inv inop)  
pSLPNEN- 77.. ........... PssI and EcoM sites "movedn to EcoRV and HpaI sites respectively (this study) 
pEnhIE3Mini ............... MCMV enhancer and ie3 transcription unit (Ked et al., 1987; Messerle et al., 1992) 
pSLPNEN-77-MCE .... &I EcoRI fiagment of pf-nhiFtMini inserted into Psd, EcoRI cut pSLPNEN-77 
pMCEL44gD ............... MCMV promoter + authentic BHV-I gD (A@) + SV40 polyA+ signal ( ~ s  study)
pMCELSgD ............... MCMV promoter + secreted BHV-1 gD (S-@) and SV40 polyA+ signal (this snrdy) 
pMCEL-Nul ................ MCMV promoter with no gene and SV40 poiyA+ signid (this study) 
pALAgD .................... MCMV promoter + authentic BHV- 1 gD and long SV40 polyA+ s i g d  (this study) 
pAL.S@ ..................... IM W promoter + secreted BHV- 1 _$I and long SV40 poIyA+ signaI (this study) 
pSLRSV-AgD ............. RSV promoter with authentic BHV-1 gD and W4O polyA+ signal (this study) 
pSLRSV.SgD .............. RSV promoter with secreted BHV- I gD and SV40 polyA+ si@ (this study) 
pSLRSV-CgD ............. RSV promoter with cytosolicBHV- 1 gD and SV40 polyA+ signal (this mdy) 
pSLRSV.Nul ............... RSV promoter with no gene and SV40 polyA+ signal (this study) 
pRSVl.3 ..................... RSV promoter with authentic BHV-1 gD on pBR322 backbone flikoo et al., 1993) 
pRSV1.3* ................... RSV promoter with secreted BHV-I gD on pBR322 backbone (Tikoo et al., 1993) 
pAA505 ...................... prokayotic expression cassette derived fiom pGH433 (Theisen et al., 1992). 
fi-agment of the SV40 polyadenylation signal from psv2neoTm (CLOhTECH Lab, Inc., 
Palo Alto, CA) into an end repaired BstEII digest, followed by BamHI digested 
pMCEL.AgD and pMCEL.AgD (van den Hoffet al., 1993). Plasmids pSLRSV.AgD and 
pSLRSV.S@ were created by ligating the 947-bp NdeI fiagment from pRSV1.3 and 
ligating it into NdeI digested pMCEL.AgD and pMCEL.SgD. The NdeI fragment from 
pRSV1.3 contains the RSV-LTR promoted enhancer region and a pomon of the 5' end of 
the gD gene. Ligation of a 585-bp NdeI-Bgm fragment from pRSV1.3 ligated into NdeI- 
Bgm digested pMCEL.Nul generated plasmid pSLRSV.NuI (Tikoo et al., 1990; Tikuo et 
al., 1993). 
Fig. 3.1 Diagrammatic depiction of expression cassettes. Fig 3.1 A depicts three null 
vectors with RSV LTR or MCMV immediate early enhancer/promoter elements. Fig. 3.1 
B depicts membrane anchored (AgD), secreted (SgD) and cytosolic (CgD) forms of 
BHV- I gD utilized in this research. Expression cassettes all utilized the high copy 
number pSL3O IT" plasmid backbone and enhancer/promoter elements from either RSV- 
LTR or MCMV. Polyadenylation signal were derived from SV40 as described. All genes 
encoding full length or truncated versions of B W-1 gD were inserted at the Bgm site 
(v). The evolution of secreted and cytosolic version of BHV-1 gD are shown (B) as are 
details regarding relevant changes in coding sequences, start codons (CgD) and 
termination codons. Gene/consmct designations are indicated to the immediate right of 
each diagram. 
Exmession Cassettes 
Membrane anchored secreted and cvtosolic 
versions of BHV-l eD 
Creation of an expression cassette expressing a secreted, or rmncated version of 
BHV-1 gD was described previously (Tikoo et al., 1993). Briefly, piasmid 
pRSV13gDt, which encodes a truncated f o m  of gD was generated by introduction of a 
unique XhoI site at the Sac11 site immediately adjacent to the transmembrane domain of 
pRSV1.3 encoding the full lecgth, or authentic. gene for BHV- 1 gD. Following 
restriction digestion and end repair this unique XhoI site was blunt-end ligated to a shon 
linker sequence encoding the unique restriction site M e  I and three stop codons (Fig. 
3.1, B). Expression of this truncated gene leads to secretion of a glycosylated product of 
approximately 62-kDa (Tikoo et al., 1993). Plasmid pSLRSV.CgD encodes a cytosolic, 
or intracellular, version of B W - l  gD that lacks both the signal sequence and 
aansmembrane domain encoded within authentic, full length, gD m o o  et ai., 1990). 
This construct was generated by subcloning the XcaI-NheI subftagment of pSLRSV.SgD 
into XcaI-NheI digested pSL301. This clone was digested with XcaI and EcoRV and the 
gD fragment blunt end ligated into SmaI digested pAA505. The prokaryotic expression 
cassette pAA505 is a derivative of pGH433 with a multiple cloning site consisting of 
.VcoI, BamHI, and SmaI downstream from a tac promoter (Theisen et al., 1992). 
Appropriate orientation of the ligation product created a novel start codon contributed by 
pAA505 followed by Asp and Pro prior to in-frame commencement of the g D  amino acid 
sequence Tyr Val Asp Pro ....... immediately downstream from the signal peptide sequence 
(Fig. 3.1, B). Clone pAACgD was digested with DdeI and Eco47m, end repaired with 
the Klenow fragment of E. coli DNA polymerase I and blunt end ligated to a BgZII linker 
containing in-frame stop codons (GTAGCTAGATCTG) . This ligation product was then 
digested with Bgm , purified with Geneclean Kit (BIO 10 1, Inc.,Vista, CA), and Ligated 
into Bgm digested pSLRSV.Nul. This construct displays 6 additional amino acids (Met- 
Arg-Lys-Phe-Lys-Ala), contributed by the NheI-EcoRV fragment of pSL30 1, at the 
carboxy terminus. 
3-22 Bacterial Hosts, Mannnalian Cell Lines and Tissue Culture Reagents. 
JM105 (New England Biolabs, Inc.), HB 10 1 (Invitrogen), and DH5a 
(CLONTECH Laboratories, Inc.) were the bacterial mains used to amplify plasmid DNA. 
Murine L929 connective tissue cell Line was received from American Type Culture 
Collection (ATCC, Rockville, MD.), (NCTC clone 929). Madin Darby Bovine Kidney 
W B K )  cell line was obtained from ATCC (# CCL 22). C3WHeNCrLBR and C57BU6 
mice were purchased from Charles River (Charles hver, St. Constante, Quebec). All 
media and media supplements were purchased from GIBCO/BRL (GIBCOlBRL, 
Burlington, Ontario) or Sigma (Sigma Chemical Co., St. Louis, MO), unless othenvise 
indicated. AU tissue cuitrne plasticware was purchased from Coming (Coming Inc., 
Coming, N.Y.) or Costar (Costar/NucIeopore Canada Inc., Toronto, Ontario), unless 
indicated otherwise. 
3 2.3 Stable Transfections 
Plasmids encoding secreted or cytosolic versions of BHV-1 gD were mixed with 
a pSV2neo (CLONTECH) encoding G4l8 (GeneticinTm ;GIBCO5R.L) resistance at a 
ratio of 8 pg :2 pg, respectively, and used to transfect L929 cells. LipofectinTm 
(GIBCO/'BRL) mediated msfection was camed out using the following protocol: DNA 
was incubated with LipofectinTm for 15 minutes in Optimem (GIBCOBRL) media, 
preconfluent cell monolayers were washed several times with warmed Optirnem and after 
the final wash the DNA:Lipofecrin mixture was added. The DNA:Lipid mixture was 
removed after 6 hours and the cells incubated overnight in MEM (GIBCOBRL) 
supplemented with 10% fetal bovine senun (FBS) (Sigma Chemical Co.), 100 U/mL of 
penicillin, and 100 pg/mL of meptornycin (Sigma Chemical Co.), 2 rnM L-glutatnine 
(GIBCO/BRL) ImM sodium pyruvate (GIBCOlBRL) . Monolayers were split (following 
trypsinization) to ten 100 mm tissue culture dishes and maintained in complete MEM 
with 400 pg/mL G4l8 for 10-14 days. Media was changed every 3 days during this time. 
Single G4 18 resistant colonies were harvested using silicon greased cloning cylinders 
(Bellco Glass Inc., Vineland, NJ.) and trypsinization. Harvested colonies were 
transferred to individual wells of either 96 or 48 well tissue culture piates. Individual 
(3418 resistant clones were expanded to 24 well plates and the culture fluids were 
harvested for detection of secreted BHV-1 gD. Monolayers were harvested for SDS- 
PAGE using a modified NP40 lysis buffer protocol (Harlow and Lane, 1988). Putative 
gD secreting stable transfectants were harvested into freezing media (90% FBS and 10% 
dimethylsulfoxide, sterile filtered) and froren ovemight at -70 OC. Frozen stable 
transfectants were then transferred into liquid nitrogen until needed. 
Immunoprecipitation of SgD involved mixing of 1.0 mL of fresh or thawed (following 
storage at -70 OC) media, harvested from confluent G418 resistant clones, with 200 pL of 
5x binding buffer (750 mM NaCI, 200 mM Tris-HC1, pH 7.6; 10 mM EDTA, pH 8.0; 
80 
0.5% NP-40) containing 5 mM phenylmethylsulfonyl flouride (PMSF) and 1 -0 pL of an 
anti-@ monoclonal antibody pool (mAbs -t 9D6,3D9, 10C2,2C8, PB 136,3E7,3C 1 
and 4C1) at a dilution of i.5:lO (in lx binding buffer) (Hughes et al., 1988; van m e n  
Littel-van den Hurk et al., 1990). Binding was allowed to proceed for 3 hours at 4 "C, 
with mixing, on an Adams nutator (Model 1 105, Clay Adams, Division of Becron 
Dickinson and Co., Parssipany, N.J.). Protein G Sepharose (Pharmacia) in a modified 
RIPA buffer (50 mM TridHCl, pH 7.4, 150 mM NaC1,1% Triton X- 100, 1 % 
deoxycholate, 0.5% sodium dodecylsulfate, 10 mM EDTA) was mixed with the samples 
and allowed to bind for 3-4 hours. Samples were precipitated by spinning for 30 seconds 
in an Eppendorf Centrifuge 5411 (Eirinlrman Instruments, Rexdale, Ontario), (16,000 x 
g). Pellets were washed two times with lx binding buffer and then solubilized in a 
nonreducing (no P-mercaptoethanol) SDS-PAGE loading buffer. Samples were loaded 
onto a 10 % SDS-PAGE minigel (Bio-Rad Lab. Ltd., Mississauga, Ontario) and 
electrophoresed at 120 volts for 60 minutes. Gels were electroblotted onto 
nitrocellulose (BIO-RAD) using the recommended blotting procedure (Bio-Rad). 
Nitrocellulose blots were blocked for 1-2 hours with 3% gelatin (Bio-Rad) in Tris- 
buffered saline with 0.05% Tween-20 (Sigma Chemical Co.) and then incubated for 1-2 
hours with a 1: 1000 dilution of the anti@ monoclonal pool in Tris-buffered saline with 
Tween 20 (TBST) with 1% BSA. Development involved a 90 minute incubation with a 
biotinylated goat anti-mouse IgG (Zyrned Laboratories Inc., San Francisco, CA) at 1: 1000 
dilution followed by a 60 minute incubation with a 1 : 1000 dilution of Streptavidin- 
alkaline phosphatase conjugate (GIBCOISRL). Development was carried out using 5- 
bromo-4-choro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium (NBT) substrates 
(Bio-Rad). The development reaction was stopped by extensive washing in tapwater. 
3.2.4 Transient Transfection of C O W  cells with pSLRSV.AgD, pSLRSV.SgD 
and pSLRSV.CgD. 
COS-7 celis at 70-80% confluency in six-well tissue culture plates, were 
transfected with 5 pg of plasmid DNA for 5 hours in serum free OptimemTm .
LipofectamineTm (GIBCO-BRL) was utilized to facilitate transfection at a ratio of 5pg 
Lipofectamine: 1pg plasmid DNA. DNA was purified with Qiagen columns (Qiagen hc., 
Santa Clarita, CA) and combined with Lipofectamine as described in the protocol insert. 
OptimemTm containing DNA:Lipid complexes was removed from cells afier 5 hours and 
complete media containing glucose (DMEM) and 15 % FBS was added to the cells. After 
12 hours msfecred cell monolayen were washed with warm phosphate buffered saline 
(PBS-0.13 7 M NaCl, 0.003 M KCI, 0.008 M Na_HPO,, 0.00 1 M NaHZPO,) and 1.5 rnL 
of methionine free MEM containing 2% dialysed FBS and 50 pCi/mL of 3sS-labelled L- 
Methionhe (Tran3SS-~abelTm, ICN Pharmaceuticals, Inc., St. Laurent, Quebec) was added 
to each well. Cells were incubated for 24 hours and harvested for immunoprecipitation. 
Media was collected and centrifbged (16,000 x g) in 1.5 rnL eppendod tubes for 5 
minutes to remove debris. Supernatants were aspirated to clean labelled tubes and either 
processed immediately or stored at -20 "C until needed. Tmmunoprecipitation of gD from 
supernatants was canied out by mixing 800 pL of media with 200 pL of 5x binding 
buffer containing the protease inhibitors: Aprotinin, Leupeptin, Antipain, PMSF (40 
ps/mL, 5 p@mL, 5 pg/mL and 200 pg/mL, respectively), and 1 pL of a 1 : 10 dilution of 
an anti-@ mAb pool. Samples were incubated, at 4"C, for 3 hours on a nutator. 
Precipitates were collected by centrifugation after incubation with 100 ng Sepharose-G 
equilibrated in RIPA buff& Detection of cell membrane associated gD was carried out by 
extensive washing of rransfected cell monolayen, with warm PBS, followed by a 37 "C 
incubation of monolayers in 500 pL PBS containing 6.0 pL of a 1: 10 dilution of an anti- 
gD mAb pool. AAer a 60 minute incubation, the monolayer was washed extensively and 
lysed on ice for 10 minutes in 500 pL  Dissociation buffer (0.5 % NP-40,0.5% Triton X- 
1 00, 15 0 mM NaCI, and 50 mM Tris-HCl, pH 7.4) containing the protease inhibitors: 
Aprodnin, Leupeptin, Antipain and PMSF, at final concentrations of, 8.0, 1.0, 1.0 and 
40.0 pgs/mL, respectively. After incubation, solubilized monolayers were pipetted up and 
down several times and collected into a 1.5 mL Eppendorf tube. Samples were 
centrifuged (16,000 x g) for 2 minutes in an Eppendorf centrifuge and supernates 
transferred to a clean 1.5 mL Eppendorf rube. Samples were mixed with 200 pL of RIPA 
buffer containing protease inhibitors and 120 pL Sepharose-G (100 ng) equilibrated in 
RIPA buffer. Samples were incubated for 3 hours, at 4 "C, on an Adam nutator prior to 
harvest. 
Cell lysates were prepared as described for detection of membrane associated gD 
except that the pre-incubation with an anti-@ mAb pool was eliminated. Following a 2 
minute centrifugation (1 6,000 x g), cleared supernatants were transferred to new 1.5 mL 
Eppendorf tubes. Aliquots (200 pL) of these cell lysates were irnmunoprecipitated by 
mixing with 800 pL, of RIPA buffer containing protease inhibitors and 1 pL of a 1 : 10 
dilution of anti-gD mAb pool. These samples were incubated for 3 hours, at 4 "C, on a 
nutator. After this primary incubation, immunoprecipitates were harvested by incubating 
for 3 hours with 100 ng Sepharose-G and centrifugation (16,000 x g) for 30 seconds in an 
Eppendorf microfbge. 
All immunoprocipitated pellets were washed 2 times in 500 & cold RIPA buffer 
containing protease inhibitors. Following the final wash, pellets were resuspended in 40 
pL of a 1.5 x reducing SDS-PAGE loading buffer. Samples were mixed, boiled for 3 
minutes and chilled on ice for 5 minutes prior to loading on a 12 x 1 6 crn SDS-PAGE 
gel (4% stacking and 10% separating). Elecrophoresis was carried out for 4 hours at 180 
volts. Gels were fixed (40% methanol, 10 % acetic acid) for 15 minutes and equilibrated 
for 30 minutes in a fluorographic agent @rnplifyT", Amersham, Oakville, Ontario). Gels 
were dried, under vacuum; at 80 O C  for 2 hours and exposed to preflashed Kodak X- 
OM AT^" AR film for 12-24 hours. 
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3.2.5 Mouse Injections and Identification of Draining Lymph Nodes 
Inbred 7 week old, female C3WHeNCrlBR mice were injected with column 
purified (QIAGEN Inc.) plasmid DNA dissolved in normal saline. All injections of DNA 
were im. while injections of purified antigen (authentic or recombinant truncated gD) 
formulated in either VSA3 (Biostar, Saskatoon, Saskatchewan) or alum (~lhydrogel'~, 
Cedarlane Laboratories Ltd., Homby, Ontario) were subcutaneous (s.q.) . Mice in 
experiment I Fig. 3.4) received injections of 100 pg plasmid DNA (2.0 pg/ pL in 
normal saline) in the left quadriceps only. All other mice received injections of 50 pg of 
plasmid DNA in the lefi and righr ~uadriceps muscle mass using DNA at a concentration 
of 1.0 pgl pL. All mice were boosted at 14 days. Nonlethal tail bleeds were canied out 
every 2 weeks until the experiments were terminated. Identification of the lymph nodes 
draining the quadriceps muscle mass was carried out by i m injection of 7 week old 
C3WHeN mice with either a 2% Evans blue dye (in normal saline) or column purified 
plasmids pSLRSV.AgD or pSLRSV.Nul. Mice receiving Evans Blue dye were 
euthanized with a HalothaneTm (MTC Pharmaceutical, Cambridge, Ontario) overdose 
between 5 and 20 minutes after injection. Colour photographs of dissected dye injected 
mice were taken using a Nikon F3 camera with a macro lens and Ektachrome 60 color 
film DNA injected mice were euthanized at either 20 minutes or 20 hours post-injection 
and iliac or inguinal lymph nodes flash fkozen in liquid nitrogen. Rash frozen lymph 
nodes were stored at -70 "C, in labelled 1.5 mL mjcrohge tubes, until isolation of cellular 
DNA and amplification of a portion of BHV-1 gD by polymerase chain reaction (PCR) 
could be camed out. Isolation of DNA for PCR was carried out using a Proteinase K 
digestion protocol (Wright and Manos, 1990). PCR was carried out using the following 
primers: Sense primer-TTCTCGMCTCGGCGCGGCT and antisense primer- 
TTCGAGGCTCGGC CAGCCTTC . These primers generate a 435 bp product that 
commences at base 53 1 downstream fiom the start codon (Tikoo et al., 1990). The PCR 
reaction for detection of BHV- 1 has been described previously (Vicek, 1993). Briefly, 
detection of the BHV-1 gD sequence, using PCR, was carried out in a final volume of 
100 @, using Taq polymerase, and included: 1.0 fi of DNA prepared fiom lymph 
nodes, 5 mM dNTPs, 50 pmol oligonucleotide primers and glycerol (final concentration 
85 
of 10 %). Following 8 minutes of denaturation at 95 O C  (under a mineral oil owelay), 5 
minutes of quick chilling on ice, the sample was cycied on a thennocycler using the 
following parameters: denaturation at 95 "C for 70 seconds., annealing at 56 "C for 60 
seconds, and extension at 73 "C for 50 seconds. Polymerase chain reaction products were 
assessed by electrophoresis on 1 .Z % agarose gel in the presence of ethidium bromide. 
3.1.6 Splenic and Lymph Node Cell Harvests 
Mouse splenocytes were prepared by mechanically grinding spleens through a 
sterile nylon mesh into a sterile Peai dish containing 10-20 mL of RPMI 1640 (Sigma 
Chemical Co.). This material was then pipetted into sterile 15 or 50 mL tubes and 
allowed to settle on ice for 10 minutes. Debris that settled to the bottom was aspirated 
with a sterile Pasteur pipette and discarded. Tubes were centrifuged at 250 x g, in a 
Beckman GPR centrifuge, for 10 minutes (at 4 "C). Red blood cells were lysed by 
resuspension of cell pellets in 1.0 Wspleen of ammonium chloride lysis buffer (0.14 M 
M,Cl and 0.0 17 M Tris-HCl, pH 7.2) for 60 seconds. Lysis was terminated by the 
addition of 14 mL of RPMI 1640 at ambient temperature. Samples were pelleted by 
cenaifugation at 250 x g, and resuspended in RPMI 1640 media. Splenocyte numbers 
were assessed by staining with trypan blue (GIBCOBRL) and counting with the aid of a 
haemocytometer. Splenocytes were centrifuged (250 x g) and resuspended at a final 
concentration of 1 x 1 O7 ceWmL in RPMl1640 supplemented with 10% FBS, 100 U/mL 
of penicillin and 100 pg/mL of ~eptomycin (Sigma Chemical Co.), 2 mM L-glutamine 
(GBCO/BRL), 1 mM sodium pyruvate (GIBCOBRL), 10 m M  HEPES (GIBCO/BRL) 
and 5 x lo-' M 2-mercaptoethanol (Sigma Chemical Co.), (complete RPMI- 1 640). 
A modification of the method for harvesting Peyers patch lymphocytes was 
utilized to prepare single cell suspensions from lymph nodes (Spalding et al., 1983) . 
Briefly, lymph nodes were collected into 15 mL tubes containing sterile chilled 
phosphate buffered saline without calcium or magnesium(PBSA)(GIBCO/BRL). Pooled 
nodes were decanted into a sterile f e m  dish and excess PBSA discarded. Nodes were 
diced with a sterile scalpel in a small volume of CXE solution {O. 1 x Hanks Balanced 
Salt Solution (HBSS), Ca" Mg" free; 10 m M  Hepes, pH 7.2; 25 mM NaHCO,, pH 7.2; 
and 2% FBS) and then mixed with 10 mL digestion buffer ( 1 x HBSS, 10% FBS, 15 
mM HEPES, pH 7.2) containing 150 UnitdmL of Collagenase (CLS 1, Worthington 
Biochemical Corporation), and 0.0 15 m g h L  DNase I (Pharmacia Biotech. Inc.). Diced 
nodes in digestion buffer were transferred to silanized 25 -50 rnL Erhlenmeyer flasks, 
containing a sterile Teflon coated stir bar, and incubated at 37 OC,with stining, for 90 
minutes. Samples were harvested into sterile 15 mL plastic tubes and allowed to sit for 
10 minutes. Large pieces of undigested material were aspirated back into the Erhlenmeyer 
flask and incubated an additional 30-60 minutes with 5.0 ml of digestion buffer. This 
material was combined with the initial harvest and cells were pelleted by cenmfitgation 
(250 x g). Digestion buffer was decanted and the cells were resuspended in phosphate 
buffered saline without Cat+ (PBSA), (GIBCOBRL). Cells were counted using a 
haemocytometer and centrifuged (250 x g) one final time. Cells were resuspended to a 
final concentration of I x 10' ceUs/mL. 
A modified protocol for splenocytes included an additonal60 minute 
digestion of pooled splenocytes with collagenase (150 Units/mL of digestion buffer) and 
DNase I ( 0.0 15 rn@ of digestion buffer). These digeaions were only carried out in 
experiments that assessed antigen-specific responses from cells prepared from lymph 
nodes. These digestions were carried out prior to cell counts and resuspension. 
3.2.7 Total IgG and IgG Isotype ELISA 
Immunlon 2 microtine plates (Dynatech Laboratories Inc., Alexandria, VA) were 
coated with purified recombinant truncated gD (Biostar Inc.) at a concentration of 0.050 
pg/we11. Coating antigen dilutions were done in ELISA Coating buffer (.012 M Na_CO,, 
-038 M NaHCO;, pH 9.6 ) and coating was allowed to proceed overnight at 4°C. Plates 
were washed 5 times in phosphate buffered saline (. 137 M NaC1, .003 M KCI, -008 M 
Na$PO,, -001 M NaH2P0, ) with 0.05% Tween-20 (PBST) prior to addition of fourfold 
dilutions of mouse sera prepared in PBST with 0.5% gelatin (PBST-g), (Bio-Rad 
Laboratories Ltd., Mississuaga, Ontario). After a 2 hour incubation, plates were washed 
in PBST and an afEnity purified biotinylated goat antimouse Ig (Zymed Laboratories Inc., 
San Francisco, CA) diluted to 1/5,000 in PBST-g was added to each plate. After an 
incubation of 60 minutes, plates were washed extensively and Streptavidin-alkaline 
phosphatase (Gibco, Life Technologies, Burlington, Ontario) diluted to 1/2000, in PBST- 
g, was added to each plate. Following a 60 minute incubation, plates were washed six 
times in PBST. Prior to addition of submate the plates were washed two additional times 
in PBS. Development of plates involved the addition of .01 M p-nitrophenyl phosphate 
(Sigma Chemical Co., St. Louis, MO) in substrate buffer (0.104 M Diethanolamine- 
Sigma Chemical Co., 0.5 mM MgCLZ- ). Absorbances were read on a Model 3550 
Microplate Reader (Bio-Rad Laboratories Ltd.) at 30 minutes and again at 60 minutes at 
405 nm with a reference wavelength of 490 nm. Antibody isotyping ELIS As were 
carried out in a similar fashion except that biotinylated goat antirnurine IgG, , IgG, , 
IgG,, , IgG, , IgM (Caltag Laboratories, San Francisco, CA) were used at a dilution of 
1/8,000 except for IgM (1!2,000 ). Incubation times with these antiiodies was 60 
minutes. Addidon of Streptavidin-alkaline phosp hatase and development of plates was as 
decribed for total IgG ELISA. 
3.2.8 ELISPOTs. 
A cytokine specific ELISPOT assay was used as described previously (Czerkinsky 
et al., 1988; Baca-Estrada et al., 1996). Briefly, single cell suspensions isolated from 
spleens, lymph nodes or bone marrow were stimulated in-vitro by incubating in complete 
RPMI 1640 at 37 "C and 5% C02 for 20 hours in the presence of recombinant authentic 
gD (0.4 pglmL). After antigen stimulation, cells were washed twice in complete media 
and diluted to a concentration of 1 x 10' ce1Wm.L of complete RPMI- 1640. 
Nitrocellulose plates (FILTAplateTm, 0.45 Polyfiltronics, Inc., Rockland, MA, USA) 
were prepared by coating overnight at 4 "C with 2.5 pg/xnL. of purified antimurine 
interleukin (IL)-4 (Cat. No. 1 1 B 1 1) or 5 pg!rnL of purified aatimurine interfkron 0 - y  
(Cat No. R4-6A2) (Pharrningen, San Diego, CA, USA) diluted in carbonatelbicarbonate 
buffer (45.3 mM NaHCO,, 18.2 mM N+CO,, pH 9.6). After coating, unbound antibody 
was washed from the wells thrice with sterile PBST followed by 3 washes with sterile 
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PBS. Wells were blocked for 2 hours at 37 "C with complete RPMI 1640. Blocking 
media was decanted and 100 pL of antigen stimulated cell suspensions were added to 
triplicate wells. After a 20 hour incubation, at 37 "C and 5% CO, plares were washed 2 
times in tapwater and 5 times in PBST to remove cells and nonspecifically bound 
cytokine. One hundred pL of biotinylated antimurine IL-4 (Cat. No. BVD6-24G2) and 
IFN-y (Cat. No. XIMG1.2) (Pharmingen Canada Inc.) monoclonal antibodies (3 pg/mL of 
each in 1% FBSPBS) were added to appropriate wells and incubated for 4-6 hours at 
ambient temperature on an oscillating mixer. Plates were washed 6 times in PBS T and 
100 pL of a 111000 dilution of Streptavidin alkaline phosphatase (BiolCan Scientific, 
Mssissauga, Ontario, Canada) in 1 % FBSPBS was added to each well. After a 2 hour 
incubation, at ambient temperature, the plates were washed twice in PBS. Plates were 
deveioped by the addition of 50 p L  of the substrates, 5-bromo43-indolyl phosphate 
(BCIP), and nitroblue tetrazolium (NBT), (Moss kc., Pasadena, MD). Plates were 
allowed to develop at ambient temperature for 10-30 minutes, after which reations were 
stopped by extensive washing in distilled water. After air drying, spots were counted 
under a dissecting microscope. B-cell ELISPOT involved the use of niaocellulose plates 
(Millipore Milliscreen-HA, Millipore, Bedford, MA) that were coated overnight at 4 'C 
with purified recombinant truncated gD at 5.0 yg/mL in c&onate/bicarbonate buffer 
(pH 9.6). Coated plates were washed three times in sterile PBST followed by 3 washes in 
sterile PBS. Nonspecific binding sites were then blocked with complete RPMI 1640 at 37 
"C for 1-2 hours. Fresh, unstimulated cells from spleen or lymph nodes, prepared as 
descnbed above, were added in a volume of 100 pL (1 x 10' cel.Is/mL) to each well. 
Uncoated but blocked control wells, for nonspecific binding of IgG, also received cells 
from each test sample in triplicate. Plates were incubated at 3 7 O C  with 5% CO1 for 1 0- 12 
hours. After the incubation period, all cells were washed out of the wells by 2 washes 
with tapwater followed by 6 washes with PBST. Biotinylated antimurine IgG, or IgG, 
antibodies (1/8,000 dilution) were added in a 100 pL volume of PBST (with 1% FBS) 
and incubated with mixing for 3 4  hours at ambient temperature. After washing in PBST 
six times, streptavidin--a1kalne phosphatase (1/1,000 dilution in PBS-T with 1% FBS) 
was added to each we11 (100 pL). After a 60 minute incubation, plates were washed six 
times in PBST and 2 times in PBS. Plates were developed as described for the cytokine 
ELISPOT. 
3 -2 -9 Saum Neutralization Assays 
Sera from mice immunized with DNA-based, or conventional vaccines were 
assayed for virus neutralizing capacity by a BHV-1 plaque reduction assay as described 
previously (Babiuk et al., 1975). Briefly, 1 10 pL of 2- or 4-fold dilutions of heat 
inactivated sera (in RPMI 1640 containing 2% FBS and 1 :40 dilution of guinea pig 
complement; GIBCO/BRL ) were mixed with 110 pL of live BHV-1 for 60 minutes. 
Following incubation, 100 pL of each dilution were placed on confluent MDBK cells, in 
duplicate, in a 96 well flat bottomed culture plate (Nunc Inc., Naperville, ll). Plates were 
incubated for 48 hours and plaques were visualized by decanting the media overlay and 
staining cells with (1% Crystal violet in 70% ethanol). Neutralizing titers are expressed 
as the reciprocal of the highest dilution of antibody that caused 50% reduction of plaques 
relative to the virus control wells. 
3 -2.10 Statistical Analysis 
Data was entered into a database in the statistical analysis program Instat 
GraphPadTm. Differences in antibody titers among vaccine groups were investigated using 
the nonparametric Mann- Whimey U test. 
3.3 Results 
3.3.1 In vitro transfection of COS-7 and L929 cells. 
Transient and stable transfection of COS-7 and L929 cells with expression 
plasmids demonstrate function and cellular compartmentalization of BHV-1 gD deletion 
mutants. Table 3.1 and Fig.3.1 depict expression cassette nomenclature and evolution of 
expression cassettes utilized in this study. Although in vino expression of the authentic 
and secreted forms of BHV-1 gD has been described previously (Tikoo, 1990; Tikoo, 
1993), we felt that subcloning of genes and novel regulatory elements to pSL30 lTm 
justified further assessment. We also needed to ensure that the cytosolic (CgD), authentic 
(A@), and secreted (SgD) forms of BHV-1 gD occurred within the appropriate, and 
predicted, cell compartment. Fig. 3 2  A clearly demonstrates that RSV-LTR and MCMV 
immediate early promoter driven secretion of the truncated version of BHV-I gD occurs 
effectively. It is difficult to accurately assess the level of expression from this 
immunoprecipitation data despite the fact that this information was generated from stable 
transfected subclones. These stable msfected lines grew with distinct kinetics and 
media requirements which made expression strength comparisons between clones 
difficult. These cell lines were also prone to exhibiting an inexplicable loss of expression. 
However, radioimmunoprecipitation of 4 of the 5 subcloned lines (the specific subclone 
stable transfected with pMCEL.SgD lost the ability to express gD) suggested that the 
pAL+.SgD construct outperformed the RSV-LTR driven constructs in vino (Fig. 3.2, B) It 
is difficult to attribute this apparent enhanced expression to either, the presence of the 
MCMV immediate early enhancer/promoter element, or the longer SV40 
polyadenyiation. However, in vivo evidence suggests the presence of the longer 
polyadenylation signal conaibutes to the expression strength of this cassette (refer to 
serum IgG titer levels in mice immunized with pMCEL constructs versus PAL constructs 
in Fig. 3.4, and Table 3.2). Despite early, in vitro evidence that PAL constructs 
outperformed the RSV-LTR constructs, the PAL plasmids were difficult to propagate in 
several bacterial strains. These plasmids w odd only replicate in HB 1 0 1 E. coli and yields 
were typically lower than observed for plasmids containing the RSV-LTR elements and 
grown in DH-5a bacterial. For these reasons, and because in vivo data suggested there 
was little advantage to be gained from using the PAL constructs, all subsequent 
experiments involved the use of pSLRSV constructs. COS-7 cells transiently transfected 
with plasrnids: pSLRSV.AgD, pSLRSV.SgD and pSLRSV.CgD clearly show that these 
constructs express gD predominantly at the plasma membrane @SLRSV.AgD), 
Fig. 3.2 i n  v i m  expression fiom plasmids encoding a secreted form of BHV-1 gD. 
Western blot (3.2 A) and radioimmunoprecipitate (3.2 B) analysis of media fkom L929 
cells stably transfected with expression cassette encoding the secreted form of BHV- 1 gD 
(SgD). Cultures at -80% confluency, in six well plates received 2.0 mL of media and 
were incubated for -30 hours. Unlabelled and radiolabelled secreted gD was 
irnrnunoprecipitated from media (1.0 mL) with a monoclonal pool and Sepharose G. 
Immunoprecipitated proteins were mixed with a nooreducing loading buffer and 
separated on a SDS-PAGE minigel (3.2 A) or a 12 x 16 cm gel (3.2 B). Western blot 
analysis (3.2 A) involved: transfer to nitrocellulose and detection of gD with anti-gD 
mAb pool followed by biotinylated Goat anti-mouse IgG and a Streptavidin alkaline 
phosphatase Figure conjugate. Colour development was carried out using BCIP and 
NBT. 
Figure 3.2 A depicts the following: Lane: 1, Prestained low molecular weight 
markers ( ~ i o r a d * ~  ).; 2, 1.0 uL of 1 in 10 uL dilution of rnAb pool; 3, immunoprecipitate 
from L929 transfected with pAL.SgD; 4, immunoprecipitate from L929 transfected with 
pSLRSVSgD; 5, immunoprecipitate fkom L929 transfected with pMCES.SgD (shortened 
version of MCMV enhancer/promoter element not described in methods); 6 ,  
irnrnunoprecipitate from L929 transfected with pRSV.gIVt 1.3; 7, immunoprecipitate from 
L929 transfected with pMCEL.SgD; 8, immunoprecipitate from L929 cells transfected 
with pSLRSV.Nu1; 9, 100 qg affinity column purified recombinant secreted (truncated) 
gD; 10, 100 qg of E. coli aggregate preparation of cytosolic gD expressed from pAA505, 
respectively . 
Figure 3.2 B depicts "S labelled gD fiom 4 of 5 stably transfected L929 cell lines 
was irnmunoprecipitated as described above and resolved on a 10% SDS-PAGE gel (3.2 
B). Lanes: 1, lysate fiom BHV- 1 infected MDBK cells; 2, secreted gD fkom L929 cells 
infected with a recombinant Vaccinia expressing a secreted form of gD; 3, pAL.SgD 
transfected cell line; 4, pSLRSV.SgD transfected cell line; 5, pMCES.SgD transfected 
cell line; 6 ,  pRSV 1.3 * ; 7, pSLRSV.Nu1 transfected cell line. The molecular weights of 
the prestained markers are indicated to the left. 

emacelluiarly @SLRSV.SgD), or in the cytoplasm @SLRSV.CgD) (Fig. 3.3). Molecular 
weights were as predicted based on cloned sequence data and previous work. 
3.3 2 Serum IgG kinetics in DNA-immunized mice. 
Immunization of C3WHeN mice with a plasmid encoding an intracellular form of 
BHV- 1 gD display antibody ldnetics that differ from mice receiving cell surface or 
secreted forms of BHV-1 gD. Fig. 3.4 shows that mice from a l l  groups immunized with 
the plasmids encoding the authentic @SLRSV.AgD) or secreted @SLRSV. SgD) versions 
of BHV-1 seroconvert as early as 2 weeks following the initial immunization. 
Interestingly, mice immunized with plasmid encoding the intracellular version of gD 
@SLRSV.CgD) showed a 2 to 4 week lag in serum titer development as compared to 
mice immunized with constructs encoding membrane anchored antigen (AgD 
consmcts), or secreted (SgD conmcts), antigen. Not all mice immunized with plasmid 
DNA, with the exception of the group immunized with PALS@, seroconverted in this 
experiment. Early, mid, and late total IgG serum titer lanetics were similar for mice 
immunized with plasmids encoding the authentic or secreted versions of gD. Mean 
serum titers for mice receiving the cytosolic version of gD @SLRSV.CgD) tended to be 
lower than mice immunized with other plasmid constructs. Table 3.2 shows that mean 
serum titers for all DNA groups were higher than those seen in mice immunized with 
purified viral gD or recombinant m c a t e d  gD (formulated in Alum or VSA3). At 12 
weeks, mice immunized with either pAL or pSLRSV constructs displayed mean titers 
greater than those seen in mice immunized with conventional vaccine formulations. Fig. 
Fig. 3.3 Autoradiograph of imrnunoprecipitated forms of membrane anchored. secreted 
and cytosolic BHV- 1 gD. Reconfluent COS-7 cells transiently transfected with 
pSLRSV.AgD, pSLRSV.SgD, pSLRSV.CgD or pSLRSV.Nu1 were grown for 48 hours in 
the presence of jSS labelled methionine and cysteine. Radioactively labelled gD was 
immunoprecipitated from media andlor cell lysates using an anti-@ mAb pool. SDS- 
polyacrylarnide gel electrophoresis of precipitates demonstrates calculated m.w. of 
mutated gD and cellular localization as predicted. Immunoprecipitates of media 
collected from COS-7 transfected with: Lane I, pSLRSV.AgD; 2, pSLRSV.SgD; 3. 
pSLRSV.CgD; and 4, pSLRSV.Nu1, respectively. lmmunoprecipitates of lysates of COS- 
7cells transfected with: Lane 5, pSLRSV.AgD; 6, pSLRSV.SgD; 7, pSLRSV.CgD, and 
8, pSLRSV.Nu1, respectively. Immunoprecipitates of plasma membrane associated gD 
are shown in Lanes 9, pSLRSV.AgD; 10, pSLRSV.SgD; 11, pSLRSV.CgD, and 12, 
pSLRSV.Nu1, respectively. Molecular weight markers are indicated on the left. 

Fig. 3.4 Kinetics of serum anti-BHV- l gD antibodies in C3WHeN mice immunized with 
DNA or conventional vaccines. Serum ELISA titers were determined by using the 
extrapolation function (MicrosofiTm Excel) based on endpoint dilutions and using 
preirnrnune sera means (plus 3 standard deviations) as cutoffs. Endpoint titers are 
expressed as Mog,,. Experimental groups contained 5 (DNA-based vaccines) or 3 mice 
(Alum or VSA formulations). Bleeds fiom each mouse were determined individually for 
each time point except at 2 weeks when bleeds for each group were pooled. Only 23 
week titers fiom mice that were seropositive at week 14 were determined. All DNA- 
based vaccines were administered intramuscularly in the left quadriceps muscle mass 
(superficial and/or deep muscles of the thigh), with doses of 100 pg (2 pg/pL in normal 
saline) at days 0 and 14. AWnity purified, full length, BHV-1 gD (AgD) ,and 
recombinant truncated gD (tgD), were given at doses of 200 qglrnouse subcutaneously 
following formulation with VSA or Alum. Vaccine designations are indicated in the top 
centre of each graph. 
6-  6 
pMCEt. AgD pStRSV.AgD Ag D/AI urn 
5- -5 
4 - 
3 - 
2 - 
1 - 
pMCEL. SgD 
5 - 
rn 
-' c 
< 6 pSLRSV. CgD 
/ - -  2 
r 
0 p-:!!? h 0 
- 
-2 
-1 
0 , , , ,  , I I t ,  ; a t I I A i i t a  1 1 , 1 1 1  
6 0 2 4 6 8 la 1214222324 
PAL. SgD Weeks tg DNSA 
5 - - 5 
4 - b - 4 
3- h 
2- 
1 - - 
0 i i i i i i b  l i  1'&&i4 
:%L: 
L I I 1 1 T 1  
0 2 4 6 8 10 12 14222324 
Weeks Weeks 
Table 3.2 Mean serum ELISA titers kom seropositive mice at various times 
following immunization with DNA-based or conventional vaccines. 
Vaccine X Seropositive Time (Weeks poa immunization) 
Groups Mice 6 12 23 
p A L - 4 9  3 50,130 * 25,960 19,260 * 6,705 I 1,740 f 5,288 
PAL. SSD 5 22,990 * 4,198 13,890 * 832 5,003 * 832 
t g D N  SA - 7 752 f 333 152 f 121 10 * 0 
Note: Values were obtained fiom mice depicted in Fig. 3.4 are represented with standard 
error (S.E.) of the mean. 
3.4, and Table 3.2, clearly show that these conventional vaccine groups all displayed 
titers that were at background levels by 23 weeks. However, mean serum IgG titers in all 
seropositive DNA-vaccine groups were significantly @s 0.05) above background at 23 
weeks. Despite clear evidence of serum titers at 23 weeks post-immunization, mean titers 
fiom several DNA vaccine groups, including: pAL.AgD/SgD, pMCEL.AgD and 
pSLRSV.AgD, showed evidence of decline. Due to relatively low numbers of 
seropositive animals in some of these groups a statistical analysis on most groups was 
unwarranted. However, using a Mann-Whitney t-test it was shown that the decline in 
titers observed in 5 seropositive mice immunized with pAL.SgD at 23 weeks was 
significant w0.05). Table 3.2 shows two DNA vaccine groups @SLRSV.SgD and 
pSLRSV.CgD) with apparent increases in serum titers fiom 12 weeks to 23 weeks. These 
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values are the result of one mouse in the pSLRSV.SgD group and one in pSLRSV.C@ 
group displaying a 5 and 15 fold increase in serum IgG titer, respectively (data not 
shown). The remaining animals in each group maintained titer levels and showed no 
evidence of decline at 23 weeks. 
Figs. 3 -5 and 3 -6 depict early serum IgG kinetics for two separate experiments in 
which mice were immunized using a split dose protocol (see methods). Fig. 3.5 shows, 
once again, the 2 -4 week lag in senun titer development in mice immunized with 
plasmid encoding the cytosolic version of g . .  It is also apparent that immunization with 
pSLRSV.CgD does not result in 100 % seroconversion at 4 or 6 weeks. Mice immunized 
with pSLRSV.AgD and pSLRSV-SgD tended to display 80 and 90% seroconversion 
efficacies at 2 weeks, respectively, with 100% seroconversion typically occurring by 4 
weeks (Fig 3.5 and 3.6). One mouse immunized with pSLRSV.SgD did not show any gD 
specific titers at 4 weeks (Fig. 3.6), however, this mouse developed low, but detectable, 
titers by 6 week. There was no significant difference in mean titer values for mice 
immunized with either pSLRSV.AgD or pSLFGV.SgD, at 6 weeks. However, mice 
immunized with pSLRSV.CgD showed significantly lower mean titers than mice 
immunized with plasmids encoding the cell surface @SLRSV.AgD) or secreted 
(pSLRSV.SgD) forms of gD (Fig. 3.5). Fig. 3.6 shows the early serum IgG kinetics for 
mice immunized subcutaneously with VSA/tgD. Only one mouse had seroconverted 
prior to boosting at 2 weeks. Surprisingly all 8 mice in this vaccine group had 
seroconverted by 4 weeks with a mean titer that was significantly lower (ps 0.05), than 
that obsmed in mice immunized with pSLRSVAgD or pSLRSV.SgD. Typically, in our 
Fig. 3.5 Early serum antibody levels after immunization with plasrnids encoding 
different forms of BHV-1 gD. C3WHeN mice were immunized with plasmids encoding 
cell associated (AgD or CgD) or secreted (SgD) antigens. These experiments represent 
serum ELISA titers determined as described for Fig. 3.4. Experimental groups had 10 
mice per group and include a Null plasmid control group. Mice 6-7 weeks of age were 
immunized in each quadriceps muscle mass with 50 pg DNA (total of 100 pg). All mice 
were boosted at 2 weeks after initial immunization with the same dose. Plasrnid construct 
designations are indicated in the top centre of each graph. 
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Fig. 3.6 Serum antibody levels in C3WHeN mice immunized with plasmids encoding 
cell associated or secreted antigens. These experiments represent serum ELISA titen 
determined as described for Fig. 3.4. Experimental groups had 8 mice per group and 
include a conventional vaccine (VSAItgD) control group. Mice 6-7 weeks of age were 
immunized in each quadriceps muscle mass with 50 pg DNA (total of 100 pg). Mice 
receiving conventional vaccines were immunized S.Q. with 400 qg affinity purified ngD 
in 100 pL VSA + HBSS. All mice were boosted at 2 weeks after initial immunization 
with the same dose. Plasmid constructs or conventional vaccines designations are 
indicated in the top centre of each graph. 

hands, C3WHeN mice are poor responders (50-60% seroconversion) to seveml different 
conventional adjuvants (Alum and VSA3) formulated with recombinant truncated BHV- 1 
gD. It is not known why all mice seroconvened in this one instance. 
3.3.3 Serum IgG isotype in DNA-immunized mice. 
To further characterize the serum antibody responses we determined the IgG 
isotype profiles in mice immunized with plasmids encoding each of three different forms 
of BHV- 1 gD. Mice immunized with plasmids encoding the cell-associated versions of 
BHV- 1 gD display a predominance of serum IgG,, while mice receiving plasmids 
encoding a secreted f o m  of gD showed a predominance of IgG, . Sera taken at 6 and 12 
weeks post 1huuization, shown in Fig. 3.4, were assessed for serum IgG isotypes using 
an indirect ELISA. Calculation of IgGJgG, ratios clearly demonstrate that mice 
immunized with plasmids encoding cell-associated versions of BHV-I gD 
@SLRSV.AgD and pSLRSV.CgD) show a predominance of IgG,, whereas mice 
immunized with plasmid encoding the secreted version of gD @SLRSV.SgD) show a 
predominance of IgG, (Fig. 3.7). In two separate experiments this trend was observed to 
be reproducible and that the predominant isotype did not occur as the exclusive isotype 
(Figs. 3.8 and 3.9). Figs. 3.8 and 3 -9 demonstrate that restriction of the plasmid encoded 
antigen to the transfected cell results in the predominance of IgG, in 100 % of 
seropositive mice immunized with pSLRSV.CgD and 86% of mice immunized with 
pSLRSVAgD. Similarly, 95% of mice immunized with pSLRSV.SgD displayed a 
predominance of serum IgG, (Figs. 3.8 and 3.9). In addition it was observed that mice 
Fig. 3.7 Serum IgG isotype ratios afier immunization with DNA vaccines. Anti-BHV-l 
gD IgG, AgG, isotype ratios in seropositive C3HlHeN mice 6 and 12 weeks after 
immunization with plasmids encoding cell associated @SLRSV.AgD or pSLRSV.CgD) 
or secreted @SLRSV.SgD) forms of BHV-1 gD. BHV-I gD specific IgG, or IgG, 
antibody isotypes were detected by ELISA with biotinylated secondary antibodies. Sera 
was assayed from seropositive mice indicated in Fig. 3.4. 
I 6 week 
r s m  12 weel 
Fig. 3.8 Serum IgG isotype profiles in mice immunized with DNA vaccines. Data is 
from individual mice after intramuscular immunization with plasmids encoding cell 
associated (pSLRSV.AgD or pSLRSV.CgD) or secreted (pSLRSV.SgD) forms of gD. 
BHV-1 gD specific IgG, or IgG, isotypes were detected by ELISA using biotinylated 
secondary antibodies. Antibody titers were calculated as described in Fig. 3.4. Values are 
taken from mice described in Fig. 3.5 and depicted as IAog,, of antibody titer (determined 
by serial end-point dilution analysis). 
Individual Mice 
Fig. 3.9 Serum IgG isotype after immunization with pSLRSV.AgD or pSLRSV.SgD. 
Data represents individual mice 6 weeks after intramuscular immunization with DNA 
vaccines or subcutaneous immunization with recombinant truncated gD (tgD) formulated 
in VSA3. BHV-I gD specific IgG, or IgG, isotypes were detected by ELISA using 
biotinylated secondary antibodies. Antibody titers were calculated as described in Fig. 
3.4. Values are determined for mice described in Fig. 3.6 and depicted as lAog,, of 
antibody titer (determined by serial end-point dilution analysis). 
12SO(K1 pSLRSV. SgD 
Individual U c e  
immunized with pSLRSV.CgD showed higher levels of IgG, , relative to I@,, than mice 
immmized with pSLRSV.A@. 
3 -3.4 Splenic cytokine profiles reflect a Th l -like phenotype. 
We assessed the cytokine profile in spleens harvested 6 months after the initial 
immunization of C3H/HeN mice with DNA-based or a conventional vaccine and found 
that splenic cytokine ELISPOT profiles did not correlate to the predominant serum IgG 
isotype. Following in v i ro  restimulation for 40 hours, we determined the number of IL-4 
and IFN y secreting splenocytes (Fig. 3.10). In all groups of mice immunized with 
plasmid DNA encoding authentic or deletion mutants of BHV-I gD the exclusive 
predominance of D?V y secreting cells was observed. Mice immunized with a 
conventional Alum formulation that had incorporated either purified viral authentic gD or 
recombinant truncated gD showed either no cytokine production (Alum/AgD) or a 
predominance of IL-4 (AIWtgD). 
3.3.5 The Iliac i p p h  node drains the deep muscles of the murine thigh. 
Prior to characterizing cytokine and B-cell IgG isotype profiles within draining 
lymph nodes we felt it was paramount to ensure that the predominant draining node was 
identified. At least one recent paper described Lymph node harvests and cytokine profiles 
from a pool of lymph nodes that included the mesenteric and superficial inguinal nodes 
(Mor et al., 1995). We were unconvinced that these nodes were the predominant draining 
nodes and demonstrated, using several approaches, that the iliac Lymph node was the 
Fig. 3.10 Splenic cytokine profiles in mice 5 1/2 months post-immunization. 
Seropositive mice depicted in Fig.3.4. were assessed for antigen specific production of 
IFN y or IL-4. Spleens from seropositive mice were pooled and stimulated, in vitro, for - 
40 hours with affinity purified BHV-I gD. In vim stimulated splenocytes were plated 
at 1.0 x lo6 or 0.5 x 1 O6 cells/well on Polyfiltronics plates. Cytokine secreting splenocytes 
are depicted as the number of spot forming cells (SFC) per million plated cells. Mean 
values of triplicate wells are depicted. 
IFN y 
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primary draining node of the deep muscles of the thigh. Euthanasia of C3H/HeN mice 5 
minutes following an i m  (quactriceps) injection of a 1% Evans Blue solution clearly 
showed dye uptake only in the iliac node (Fig. 3.11). Careful dissection showed that a 
substantial amount of dye also occurred within the subcutaneous fatty tissue occurring in 
the inguinal region of these dye injected mice and that, despite the presence of this dye, 
the inguinal node, which is found embedded in this fatty tissue, remained relatively 
unstained (Figs. 3.1 1, A and B). We felt that reflux of injected material back along the 
needle tract was the most likely explanation for the presence of blue dye in the 
subcutaneous inguinal region. 
We also utilized PCR to detect the presence, or absence, of BHV-1 gD encoding 
sequences using primers described in materials and methods. Surprisingly, a 435 bp gene 
fragment was identified by PCR in not only the iliac lymph node, but also the in,guhal 
node (Fig. 3.12). In both instances gD specific sequences were identified at 20 minutes 
post injection but not at 20 hours. BHV-1 gD specific sequences in the superficial 
inguinal node may have occurred in one of s e v d  manners, including: contamination of 
the node tissue sample with adjacent contaminated fatty tissue, or access to the node as a 
result of drainage of the adjacent contaminated fatty tissue. Despite the equivocal PCR 
data, we felt that the iliac node was indeed the primary draining node of the deep muscles 
of the thigh and that post injection healing of the needle tract followed by antigen 
production by aansfected myocytes would drain to the iliac node and not the superficial 
inguinal node. Furthermore, immunological data h m  both iliac and inguinal nodes, 
following immunization with pSLRSV.AgD and pSLRSV.SgD, supports this conclusion 
Fig. 3.11 Identification of iliac lymph node as pri- draining node for the deep 
muscles of the murine thigh. Mice were sacrificed 5 minutes after an intramuscular 
injection of 1% Evans blue dye into the quadriceps muscle mass. The iliac lymph node is 
identified by an arrow (Fig. 3.1 1, A). Fig. 3.1 1, B shows blue stained iliac nodes flanking 
an unstained superficial inguinal node after removal from the same mouse. 

Fig. 3.12 Injected plasmid DNA is detectable by PCR in two lymph nodes. DNA purified 
From the iliac and superficial inguinal lymph nodes show that injected DNA gains access 
to these sites shortly after injection. iMice were injected with 100 pg of ~ S L R S V - A ~ D  
and sacrificed 20 minutes or 20 hours post-injection. huified DNA was screened by 
PCR for the presence of BHV-I gD sequences. Lane 1, plasmid pSLRSV.AgD positive 
template control; 2, inguinal node 20 minutes post-injection; 3, inguinal node 20 hours 
post- injection; 4, iliac node 20 minutes post-injection; 5, iliac node 20 hours post- 
injection; 6, iliac node 20 minutes following injection with pSLRSV.Nu1 vector, 7, @X- 
174 DNA-Hae I11 marker digest (Phannacia) (base pair number of first five bands from 
top to bottom: 1358, 1078, 872,603, 3 10) ; 8, pSLRSV.Nul template negative control; 
9, pSLRSV.AgD positive template control. 
Lane 7, marker lengths ( base pairs) 
Top to bottom, 1358,1978,872,603,310) 
(Fig. 3.13). 
3.3.6 Cytokine and anhbody forming cell profiles in the iliac node. 
The draining lymph node cytokine and B-cell isotype ELISPOT profiles correlate 
to the predominant serum isotype. Fig. 3.13 demonstrates that early splenic cytokine 
kinetics still show a predominance of IFN y secreting cells. There appears to be a 
predominance of IFN y secretion occurring in mice immunized with a conventional 
vaccine (VSA3:tgD), however, this value becomes negligible when background cytokine 
production is subtracted (see Null plasmid group in Fig. 3.13). Subtraction of Null group 
IFN y levels from the displayed inguinal lymph node cytokne secreting cell numbers 
suggests that little antigen-specific immunological responses are occurring in this 
nondraining node at 7 weeks post immunization. The iliac lymph node shows a 
predominance of IFN y secreting cells in mice immunized with the cell-associated 
pSLRSV.AgD, and a significant increase in the level of E-4 secretion in mice 
immunized with pSLRSV.SgD. Upon subtraction of the IFN y counts from the Null 
plasmid group the level of IL-4 production becomes significantly greater than the number 
of antigen-specific IFN y secreting cells in the pSLRSV-SgD vaccinated group. There 
was a significant level of IL-4 production in restimulated inguinal node cells taken from 
mice immunized subcutaneously with VSAMgD. B-cell isotype ELISPOT data from 
mice immunized with a DNA-based, or a conventional (VSA3/tgD) vaccine, is illustrated 
in Fig. 3.1 4. Numbers of splenic antibody forming cells (AFCs) are either absent or 
below detection limits in all groups except mice immunized with pSLRSVAgD. The 
Fig. 3.13 Cytokine profiles in lymph nodes and the spleen after immunization with DNA 
vaccines. Antigen specific cytokine profif es were measured in several different lymphoid 
tissues of C3WHeN mice immunized with plasmids encoding cell associated or secreted 
version of BHV-1 gD. Seropositive mice were euthanized 5 weeks after boosting and 
spleens, draining and nondraining lymph nodes were excised and pooled. Pooled cell 
populations were stimulated in vitro for 18-20 hours with 400 qg affinity purified BHV- 1 
gD. Following in v i m  stimulation cells were harvested and plated on Polyfiltronics 
plates at 1.0 x lo6 cells/well in triplicate. Pooled values are represented as mean values 
and as number of cytokine secreting cells per million plated cells. Plate control wells for 
nonspecific binding of cytokine were set up for all groups and mean values were 
subtracted from all groups. 
Spleen l Liac L.N. l nguinal L.N. 
Fig. 3.14 Number of antibody fonning cells secreting IgG, or IgG, after immunization 
with DNA vaccines. Data depicts antigen specific IgG, and IgG, production in several 
different lymphoid tissues of C3H/HeN mice immunized with plasmids encoding cell 
associated or secreted version of BHV-I- gD. Seropositive mice were euthanized 5 
weeks after boosting and spleens, draining and nondraining lymph nodes were excised 
and pooled. Following a collagenase/DNaseI dissociation digestion pooled cell 
populations were plated at 1 x lo6 cells/well on Millipore ELISPOT plates, in triplicate. 
Pooled values are represented as mean number of Ig secreting cells per million plated 
cells. Plate control wells for nonspecific binding of immunoglobulin isotypes were set up 
for all groups and mean values were subtracted from all groups. 
Spleen Iliac LA. Inguinal L.N. 
total number of AFCs, in the spleens of mice immunized with pSLRSV.AgD would 
amount to approximately 200 - 250kpleen. The IgG isotype of AFCs taken from the iliac 
lymph node correlated well with the predominant cytokine (IFN y + IgG,, IL-4 + IgG,) 
secreted within this node and with the predominant serum IgG isotype. Mice immunized 
with plasmid DNA encoding the cell-associated gD @SLRSV.AgD) displayed a 
predominance of IgG, while mice immunized with plasmid encoding the secreted form 
of gD @SLRSV.SgD) displayed a predominance of IgG,. The subcutaneously occurring 
inguinal lymph node showed a substantial and exclusive number of IgG, secreting AFCs 
taken from mice immunized with VSA3:tgD. 
3.3.7 DNA vaccines elicit viral neutralizing antibodies. 
Serum antibodies taken from mice immunized with p lamids encoding the 
authentic or secreted versions of BHV- 1 gD were able to neuualize virulent BHV-1 in 
vim. Individual immune sera from mice 7 weeks after an initial immunization (5 weeks 
post boost) with 100 pg plasmids: pSLRSV-NL& pSLRSV.AgD, pSLRSVSgD and 
pSLRSV.CgD showed that only mice immunized with plasmids encoding the authentic 
and secreted versions of gD were able to effectively neutralize virulent BHV-1 (Fig. 
3.15). In this assay there was no significant advantage in neutralizing capacity noted 
between groups immunized with pSLRSVAgD or pSLRSV.AgD. 
3.3.8 Mouse strain affects serum isotype profile. 
We wished to determine if mouse strain had an impact on the serum IgG isotype 
profile following immunization with different forms of plasmid encoded BHV-I gD. We 
found that IgG, was the predominant serum isotype in C57BLA (H-2" mice immunized 
with either pSLRSV.S$ or pSLRSV.AgD. Fig. 3.16 illustrates mean IgG isotype titers 
occming in C57BL16 mice immunized with the pSLRSV.AgD (cell-associated antigen) 
or pSLRSV.SgD (extracellular antigen). Surprisingly the serum isotype mend observed in 
C3H/HeN (H-27 did not manifest itself in C57BY6 mice. Antigen-specific, total IgG 
serum antibody kinetics mirrored those seen in C3H/HeN, however, the predominant 
serum isotype was, in most animals, IgG,. Despite the apparent predominance of serum 
IgG, , as indicated by mean isotype titers in these mice, there was clear evidence that 
mice receiving pSLRSV.AgD (cell-associated gD) did develop significantly higher IgG, 
titers than mice immunized with pSLRSV.SgD. Indeed three mice (of eight) in the 
pSLRSV.AgD group showed IgG, serum titers equivalent to, or greater than, the IgG, 
titers. Also, the IgG,:IgG, ratio dropped from 85: 1 @SLRSV.SgD) to 4.4: 1 
@SLRSVAgD) and this difference was due, in large part, to the significant increase in 
IgG, levels in mice inunllnized with pSLRSV.AgD (data not shown). Thus, although 
C57BL/6 mice did not show the serum isotype polarity existing in C3WHeN mice 
immunized with plasmids encoding either the cell-associated or extracellular versions of 
gD, the tendency for the cell-associated version of gD @SLRSV.AgD) to skew serum 
isotype responses towards greater levels of IgG, was reproduced. 
3.4 Discussion 
DNA-based vaccines offer a number of potential advantages o v a  conventional 
Fig. 3.15 Functional differences in serum antibodies after immunization with plasmids 
encoding different forms of BHV- 1 gD. Serum antibody responses following 
immunization and boost (2 weeks) of mice with plasmids encoding cell membrane 
anchored gD (pSLRSV.AgD), secreted gD (pSLRSV.SgD) cytoplasmic gD 
@SLRSV.CgD), or Null vector (pSLRSV.Nu1). gD-specific ELISA titers are expressed as 
the reciprocal of the extrapolated (see Methods) dilution resulting in three standard 
deviations above the control value (prebleed sera). BHV-1 neutralizing antibody titers are 
expressed as the reciprocal of the highest dilution of antibody that caused a 50% 
reduction of plaques relative to virus control. Results are expressed as geometric mean 
and bars indicate the standard error of 4 @SLRSV.CgD and pSLRSV.Nul), 8 
(pSLRSV.SgD), or 9 (pSLRSV.AgD), mice. 

Fig. 3.16 Serum antibody profiles in C57BU6 mice after immunization with DNA 
vaccines. Serum antibody isotype ELISA titen for C5 7BU6 mice immunized 
intramuscularly with plasmids encoding the anchored (pSLRSV-AgD) or secreted 
@SLRSV.SgD) version of BHV-I gD. Isotype titers represented above were detemiined 
from bleeds harvested 6 weeks post immunization. The differences between IgG, titers 
was not statistically different @<0.05), however, the difference between IgG, titers was 
found to be statistically different (p<0.05). 

vaccines that include: breadth of efficacy (single dosing, long lasting immunity, both cell- 
mediated and humoral immunity, and the potential to polarize immune responses) 
reduced downstream processing, and vaccine stability @onnelly et al., 1993; Babiuk et 
al., 1996; Ertl and Xiang, 1996; ULmer et al., 1 W6a; Ulmer et al., 1996b). Among these 
advantages it would seem that duration and the protective efficacy of the resulting 
immune responses are of the utmost significance when consideration is given to the 
development of vaccines. We demonstrated, using a moderate men@ RSV-LTR 
regulatory element, that serum IgG ELISA titers in excess of 100,000 were achievable 
and that significant levels of antigen-specific antiiody were still evident 23 weeks post 
immunization. We also demonstrated that the cellular compartment in which the 
plasmi d encoded antigen was expressed could profoundly influence the ensuing immune 
character. 
Evidence in most mice, immunized with plasmids encoding secreted and membrane 
anchored versions of BHV-1 gD, suggested a decline in anti-gD serum IgG titers with 
time. However, there was also clear evidence of serum titer maintenance, and in some 
instances increases, in several mice immunized with plasmids encoding the inmacellular 
or secreted version of gD at 23 weeks post immunization. These observations lend 
credibility to the suggestion that DNA-based vaccines have the potential to elicit long 
term humoral immune response. However, in mice immunized with the inaacellular 
version of gD, the trade off for a durable humoral immune response appears to be a lag in 
senun antiiody appearance and lower overall serum antibody titers . It also seems 
apparent that neutralizing serum antibody titers raised against this cytosolic, 
nonglycosylated antigen, were lower than those occuning in mice receiving the 
appropriate post-translational modifications of BHV- 1 gD (Tikoo et al., 1993). Indeed, it 
has been demonstrated previously that recombinant gD produced in E. coli generate 
excellent antibody titers when used to immunize cattle, however, serum neutralizing titers 
are nonexistent (van h e n  Liael-van den Hurk et al., 1993b). It was also hypothesized 
that the inability to induce good serum neutralizing titers was likely due to the lack of N- 
linked glycans at one of two glycosylation sites on the 111 length glycoprotein (Tikoo et 
ai., 1993). The immmological significance of systemic anh'body responses to antigens not 
normally occurring at the surface of pathogens or host cells (nonstructural proteins) is not 
well understood. However, there is recent evidence that humoral responses against 
nonmctural viral proteins of Yellow Fever, Dengue, murine hepatitis and rabies viruses, 
do confer significant levels of protection to the respective viruses (Nakanaga et al., 1986; 
Schlesinger et al., 1986; Lodmell et al., 1993; Slifka and Ahmed, 1996). Thus, the 
potential for more durable humoral responses and protective immuniw may outweigh the 
apparent negative impact of intracellular antigens, delivered as DNA-based vaccines, on 
the magnitude and onset of senun IgG titers. 
Several studies have been canied out that have addressed the longevity of humoral 
immune responses following immunization with DNA-based vaccines (Rhodes et ai., 
1993; Raz et al., 1994; Michel et al., 1995). A single  is^ injection of human 
cytomegalovirus (HCMV) immediate-early promoter driven genes encoding the major 
middle @reS2 and S) and large @reS 1, preS2 and S) envelope proteins, as well as, 
plasmids encoding the major and middle envelope proteins of Hepatitis B virus achieved 
serum ELISA titers between 10,000 and 50,000 in C57BU6 @-2b) mice (Michel et al., 
1995). Mice immunized with plasmids encoding the major middle and large envelope 
proteins of Hepatitis B virus showed some evidence of decline in serum antibody levels 
at 21 weeks, however, animals immunized with plasmids encoding only the major 
envelope protein showed no evidence of decline of senun IgG levels over the same time 
period. Balbk (H-2kd ) mice injected im with a single dose of plasmid utiIizing 
regulatory elements from the RSV-LTR and encoding the influenza nucleoprotein @ I )  
antigen resulted in excellent serum antibody titers that persisted, in at least 75% of mice, 
with little decay until 5 1/2 months post immunization (Rhodes et al., 1993). However, a 
consistent subpopulation of these mice developed peak titers between 2 and 3 months 
followed by a relatively rapid decay in titers. An explanation for this observed 
divergence in serum titer kinetics is not immediately forthcoming. However, we cannot 
rule out the possibility that CD8+ cytotoxic T-cells directed against host cells expressing 
foreign antigen are responsible for clearing an important source of antigen (Davis et al., 
1997). Finally, Balb/c mice injected i.d. with plasmids encoding the influenza NP gene 
under the control of the HCMV immediate-early promoter in the context of the HCMV 
intron A regulatory element showed maintenance of serum titers for 68 weeks (Raz et al., 
1994). 
We do not yet know if lifelong immmity will be a ubiquitous feature of DNA- 
based vaccines that are expected and able to elicit efficacious humoral immune responses. 
It was hypothesized that long term humoral responses were a likely result of 
demonstrated in-vivo persistence of plasmid DNA and reponer gene expression in mice 
(Wolff et al., 1992). It now seems apparent that long term, exrrachromosomal, persistence 
and expression of encoded genes may be largely dependent on the encoded antigen. For 
example, a recent study utilizing the reporter gene lucifaase clearly demonstrated a 
decline to background 8 weeks following injection (Wolff et al., 1990; Norman et al., 
1997). While this recent work suggests plasmid persistence and encoded gene expression 
can be highly variable it does not provide any insight into the mechanistic 
(emchromosomal plasmid instability, cell toxicity, or antigen-specific cytotoxicity ), 
causes responsible for the reduction in expression. Surprisingly our preliminary research 
suggested that a more durable humoral immune response occurred if the antigen was 
"restricted" to the intracellular companment (Fig. 3.4, pSLRSV.CgD). Obviously, for a 
B-cell response to occur antigen must appear extracellularly. However, as with other 
studies demonstrating humoral immunity to inmce1lula.r antigens, the specific mechanism 
whereby cytosolic antigens gain access to the extracellular space is unknown (LTlmer et 
al., 1993; Kuhober et al., 1996; Geissler et al., 1997). One could hypothesize that 
nonspecific and/or specific cytolytic activity by NK cells and CD8' CTLs may be 
responsible for an intermittent release of a l'bolus'l of cytosolic antigen and that these 
pulses of antigen are effective at "charging" follicular dendritic cells with immune 
complexes thereby maintaining long tern sewn titers (Gray and Skarvall, 1988; 
Bachman et al., 1994; Karre, 1995; Bachman et al., 1996; Helander et al., 1 996). 
Certainly, recent evidence describes inflammatory reactions at the sites of DNA injection 
and supports the contention that in vivo transfected cells can become immunological 
targets as antigen-specific immunity develops (Davis et al., 1997). We have not been able 
to identify specific major histocompatibility (MHQI restricted epitopes within BHV- 1 
gD in several mouse strains. While this phenomenon does not completely rule out the 
existence of antigen-specific CD8' CTL activity, it suggests that in this particular instance 
durability of the humoral response may be a feature of diminished CTL activity unique to 
BHV-1 gD in mice. 
Interestingly, the cell compartment in which the antigen was expressed had little 
impact on the character of the splenic T-cell cytokine profile. Initial experiments 
demonstrated an almost exclusive production of IFN-y from in v i m  stimulated 
splenocytes taken from C3-N mice 2 1 weeks after boosting (Fig. 3.10). This data is 
consistent with current published research demonstrating a Th 1 -type of immune response 
to mmy i.m or i.d. administered DNA-based vaccines (Donneliy et aI., 1993; Erti and 
Xiang, 1996; Hassett and Lindsay Whitton, 1996; Ulmer et al., 1 %a; Ulmer et al., 
1996b). The tendency for DNA-based vaccines administered i.m or i.d to skew the 
immune response towards a Th 1-type of responses is significant because protective 
immune response to many viral, Gram-negative bacterial, and some parasitic diseases are 
characterized by a potent Th 1 type of immunity (Coutelier et al., 1988; Peterson et al., 
1992; Scott, 1993; Nguyen et al., 1994; Mahon et al., 1995; Brubaker et ai., 1996; 
Mosmann and Sad, 1996; Pope et al., 1996; Waris et al., 1996; Fresno et al., 1997; Gause 
et al., 1997). Splenic cytokine profiles may relect the potency of cell-mediated immunity, 
when measured, CD8+ cytotoxicity. However, splenic cytokine profiles do not appear to 
accurately reflect the serum antibody character (Figs. 3.7,3.8,3 .9,3.10,3.13 and 3.14). 
It is paramount that problems associated with reliance on splenic cytokine profiles 
and adherence to dogma describing cytokine involvement in isotype switching be 
considered when assessing immune responses in mice (Snapper and Paul, 1987; Snapper 
and Mond, 1993). The serum isotype profiles represent the s u m  of Ig secretion from 
plasma cells upon exit from the spleen and the draining lymph nodes (Slifka and Ahmed, 
1996). Despite the prevalence of IFN-y production in spleens of immune mice, and the 
ovenwhelming tendency to declare this a Thl-type immune response, we found that the 
expected preponderance of IgG, occurred only in mice immunized with plasmids 
encoding cell-associated gD (cytosolic or membrane anchored) (Figs. 3.7,3.8,3.9 and 
3.10). Surprisingly, despite the predominance of IFN-y produced in restimulated 
splenocytes , mice immunized with plasmids encoding the secreted form of gD 
consistently showed senun isotypes that were predominantly IgG, (Figs. 3.7,3.8, 3.9 and 
3.10). This immunoglobulin isotype dominated the serum IgG profile consistently over 
several different time points during three separate experiments (data not shown). It is 
becoming increasingly evident that despite clear evidence that EN-y and IL-4 play 
important roles in the generation of IgG, or IgG,, respectively, the mechanistic routes to 
a specific Ig isotype are more complex than the singular presence, or absence, of either of 
these two cytokines (Coutelier et al., 1988; Kuhn et al., 199 1; Nguyen et al., 1994; 
Cofb.an and von der Weid, 1997). However, in order to fully investigate the T and B- 
cell phenotype in mice receiving plasmids encoding secreted or cell-associated forms of 
BHV-1 gD we used ELISPOT to quantify the antigen-specific Ig isotype and cytokine 
profile within the primary draining lymph node. We found an antigen-sp eci fic elevation 
of IL-4 and IgG, secreting B-cells in the iliac lymph nodes of mice receiving this 
construct as compared to mice receiving the plasna membrane anchored gD (Fig. 3.1 3). 
Thus, the draining lymph node cytokine and IgG isotype character may prove to more 
accurately correlate to the systemic immune character, at least at the time points assessed, 
than splenic immune responses. This apparent dichotomy between splenic cytokine 
profiles and those seen in draining lymph nodes, and in the context of published data 
describing kinetic differences in developing cellular immune repertoires in spleens, 
lymph nodes and bone marrow, underscore the importance of recognizing the temporal 
compartmentalization of immune responses to single antigens (Justewicz et al., 1995; Mo 
et al., 1995; Boyle et al., 1996) . Compartmentalization of immune responses is not a 
novel concept. However, the mechanism whereby a given antibody isotype predominates 
within a single, secondary Lymphoid tissue remains unresolved. Historically, evidence 
suggested that the predominant, post pathogewantigen exposure, cytokine profile within 
a given lymphoid tissue acts in a cognate and noncognate fashion to determine the B-cell 
immunoglobulin isotype (Coutelier et al., 1988). More recently, this hypothesis has been 
challenged with data showing simultaneous development of divergent, antigen-specific, 
antibody isotypes within the same draining lymph node (Sangster et al., 1997). In this 
instance it was hypothesized that noncognate activity by lymphoid cytokines could not be 
occurring and that dendritic cell cofactors, reflecting the anatomical source (mucosal 
versus subdermal) of pathogen, determined the isotypic outcome (IgA versus IgG2a). 
This information is not without precedence, for it has been demonstrated that dendritic 
cells from different tissues are able to facilitate Th2 or Thl-type immune responses that 
are dependent on the tissue of origin (Everson et al., 1996). 
The apparent potential to polarize the immune character by simply altering the gene 
sequence encoding the antigen, such that expression generated either a cell-associated or 
secreted fom of the antigen, is critical for vaccine design. Surprisingly, immunization of 
C57BL/6 @Mb) mice with the plasma membrane anchored form of BHV-1 gD did not 
result in a predominance of serum I&. While there was an increase in the levels of 
IgG, in these mice, as compared to animals receiving plasmid encoding the secreted form 
of gD, this outcome was surprising given that this main of mouse, like QK'HeN, show 
a similar Thl type response to Leishmania infection (Locksley and Scott, 1991). While it 
has been demonstrated that C3WHeN mice tend to overproduce IFN-y in response to 
certain antigens, it does suggest the important influence mouse main can have on 
immune responses to a given antigen (Major and Cuff, 1996). Based on senun IgG 
subclass profiles in C57BU6 mice immunized with plasmids encoding secreted and 
membrane anchored BHV-1 gD, one might predict that the Th2 predisposed Balbk (H-Zd) 
mice would show an exclusively IgG, response to all of these antigens (Major and Cuff, 
1996). However, several papers published recently have demonstrated that Balbk mice 
are capable of systemic IgG, predominance following immunization with a variety of 
DNA-based vaccines (Manickan et al., 1995; Pertmer et aL., 1996; Raz et al., 1996). In 
Light of these data, the danger of making claims describing the universaliry of the 
immune responses to DNA-based vaccines is premature. It is also important to recognize 
that vaccine testing in different mouse strains, showing genetic predispositions (H-2* 
linkage to IgG,) towards development of a particular immune outcome, represents an 
opportunity to emulate responses in outbred target populations. 
There are three other factors which can influence the type of immune response 
that occurs following immunization of DNA-based vaccines: intrinsic, immunologically 
unique features of encoded antigens, route and method of immunization, and the 
development of CTL responses (Huygen et al., 1996; Mancini et al., 1996; Pemner et al., 
1996; Feltquate et al., 1997). Immunization of C57BU6 mice im. with a plasmid 
encoding the secreted antigen Ag85 from M. tuberculosis, resulted in a predominance of 
senun IgG, and IgG, (Huygen et al., 1996). However, immunization of C57BU6 mice 
with plasmids encoding the Hepatitis B surface antigen results in secretion of virus like 
particles (VLPs) and in the predominance of IgG, (Mancini et al., 1996). Similarly, the 
secreted form of BHV-1 gD elicited an almost exclusive production of IgG, in these H-2b 
mice. Cardoso et. al. (19961, demonstrated hat im. immunization of Balb/c mice with 
plasmids encoding either cell membrane anchored, or partially secreted, f o m  of 
Measles virus hemagglutinin elicited a predominance of serum IgG, and IgG, , 
respectively (Cardoso et al., 1996). Conversely, a plasrnid encoding a secreted form of 
the amino-terminal portion of Hepatitis C virus nucleocapsid failed to deviate the serum 
IgG isotype towards greater levels of IgG, following im. injection into the tibialis 
anterior muscles of Balbk mice (Inchauspe et al., 1997). Despite this apparently 
controversial data, it is evident that soluble antigen is handled in a manner unique from 
that occuning with cell-associated antigen. For example, administration of soluble 
aqueous antigen has been demonstrated to either tolerize both Th subsets or, in some 
cases, to selectively tolerize Th 1-iype cells (Burstein et al., 1992; Chu et al., 1995). 
Subcutaneous immunization with mini-osmotic pumps designed to release a chronic low 
dose of soluble antigen has been demonstrated to selectively expand antigen-specific Th2 
responses (Guery et al., 1996). The mechanism for this outcome is unhown. However, it 
was hypothesized that targeting a specific antigen presenting population may be 
responsible for the observed immune character. Indeed B-cells of spienic origin have 
been demonstrated to selectively expand Th2 clones (Gajewski et al., 1991) and to 
preferentially activate interleukin 4 production (Rossi-Bergman et al., 1993). It has also 
been demonstrated that dendritic cells from different tissues can been fictionally distinct 
and induce profound polarization of T-cell phenotypes (Hill et al., 1994; Everson et al., 
1996). In short, a clear mechanistic understanding for the observed differences in 
immune character to soluble and cell-associated antigens is not immediately forthcoming. 
However, our preliminary data suggests that DNA-based vaccine delivery of antigens 
engineered to be expressed within, or outside of, host cells may offer a mechanism 
whereby the immune response can be manipulated to some extent. 
The route, or rather the method of immunization, has also been demonstrated to 
have a major impact on the character of the ensuing immune repertoire (Perhner et al., 
1996; Feltquate et al., 1997). Gene gun administration of DNA-based vaccines tends to 
result in a predominance of senun IgG, However, it has been demonstrated that ballistic 
immunization of C3WHeN mice with plasmid encoding the influenza nucleoprotein 
resulted in IgG, as the predominant serum isotype (Pertmer et al., 1996). While it does 
seem that ballistic and i.m delivery of DNA-based vaccines represent opposite ends of 
the humoral isotypic spectrum it is no& perbaps, surprising when one considers the vast 
difference in immunological microenvironments these two anatomical sites represent 
(Bos and Kapsenberg, 1993; Hohlfeld and Engel, 1994). Furthennore, the importance of 
the specific IgG isotype may be of questionable protective value, particularly if high 
neutralizing titers of IgG are present in the sera of animals (Bachmam et al., 1997). 
However, given that most protective immune responses to viral infections in mice are 
charactemed by a predominance in IgG, , and that this i sowe is much more efficient at 
complement fixation, it remains an issue of some importance in vaccine strategy (Klaus 
et al., 1979; Coutelier et al., 1988; Coutelier et al., 199 1; Nguyen et al., 1994). 
Although we have not been able to demonstrate BHV-1 gD specific (38' mediated 
cytolytic activity in several strains of mice, the irnponance of this component of the 
immune repertoire in controlling many noncytopathic viral, and possibly cytopathic, 
diseases must not be understated (Ramsay et al., 1993; Bloom and Zinkernagel, 1996; 
Zinkernagel, 1996). Generally speaking, DNA-based vaccines, regardless of the route of 
vaccine administration, type of antigen, or strain of mouse, are highly effective in 
generating a potent CTL population against encoded antigens (Annas et al., 1996; Ciemik 
et al., 1996; Tascon et al., 1996) . We have demonstrated that immunization of mice with 
plasmid encoding authentic as well as deletion mutants of BHV- 1 gD results in highly 
efficacious humoral and cell-mediated immunity. We have also demonssated that im 
w e a t i o n  of C3WHeN mice with cell-associated forms of BHV-1 gD antigen leads 
to a splenic, lymph node and serum antibody isotype profile consistent with a Th 1-like 
immune phenotype. However, mice immunized with a secreted form of this same 
antigen display immune responses characterized by greater levels of the IL-4 in the 
draining lymph node and IgG, as the predominant serum isotype. 
DNA-based vaccines represent a novel, simple method to achieve potent immune 
responses that include humoral and cellmediated immunity. Clearly the potential for 
these vaccines to induce potent Th 1-type *immune responses, often in conjunction with 
high levels of IgG, and cytolytic activity, necessitates firher exploration. We have also 
reached the point where modulation of these immune responses are being investigated 
such that the appropriateness, magnitude, duration, and balance of resulting repertoires 
emulate "normai" protective immune responses observed in convalescent animals. In light 
of the demonmation that cell association of plasmid delivered antigens has a significant 
impact on the developing immunological phenotype, we might consider utilizing several 
different antigens from the same pathogen as the basis for generating a balanced, 
comprehensive immune response @oolan et al., 1996). Funher, the evidence that Th 1 
and Th2 (as well as IgG, and IgG,) responses are not mutually exclusive within the same 
animal, and that early compartmentalization of B-cell and T-cell responses m y  ailow the 
propagation of this apparent immunological paradigm, suggests that multivalent vaccines 
encoding both cell surface (ie. viral envelope glycoprotein) and intracellular (viral 
inaacellular strumal and nonstructural proteins) nonshuctural proteins may be a more 
logical mode of generating the appropriate protective immune response. Whether this 
approach will require anatomically separate dosing to avoid bystander modulation effects 
remains to be seen (Sangster et al., 1997). Finally, research with HIV has led to the 
development of the hypothesis that strong CMI or humoral immunity may be mutually 
exclusive within the same animal and that forced maintenance of both may be 
immunologically deleterious to the individual in which they occur (Shearer and Clerici, 
1997). Ultimately, the potential for mauy DNA-based vaccines to elicit both cell- 
mediated and humoral imrmlnity, in conjunction with longevity of these responses, will 
test theories regarding self regulation of  each, or both, arms of the immune repenoire. 
4.0 hfMU?lE AUGMEXL~TIOS A$?) DEVIATIOS IS' MICE IMML~~TzED WITH PLASMIDS 
ESCODISG EIGHT C Y T O ~ ~ E S  CO-ADMIS?STERED WITH A DNA-BASED V A C C ~ X  
ESCODIXG A SOLUBLE FORM OF Bomx HERPESVIRUS-1 GLYCOPROTE~- D 
4.1 Introduction 
Immunization with naked DNA, variously described as genetic. polynucleotide, 
nucleic acid or DNA-based immunization, involves the in vivo delivery of, typically, 
plasmid DNA comprised of gene expression regulatory elements and gene(s) encoding 
antigen (Tang et al., 1992; Hassettmd Lindsay Whitton, 1996). Immunogens derived 
from viral, bacterial, and parasitic pathogens, as well as, reporter genes, genes encoding 
turnour rejection antigens, and those involved in modulation of autoimmune disorders, 
have been introduced in vivo as plasmid encoded constructs and many have resulted in 
significant immune responses including, in appropriate animals models, protection 
following challenge (Donnelly et al., 1993; Barry et al., 1995; Waine and McManus, 
1995; Anderson et al., 1996; Conry et al., 1996; Doolan et al., 1996; Haynes et al., 1996; 
Hsu et al., 1996; Inrine et al., 1996; Raz et al., 1996; Syrengelas et al., 1996; Tascon et 
al., 1996; Waisman et al., 1996; Whalen, 1996; Ulmer et al., 1996a; d'oliveira et al., 
1997; Luke et al., 1997; McDaniel et al., 1997). Routes and methods of delivery of 
plasmids encoding reporter genes and a variety of protective immunogens includes: 
topical, unfacilitated delivery, (mucosal) (Fynan et al., 1993) injection (intramuscular, 
intradermal, intraperitoneal and intravenous) w o l f f  et al., 1992; Robinson et al., 1993; 
Zhu et al., 1993; Raz et al., 1994), ballistic (primarily dermal and epidermal)(Haynes et 
al., 1996): liposomal (Li and Hoffman, 1995; Wheeler et al., 1996), modified live viral 
(Yoshimura et al., 1993), bacterially facilitated delivery (epidermis and 
mucosa)(Sizemore et al., 1995), and msfected cell delive~y (Ulmer et al., 1996~). Many 
of these delivery mechanisms have resulted in demonstrable numbers of aansfected cells 
in vivo, and moa have resulted in antigen-specific immune responses representing both 
humoral and cell-mediated arms of immunity (Wow et al., 1 992; Condon et al., 1 996; 
Norman et al., 1997). Despite initial successes with this novel technology, researchers 
-dying immune responses to DNA-based vaccines are now discovering that not all 
antigens are created, or perceived, equally (Mougneau et al., 1995; Hermann et al., 1996; 
MiIich et al., 1997; van Drunen Littel-van den Hurk et al., 1998). Indeed, there is ample 
evidence that the intrinsic antigenic qualities associated with specific immunogens may 
deviate or modulate immune responses in a variety of ways (Cardoso et al., 1996; 
Spriggs, 1996). We have demonstrated, using DNA-based vaccines, in mice and cattle 
that the cellular compartment in which the same antigen is expressed can significantly 
alter the immune outcome following immunization (Lewis et al., 1997; van Drunen 
Littel-van den Hwk et al., 1998). Despite immunogenic features inninsic to individual 
antigens, it seems apparent that many, but not all, immune responses, following im. or 
id.  delivery of DNA-based vaccines in mice are characteristic of a Th 1 -type immune 
response and typically includes a potent CD8' CTL response (Ertl and Xiang, 1996; 
Ulmer et al., 1996b). Thl-type phenotypes are characterized by a predominance of 
antigen-specific IL-2, y and lymphotoxin secreting CD4' Tcells, potent DTH, and 
often a predominance of serum IgG, (Mosmann et al., 1986; Snapper and Paul, 1987). 
Th2-type phenotypes are characterized by CD4' T-cells that secrete IL-4,5,6, 10 and 13 
and often display elevated s e w  IgE or a predominance of IgG, (Mosrnann et al., 1986; 
Snapper and Paul, 1987). What is becoming increasingly apparent is that inainsic 
antigenicity, microenvirollfnental locale of the antigen, route or method of DNA delivery, 
as well as dose of the vaccine dl influence the magnitude and character of the ensuing 
immune response (Pertmer et al., 1996; Coffinan and von der Weid 1997; Feltquate et 
al., 1997; Lewis et al., 1997; Roman et al., 1997). 
CelIuiar and moiecular events at the site of vaccination, in transit fiom the site of 
vaccination, within the various subcompartments of lymphoid organs draining the 
vaccination site, and ultimately redistribution of mediators of humoral and cellmediated 
immunity are orchestrated to a large extent by cytokines and chemokines @ughes and 
Babiuk, 1992; del Pozo et al., 1996; Lofthouse et al., 1996; Premack and Schall, 1996). 
While a wide array of recombinant cytolohes and chemokines are available for humans 
and mice, this has not been the case for many species of interest in veterinary medicine. 
Also, research involving use of conventionally prepared recombinant cytokines is often 
prohibited by large, occasionally toxic doses required, and by exorbitant costs of 
production (Heath and Playfair, 1990; Hughes and Babiuk, 1992; Finkelman and 
Maliszewski, 1 997). DNA-based vaccine technology has provided justification and 
impetus to clone new cytokines and chemokines fiom both food and companion animals 
of veterinary interest. The impetus to do so is on the understanding that costs of protein 
purification and administration would be greatly reduced because injection grade 
expression plasmids encoding cytokines are easily created and purified and may be 
administered prophylactically in the context of conventional, or DNA-based vaccines. A 
relatively cost effective sysrem for prescreening of cytokines, or chemokines, sets the 
stag for rapid and efficient identification of adjuvant potential, and for the 
immunological or molecular dissection of the mechanisms of immune response. A 
variety of recombinant cytokines including; IL-1 a and P, IL-2, IL-4, IL-6, IL-7, GM-CSF, 
IFN y, MF a, TGF P and IL-12 have been utilized to modulate immune responses to 
specific antigens @ranoff et al., 1993; Raz et al., 1993; Taylor, 1995; f i n e  et al., 1996; 
Lofthouse et ai., 1996; Rao et al., 1996). We chose to investigate the potential 
immunomodulatory effects of plasmids encoding IL- 1 or,. IL-2, I L I ,  IL-6, IL- 1 0, GM- 
CSF, EN y and TNF a when co-administered im with plasmids encoding a viral 
antigen. 
Interleukin (L)- 1 cr and @I,)- 1 P display many similarities in biological function and 
have both been demonstrated to enhance antigen-specific immune responses @Inarello, 
199 1). These cytokines are secreted from a variety of lymphoid and nonlyrnphoid cells 
including: most professional antigen presenting cells, epithelial cells, keratinocytes, as 
well as, B- and Tcells. The specific immunological role of these cytokines are unclear, 
however, they have been demonstrated, in vino, to play a role in B-cell differentiation, 
antibody secretion and induction of IL-2. Certainly, the early, post insult, appearance of 
these cytokines suggests a pivotal role in the development of innate and cognate 
immunological responses that follow the early stages of infection. Interleukin (IL>2 is 
secreted by activated Tho and Thl cells, and is instrumental in the induction of CTL 
ac~vity, EN y production, and Bcell stimulation (Weinberg and Merigan, 1988). 
Administration of this cytokine at the time of immunization has been observed to 
augment protective immunity to several viral and parasitic vaccines fiofthouse et al., 
1996). Interieukin a ) - 4  is secreted by a variety of cells, including cells of the Tho and 
Th2 phenotype, as well as CD4+ , NK 1. 1 + T-cells (Mosmann et al., 1 986; Street et al., 
1990; MacDonald, 1995). L-4 has been demonstrated to block IL-2 dependent 
proliferation of T-cells and promote the differentiation of Tm into noncytolytic TJ IL- 
4 secreting phenotype, and also appears to indirectly inhibit IL- 12 and y mediated 
immune deviation towards a Thl-type phenotype (Powrie and Cofkan, 1993; Croft et 
al., 1994; Seder and Le Gros, 1995; Rocken et al., 1996). IL-4 has also been shown to 
influence the switching of B-cell immunoglobulins to the IgG, and IgE isotypes and to be 
involved in maintenance of dendritic cell antigen processing capabilities (Snapper and 
Paul, 1987; Sallusto and Lanzavecchia, 1994). In this way IL-4 is an inhibitor of Thl 
responses and a promoter of Th2 responses to antigens @ranoff et al., 1993; Sharma et 
al., 1996; Resch et al., 1997). Interleukin (IL)-6 is a dtifunctional cytokine produced 
by a number of lymphoid (macrophages and activated CD4' T-cells of the Th2 
phenorype) and nonlymphoid (keratinocy-tes, fibroblasts, endothelid ) cells, (Hirano et 
al., 1990). This cytokine is vexy pleiotropic in function and has been demonstrated to 
induce terminal B-cell differentiation and to enhance the production of IgA at mucosal 
surfaces (Ramsay et al., 1994). Furthermore, creation of attenuated recombinant Vaccinia 
or Fowlpox viruses that express IL-6 can enhance priman, and recall humoral antibody 
responses in mice (Leong et al., 1994). Interleukin a) -10  is secreted primarily by ThZ- 
type T-cells and inhibits Thl -type immune responses possibly through downregulation of 
macrophage and possibly dendritic accessory cell fuactions piorentino et al., 199 1 ; De 
Smedt et al., 1997). Tumour necrosis factor (TNF)-a is secreted primarily by monocytes 
and macrophages and induces hemomhagic necrosis of mutours and initiates a metabolic 
cascade leading to systemic shock associated with severe disease conditions (Manogue et 
al., 199 1). TM a also shares some biological properties with IL- 1 and has been 
demonstrated to play a role in onset, and augmentation, of immune responses to 
pathogens or vaccines @unun et al., 1985; Nathan, 1987). Recently TNF CY has been 
demonstrated to play an important role in the maturation, and perhaps mobilization of 
nonlymphoid tissue resident dendritic cells (Sallusto and Lanzavecchia, 1994). In vivo 
work in cattle showed an increase in peripheral blood monocyte numbers and function 
after administration of recombinant, E. coli derived, bovine TNFa, (Bielefeldt-Ohmann 
et al., 1989). This cytokine has also been demonstrated to specifically enhance in vivo 
immune responses to a Tdependent antigen in mice (Ghiara et al., 1987). Interferon 
0 - 1  is produced by activated Tho and Th 1-type CD4' T-cells and by IL-12 (or IL-1) 
activated NK cells (Mosmann and Coffman, 1987; S ~ e e t  et al., 1990; Scharton and Scott, 
1993). It has been primarily characterized in terms of i~ ability to upregulate MHC class 
I and II expression on antigen presenting cells (Rosa and FeUous, 1984; Mosmann and 
Cofkm,  1989). More recently this cytokine has been shown to regulate, in part, 
deviation of the immune response towards a Thl phenotype and as an immunoglobulin 
isotype switching factor involved in the generation of IgG, by T-independem and T- 
dependent B-cell responses (Snapper and Mond, 1993). It also appears that this cytokine 
is more effective in deviating immunity towards a Thl -type of response when synergized 
with IL-11 (Schijns et al., 1995; Ahlers et al., 1997). There is also direct evidence in mice 
that co-administration of recombinant m d e  IFN y with conventional vaccines, results 
in enhanced humoral responses (Lofthouse et al., 1996). Finally, 
granulocyte/macrophage-colony stimulating factor (GM-CSF) acts on bipotential bone 
m o w  stem cells to produce mononuclear phagocytes. including dendritic cells. and 
granulocytes (Monissey et al., 1987; Fischer et al., 1988). GM-CSF has also been 
demonstrated to recruit and enhance the activation of professional antigen presenting 
cells (APCs), to upregulate major histocompatibility antigen II (MEIC I) on APCs and 
augment the primary antibody response following vaccination (Heufler et al., 1 98 7; 
Fischer et al., 1988; Elliot et al., 1991; haba et al., 1992). 
A number of recent publications have characterized immune responses to several 
antigens, delivered as protein or as DNA-based vaccines, following co-delive~y of 
plasmids encoding a variety of cytoldnes. Cytokines tested to date include: IL-2, IL-4, 
DL-6, IL-7, IL-12, GM-CSF and TGF P (Raz et al., 1993; Xiang and Ertl, 1995; Irvine et 
al., 1996; Chow et al., 1997; Tsuji et al., 1997). Prior to the commencement of 
experiments described in this section , no single published report desmied immune 
responses to plasmids encoding cytokines co-administered with DNA-based vaccines. We 
chose to investigate 8 different murine cytokines based on historical data describing either 
adjuvant or specific APC modulatory capacity. Interleulohs 1 a, 2,4, 6, 10, as well as, 
TNF a, EN y and GM-CSF, were subcloned into an expression cassette and co- 
administered with a second plasmid encoding a secreted version of bovine herpesvirus- 1 
(BHV- I ) glycoprotein D (SgD). Authentic gly coprotein D normally displays a 
transmembrane domain that anchors it within the host cell plasma membrane, and 
subsequently on the viral lipid envelope (Tikoo et al., 1990). This Alphaherpesvirus is of 
significant economic importance in the cattle industxy due to its involvement in a variety 
of clinical and subclinicaI diseases conditions. It is the causative agent of Infectious 
Bovine Rhinotrachei tus @R) and infectious pustular ~ u l v o v a ~ i t i s  and balanosposthitis 
(IPV and IPB respectively) in cattle (Roirman et al., 198 1; van Drunen Liael-van den 
Hurk et al., 1993a). BHV-I is also believed to play a significant role in abortions, 
meningoencephalitis and conjunctival diseases (Schuh, 1994). Finally, BHV- 1 is 
considered to be the single most important agent predisposing cattle to secondary, 
opportunistic, bacterial infections leading to a bovine respiratory disease complex 
commonly referred to as Shipping Fever Wates, 1982; Babiuk et al., 1996). 
Protetive immune responses are elicited in cattle immunized with BHV- I gD as 
detamined by reduced shedding of virus and a significant reduction in clinical signs and 
susceptibility to secondary bacterial infection (van Drunen Littel-van den Hurk et al., 
1993b). Immhty to this antigen in mice, both as a conventional vaccine and as a DNA- 
based vaccine, has aIso been studied extensively (Cox et al., 1993; Baca-Estrada et al., 
1996; Braun et al., 1997; Lewis et al., 1997; van h e n  Littel-van den Hurk et al., 19%). 
Although it is not possible to carry out viral challenges, in mice, because of the inability 
of this species to support a full replication cycle of BHV-1, we feel that preliminan, 
screening of cytolo'ne modulatory capabilities in this species is justified. Criteria for the 
determination of moduiatory capacity of co-administered cytolo'nes included: impact on 
serum antigen-specific serum antibody levels, ratio of serum IgG, and IgG,, and the 
impact on serocoaversion efficacy. We included T- and B-cell ELISPOT data from cell 
populations harvested from spleens and draining lymph nodes to funher understand what 
factors might be contributing to observed deviations or augmentations in the immune 
responses observed We were able to demonstrate that augmentation of humoral 
responses, as well as, seroconversion efficiency, occwed if a single low dose of plasmids 
encoding GM-CSF, IL-4, IL-6 and TNF er were co-administered with a suboptimal dose 
of plasmids encoding a secreted form of BHV-I gD. Enhancement of the serum levels of 
IgG, occurred when plasmids encoding IFN y and TNF a were co-administered with 
plasmids encoding a secreted form of BHV-I gD. Finally, dose ti~ation studies with 
plasmids encoding GM-CSF and IFN y showed unequivocal evidence that dose of 
plasmid encoded cytokine and the presence or absence of boosting can have dramatic 
effects on the character of the ensuing immune response. 
4.2 Materials and Methods 
4.2.1 Mouse Strain 
Female 5-6 week old C3-N mice were purchased from Charles River 
(Canada). All mice were acclimated to new housing for 1-2 weeks prior to vaccination 
with DNA-based or conventional vaccines. All mice were immunized with DNA-based 
vaccines in the left and right quadriceps muscle masses with or without boosts 2 weeks 
later- 
4-22 Bacterial Strains, Mammalian Cell Lines and Tissue Culme Reagents. 
Bacterial E. coli cells included: M I 0 5  (New England Biolabs, hc., Mssisauga, 
Ont.), HBlOl (hvinogen Corp., San Diego, CA), DH j c r  (CLONTECH Lab., Inc., Palo 
Alto, CA), and SUREs cells (Stratagene, La Jolla, CA). Murine cell lines included: L929 
(ATCC No. CCL 1 ); D 1 0.G4.l (ATCC No. W 224); m-2 (ATCC No. CRL 1841 ); 
CTLL-2 (ATCC No. W 2 14); 7TD1 (ATCC NO. CRL 185 1); COS-7 (ATCC No. CRL 
1651); P388D1 (ATCC No. W-63); WEHI-3 (ATCC No. W-68) and the GM-CSF 
sensitive cell line DA-1k (T. Mossman, DNAX Corp., 1986). LM-1 is a subline of 
D 1 0.G4.l developed in our lab (L. McDougall, Veterinary Infectious Disease 
Organization, Saskatoon, Saskatchewan, Canada) that does not require spleen feeder cells 
or conalbumin. LM- I cell growth requires only the presence of 10% rat growth factor. 
All media and media supplements were purchased from GIBCO-BRL (Gibco, Life 
Technologies, Burlington, Ont.) or Sigma (Sigma Chemical Co., St. Louis, MO) unless 
othenvise indicated. All tissue culture plasticware was purchased from Corning (Coming 
Inc., Corning, N.Y.) or Costar (Costar/Nucleopore Canada Inc., Toronto, Ont.) unless 
indicated otherwise. 
4.2.3 Plasmid DNA and Molecular Reagents 
Commercial plasmids included pSL30 1 and pCDNA3 (Invitrogen), and pGEMl 
(Promega Corp., Madison, WI). The construction of expression cassette pSLRSV.Nu1 has 
been described previously (setion 3.2.1). Two additional expression cassettes were 
created based on pSLRSV.Nul, that involved ablation of the unique Bgl II site within this 
plasmid and insenion of an Afl11 or Pst I site (Fig. 4.1). An Af7 I1 site was inserted by 
blunt- end ligation of an Afl I1 linker (dCGCTTAAGCG-New England Biolabs, 
Mssissauga, Ont-) or Psr I linker (dCCTGCAGG). The DNA-based vaccine expressing a 
secmed form of glycoprotein D from BHV- 1 has been described previously (section 
3.2.1). All restriction endonucleases and DNA/R.NA modifying enzymes were from 
Pharrnacia (Pharmacia Biotech., Quebec) or New England Biolabs. All purifications of 
mRNA and first strand cDNA synthesis was canied out using kits purchased from 
Pharmacia. Ail injection quality plasmid DNA was prepared by anion-exchange column 
purification (Qiagen, Inc., S a m  Clarita, CA) and assessed by restriction analysis and 
agarose gel elemophoresis prior to injection. 
4.2.4 Construction of plasmids expressing murine cytokine genes 
All eight cytokine cDNAs a-1 a, IL-2, IL-4, IL-6,I.L- 10, GM-CSF, m a  and 
IFN y) were inserted into the expression cassette pSLRSV.Nu1 which had been modified 
to receive Psz I (pSLRSV-Nul-P) or Af2 11 (pSLRSV.Nul-A) restricted genes (Fig. 4.1). 
Murine cDNAs encoding IL-2 (1 170 bp) and GM-CSF (940) in pGEM1" (Romega) 
vector was kindly provided by Dr. J. Elliot (Dept. Medical Microbiology and Infectious 
Diseases, University of Alberta, Canada). 
Plasmid pSLRSV.L-2 was generated by first ligating an Af7 I1 linker sequence (New 
Fig. 4.1 Schematic diagram of the eukaryotic expression cassettes. Gene expression 
modulatory elements are on a pSL3O lT" plasmid backbone and are comprised of the 
promoter/enhancer from Rous sarcoma virus long terminal repeat and the polyadenylation 
signal from SV40. Creation of a plasmid with unique Pst I (pSLRSV-NUL-P) or Afl I1 
@SLRSV.NUL-A) gene insertion sites was carried out by digestion of the parent cassette 
(pSLRSV.NUL-B) , containing a unique BgZ TI insertion site, with Bgl II followed by end- 
repair and ligation of either an Afl II or Pst I linker sequence. Murine cytokine cDNAs 
were inserted in these unique restriction sites depending on the presence or absence of 
these sites in the sequence of the particular cytokine. Murine cytokines: IL- 1 a, IL-1 0, 
GM-CSF and IFN y were inserted into the pSLRSV.NUL-B vector. Murine cytokines IL- 
2 and IL-6 were inserted into the pSLRSV.NUL-A vector and murine cytokine TNF a 
was inserted into the pSLRSV.Nu1-P vector. 

England Biolabs) into the unique Pst I site within the 5'-untranslated (LJT) region , by 
Pst I digestion followed by Klenow end-repair and blunt-end linker ligation. Excision of 
the IL-2 gene fiom pGEMl was carried out by Afl 11 - Ssp I (3'-UT region) digestion and 
ligation into Afl II - Eco47 DI digested pSUOl (Invitrogen ). A positive clone was 
digested with Eco RV and the Afl II linker ligated into this site. Transformation and 
identification of IL-2 with Afl II unique restriction sites within the 5' and 3'-UT regions 
dowed excision and ligation into the unique Afl II restriction site within the expression 
cassette pSLRSV.Nul-A to create the plasmid pSLRSV.L-2. 
Plasmid pSLRSV.CSF was created by digesting the pGEM vector containing this 
cDNA with Sau I and Tfi I. For convenience we chose to utilize the second intitation 
codon within the translated region of the gene. It has been demonstrated that this second 
ATG start site is utilized to the same extent as the initial intiation codon and that the 
resulting product maintains biological activity equal to its longer counterpart (Gough et 
d., 1985). Bgl I1 Linkers were Ligated to the end-repaired Sau Y Tfi I fragment. After 
ligation the DNA fragment was predigested with Bgl 11 , heat inactivated, and purified 
following agarose gel electrophoresis using a GeneCleanTm (BIO 10 1, Inc., Vista, CA) kit. 
The GM-CSF cDNA with Bgl I1 ends was ligated into vector pSLRSV.Nu1-B to generate 
pSLRSV.GM-CSF. 
Plasmid pSLRSV.E-4 was created by amplifying the IL-4 first strand cDNA using 
polymerase chain reaction (PCR) from reversed transcribed messenger RNA (mRNA) 
harvested fiom C57BU6 immune splenocytes harvested 3 weeks post-boost, and 
stimulated with antigen (1 50 nghL at 10 W 2 5  million splenocytes) for 48 horn in 
vitro. Sense and antisense primers (Table 4.1) commenced at bases 41 and 506, 
respectively, of the published IL-4 cDNA sequence (Lee et al., 1986). These primers 
introduced unique Bgl II restriction sites within the 5' and 3' manslated regions. The 
amplified IL-4 sequence was phospho~y lated with T4 polynucieotide kinase, 
pheno1:chlorofom emacted, and purified using a GenecleanT= kit. This 465 bp cDNA 
was blunt-end ligated into Eco RV cut pCDNM' (Inviuogen) and used to transform 
competent DH 5 a cells. Positive clones were identified and used to provide an IL-4 
cDNA with Bgl I1 ends that was subsequently ligated into expression cassette 
pSLRSV.Nul to create plasmid pSLRSV.IL-4. 
Plasmid pSLRSVIL-6 was created by amplifying reverse transcribed mRNA 
prepared from splenocytes harvested from C3WHeN mice immunized with a DNA-based 
vaccine @SLRSV.SgD) and boosted two times with recombinant, affinity column 
purified, truncated gD (tgD) formulated with VSA3 (Biostar Inc., Saskatoon, 
Saskatchewan, Canada). Sense and antisense primers (Table 4.1) commenced at bases 
15 and 671, respectively, of the published cDNA sequence (Van Snick et al., 1988). 
These primers also introduce unique Af7 II restriction sites into the 5' and 3'-UT regions. 
Amplified 1L-6 cDNA was phosphorylated and Ligated into Eco RV digested, 
dephosphorylated vector, pSL30 1. Following transformation of competent DH 5c( 
bacterial cells, positive clones were identified and the IL-6 cDNA, with unique flanking 
Afl II ends, was subcloned into the Afl II site of pSLRSVNul-A to create plasmid 
pSLRSV.IL-6. 
Plasmid pSLRSVJL-10 was created by amplifving, by PCR, reverse transcribed 
Table 4.1 Primer sequences utilized to generate PCR amplified cytokine cDNAs. 
Rimer Sequences Resuiction 
Sites 
5' and 3' ends 
Pst I 
S - sense strand 
A - Antisense strand 
mRNA prepared from the m d e  helper T-cell line D 10.G4.1. A subclone of this Line 
(LM- 1), was grown in Click's media (GIBCO-BRL) with 50 pn 2-mercaptoethanol, 10% 
rat growth factor containing 20 mg/ml a-methyl-D-mannoside and 10% fetal bovine 
serum (FBS). LM-1 cells were stimulated with conalbumin A, at 4 p g m ,  for 24 hours 
prior to extraction of total RNA. Sense and antisense primers (Table 4.1) commenced at 
bases 6 1 and 6 19, respectively, of the published sequence (Moore et al., 1990). Primers 
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also introduced unique Bgl 11 sites into the 5' and 3'-UT regions. PCR products were 
purified, following agarose gel electrophoresis, and phosphorylated prior to blunt-end 
ligation hto Eco RV digested dephosphory lated, pS L3 0 1. Following transformation of 
competent SUREZ cells, positive clones were identified and anion-exchange column 
purified plasmid DNA from a single positive clone was digested with Bgl II to generate 
an lL- 10 cDNA fragment with Bgl II sticky ends. This fragment was ligated into the Bgl 
II site of pSLRSV.Nul to generate plasmid pSLRSV.IL- 10. 
Plasmid pSLRSV.TNFa was generated by amplifjmg reverse transcribed total R.KA 
from the macrophage cell line P388D1. P388D1 cells were stimulated with LPS (10 
@mL) for 2 and 5 hours and total RNA extracted and pooled. Following first mand 
cDNA synthesis, sense and antisense primers (Table 4.1) were utilized to generate a 765 
bp PCR product that commenced at bases 107 and 872, respectively, of the published 
sequence (Pemica et al., 1985). These primers introduced unique Pst I sites into the 5' 
and 3'-bT region of the cDNA. This PCR product was digested with Psr I prior to 
Ligation into dephosphorylated, Pst I digested, pSL30 1. Positive clones were identified 
and anion-exchange column purified plasmid DNA, from a single positive clone, was 
digested with Pst I to provide TNF a cDNA . Following agarose gel electrophoresis and 
purification, this cDNA was ligated into Psr I digested expression cassette pSLRSV.Nul- 
P to generate plasmid pSLRSV.TNF a. 
Plasmid pSLRSV.IFN y was created by PCR facilitated amplification of reverse 
transcribed mRNA from immune murine spleens. C57BU6 mice were immunized with 
recombinant truncated gD (500 nghouse) formulated in VSA3. Mice were boosted at 3 
weeks and spleens harvested 3 weeks following boost. Splenocytes were stimulated 48 
hours in W o ,  with truncated gD (1 50 ng/tgD/mL and 10 mV25 million splenocytes). 
Sense and antisense PCR primers (Table 4.1)' commenced at bases 55 and 558 , 
respectively, of the published sequence (Gray and Goeddel, 1983). These primers 
introduce unique Bgl II sites within the 5' and 3'-UT regions. The 503 base pair, purified 
PCR product, was phosphorylated and blunt-end ligated into Eco RV digested, 
dephosphorylated, pSUO 1. Positive clones were identified and anion-exchange colum.n, 
purified plasmid DNA from a single clone was digested with Bgl I1 and the E N  y cDNA 
Ligated into the expression cassette pSLRSVNul to create the plasmid pSLRSV.IFN y. 
Plasmid pSLRSV.IL- I a was created by PCR amplification of reverse transcribed 
mRNA prepared from LPS stimulated P3 88D 1 celis. Sense and antisense primers 
commenced at bases 46 and 9 19 of the published sequence and generate an 873 bp 
product (Lomedico et ai., 1984). These primers introduce unique Bgl II restriction sites 
into the 5' and 3'-UT regions. Following agarose gel electrophoresis and purification, the 
PCR product was digested with Bgl I1 purified once again and ligated into Bgl II digested, 
dephosphorylated, expression cassette pSLRSV.Eiul. All polymerase chain reactions 
were carried out using VentTm DNA polymerase (New England Biolabs), 32 cycles of 
amplification on a Model PTC-1 (GIBCO BRL, Inc.) thexmocycler. Restriction pattern 
analysis (all cytokine cDNAs), partial dideoxy sequencing (11-6, IL- 1 0, TNF a and IFN 
y) and functional bioassays (all cytokine expression constructs) were utilized to confirm 
identity of cytokine cDNAs utilized in this research. 
42.5 Tmsient transfedon of COS-7 cells with cytokine expression cassettes. 
COS-7 cells, at 7040% confluency, in six well tissue culture plates were washed 
twice with Hanks Balanced Salt Solution (GIBCO/BRL). Expression cassettes encoding 
eight different murine cytokine cDNAs were purified by anion-exchange column 
chromatography. Two pg of each plasmid, as well as a control pSLRSV.Nu1 plasmid was 
diluted into 500 pL serum free Dulbecco's Modified Eagle Medium @MEW 
(GIBCOIBRL). Transfectamf (Promega), (5.0 pL of 2.5 pg/ pL stock) was diluted in a 
separate 500 pL, volume of DMEM and vortexed briefly. DMEM containing plasmid 
DNA and Transfectams were mixed and immediately added to washed COS-7 
monolayers. Monolayers were incubated for 5 hours with the Transfectamf /DNA rnixnne 
at which point 1.5 mLs of DMEM containing 20% FBS (GIBCO-BRL) was added to each 
transfection well. Media fiom each transfection were harvested after 24 hours and 
centrifuged (30 seconds at 16,000 x g) briefly to remove cellular debris. Cleared media 
was transferred to clean sterile 1.5 mL Eppendorf tubes and stored at -20 "C until needed 
for cytokine bioassays. 
4.2.6 Cytoldne bioassays 
Commercially prepared recombinan& human IL-6, murine IL- 10, IFN y , and 
GMCSF were purchased from Genqme Coq. (Cambridge, MA)), recombinant murine 
IL-4 was purchased fiom Pharmingen (San Diego, CA), recombinant murine L-1 P and 
TNF a were purchased from Boehringer Mannhein Canada Ltd. (Zaval, Quebec), and 
recombinat murine IL-2 was purchased fiom ICN Biomedicals Canada Ltd. (St-Laurent, 
Quebec). Cytokine bioassays using media from COS-7 cells transiently transfected with 
each of the cytokine expression constructs (excluding pSLRSV.IL- 10) were carried out 
according to described protocols (Coligan et al., 1996). Briefly, IL- la, IL-2, IL-4, IL-6 
and GM-CSF were assessed for the ability to support growth of LM- 1, HT-2, CTLL, 
7TD1 and DA-1 k cell lines, respectively. Bioassay for murine IFN y involved assessing 
the antiviral activity of IFN y after stimulating L929 cells to resist infection with 
vesicular stomatitus virus (VSV). TNF a mediated L929 cell lysis was utilized to 
determine the presence and biological function of this cytokine. A biological assay of 
IL- 10 was not carried out, however, a capture ELISA performed on media harvested 
from pSLRSV.IL- 10 transfected COS-7 cells verified the presence of this murine 
cytokine. In each instance transfection samples were assessed relative to media harvested 
from COS-7 cells transiently transfeaed with a control pSLRSV.Nui plasmid. 
42.7 Mouse injections 
Inbred 7 week old, female C3WHeN mice were injected with plasmid DNA 
purified by anion-exchange column chromatography and dissolved in normal saline. All 
injections of DNA were i.m while injections of purified antigen (authentic or 
recombinant truncated gD) formulated in either VSA3 (Biostar, Saskatoon, 
Saskatchewan, Canada) or durn (~lhydrogel~~,  Cedarlane Laboratories, Ltd, Hornby, 
Ontario) were subcutaneous (s. q.). Mice were physically restrained and injected using a 
0.5 mL disposable Monoject@ (Sherwood Medical, St. Louis, MO) syringe with a 29 
gauge needle. AU mice received doses of plasmid DNA split between the left and right 
quadriceps muscle mass. Mice were boosted at 14 days unless otherwise stated. 
Nonlethal rail bleeds were canied every 2 weeks until the experiments were terminated. 
Mice were euthaaized by HalothaneTm (MTC Pharmaceuticals, Cambridge, Ontario) 
overdose. 
4.2.8 Splenic and lymph node cell harvests 
Mouse splenocytes were prepared by mechanically grinding spleens through a 
aeriie nylon mesh into a sterile Petri dish containing 10-20 mL of RPMI 1640 (Sigma 
Chemical Co.) This material was then pipetted into sterile 15 or 50 rnL rubes and 
allowed to sit on ice for 10 minutes. Debris that settled to the bottom was aspirated with 
a sterile Paaeur pipette and discarded Tubes were centrifuged at 220 x g, in a Beckman 
GPR cenaifuge, for 10 minutes (at 4 "C). Red blood cells were lysed by resuspension of 
the cell pellet in 1.0 mUspleen of arnmonium chloride lysis buffer (0.14 M NHJI and 
0.01 7 M Tris-HC1, pH 7.2) for 60 seconds. Lysis was terminated by addition of 14 mL of 
RPMl 1640 at room temperature. Samples were pelleted by centrifugation (250 x g) and 
resuspended in RPMI 1640. Splenocyte numbers were assessed by staining with Trypan 
blue (GIBCOBRL) and counting on a haemocytometer. Splenocytes were centrifuged 
(250 x g) and resuspended at a final concentration of 1 x lo7 cells/rnL in RPMI 1640 
supplemented with 10% (FBS) (Sigma Chemical Co.), 100 U/mL of penicillin, and 100 
@mL of streptomycin (Sigma Chemical Co.), 2 mM L-gtutamine (GIBCOBRL ) 1mM 
sodium pyruvate (GIBCO/BRL), 10 mM HEPES (GIBCO/BRL) and 5 x 1 0-s M 2- 
mercaptoethanol (Sigma Chemical Co.)(complete RPMI 1640). A modification of a 
method for hamesting Peyers patch lymphocytes was utilized to prepare singie cell 
suspensions from lymph nodes (Spalding, 1983) . Briefly, iliac lymph nodes were 
collected into 15 rnL tubes containing sterile chilled Phosphate Buffered Saline without 
calcium or magnesium chloride (PBSA)(GIBCO/BRL). Pooled nodes were placed into a 
sterile Peni dish and excess PBSA discarded. Nodes were diced with a sterile scalpel in a 
s m d  volume of CMF solution ( 0.1 x Hanks Balanced Salt Solution, Ca" Mg'- free; 10 
mM Hepes, pH 7.2; 25 mM NaHCO,, pH 7.2; and 2% FBS) and then mixed with 10 mL 
digestion buffer ( 1 x Hanks Balanced Salt So1uti.011, 10% FBS, 15 mM HEPES, pH 7.2) 
containing 150 Units/mL of Collagenase (CLS 1, Worthington Biochemical Corporation), 
and 0.015 mg/mL DNase I (Pharmacia Biotech hc., Baie d'Urfe, Quebec, Canada ). 
Diced nodes in digestion buffer were transferred to siianized 25 -50 mL Ehrlenmeyer 
flasks, containing a sterile Teflon coated stir bar, and incubated at 37 O C  ,with stirring, 
for 90 minutes. Samples were harvested into sterile 15 mL plastic tubes and allowed to 
sit for 10 minutes. Large pieces of undigested material were returned to the Erhlenmeyer 
flask and incubated an additional 30-60 minutes with 5.0 ml of digestion buffer. This 
material was combined with the initial harvest and cells were centrifuged (250 x g) to 
pellet. Digestion buffer was decanted and the cells were resuspended in PBSA (GIBCO- 
BRL). Cells were counted using a haemocytometer and centrifbged(250 x g) one final 
time. Cells were resuspended to a final concentration of 1 x 1 O7 ceils/mL. 
A modified protocol for splenocytes was also used that included an additma160 
minute digestion of pooled splenocytes with collagenase (150 UniWmL of digestion 
buff=, Sigma Chemical Co.) and DNase I (0.0 1 5 mg/ml of digestion buffeq Pharmacia 
Biotech Inc.). These digestions were only carried out in experiments that included 
assessment of antigen-specific responses from cells prepared from lymph nodes. These 
digestions were carried out prior to cell counts and resuspension. 
4.2.9 Total IgG and IgG isotype ELISA 
Immunlon 2 microtitre plates -tech Laboratories Inc., Alexandria, VA) were 
coated with purified recombinant mmcared gD (Biostar hc.) at a concentration of 0.050 
pglwell. Coating antigen dilutions were done in ELISA Coating buffer (-0 12 M Na&OI, 
-038 M NaHCO,, pH 9.6 ) and c o a ~ g  was allowed to proceed overnight at 4 "C. Plates 
were washed 5 times in phosphate buffered saline (. 137 M NaCl ,003 M KCl, .008 M 
NaHPO,, -001 M NaH,P03 with 0.05% Tween20 (PBST) prior to addition of fourfold 
dilutions of mouse sera prepared in PBST with 0 -5 % gelatin (PBST-g), (Bio-Rad 
Laboratories Ltd., Mississuaga, Ontario). After a 2 hour incubation, plates were washed 
in PBST and an affinity purified biotinylated goat antimouse Ig (Zymed Laboratories Inc., 
Sari Francisco, CA) diluted to 1/5,000 in PBSTq was added to each plate. After an 
incubation of 60 minutes, plates were washed extensively md Streptavidin-alkaline 
phosphatase (Gibco, Life Technologies, Burlington, Ontario) diluted to V2000, in PBST- 
g, was added to each plate. Following a 60 minute incubation, plates were washed six 
times in PBST. Prior to addition of substrate the plates were washed two additional times 
in PBS. Development of plates involved the addition of -01 M p-nitrophenyl phosphate 
(Sigma Chemical Co., St. Louis, MO) in substrate buffer (0.104 M Diethanolamine- 
Sigma Chemical Co., 0.5 mM M g C '  ). Absorbances were read on a Model 3550 
Microplate Reader (Bio-Rad Laboratories Ltd.) at 30 minutes and again at 60 minutes at 
405 nM with a reference wavelength of 490 nm. Antibody isotyping ELISAs were 
carried out in a similar fashion except that biotinylated goat antimurine IgG, and IgG, 
(Caltag Laboratories, San Francisco, CA) were used at a dilution of 1/8,000 except for 
IgM (1/29000 ). Incubation times with these antibodies was 60 minutes. Addition of 
Strepavidin-alkaline phosphatase and development of plates was as decribed for total 
IgG ELISA. 
4.2.1 0 ELISPOTs 
A cytokine specific ELISPOT assay was used as described previously (Czerkinsky 
et al., 1988; Baca-Estrada et al., 1996). Briefly, single cell suspensions isolated from 
spleens, lymph nodes or bone marrow were stimulated in-vitro by incubating in complete 
RPMI 1640 at 37 "C and 5% C 4  for 20 hours in the presence of recombinant authentic 
gD (0.4 pg/mL). After antigen stimulation, cells were washed twice in complete media 
and diluted to a concentration of 1 x 10' cells/& of complete RPMI- 1640. 
Nitrocellulose plates (FIL~~plate~",  0.45 p x  Polyfiltronics, hc., Rockland, MA, USA) 
were prepared by coating overnight at 4 "C with 2.5 &m.L of purified antirnwine 
interleukin (IL)-4 (Cat. No. 1 1Bll) or 5 pg/mL of purified antimurine interferon 0 - y  
(Cat No. R4-6A2) (Pharmingen, San Diego, CA, USA) diluted in carbonatehicarbonate 
buffer ( 45 -3 mM NaHC03, 1 8 2 mM N%CO,, pH 9.6). After coating, unbound antibody 
was washed from the wells thrice with sterile PBST followed by 3 washes with sterile 
PBS. Wells were blocked for 2 hours at 37 "C with complete RPMI 1640. Blocking 
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media was decanted and 100 pL of antigen stimulated cell suspensions were added to 
triplicate wells. After a 20 hour incubation, at 37 "C and 5% C02, plates were washed 2 
rimes in tapwater and 5 times in PBST to remove cells and nonspecifically bound 
cytokine. One hundred pL of biotinylated antimurine IL-4 (Cat. No. BVD6-21G2) and 
IFN-y (Cat. No. XMG1.2) (phanningen Canada Inc.) monoclonal antibodies (3 pg'rnL of 
each in 1% FBSRBS) were added to appropriate wells and incubated for 3-6 hours at 
ambient temperature on an oscillating mixer- Plates were washed 6 times in PBST and 
100 pL of a 1/1000 dilution of Streptavidin alkaline phosphatase (BioKan Scientific, 
Mississauga, Ontario, Canada) in 1% FBSlPBS was added to each well. Afier a 2 hour 
incubation, at ambient temperature, the plates were washed as before twice in PBS. 
Plates were developed by the addition of 50 pL of the substrates, 5-bromo-4-3-indolyl 
phosphate (BCIP), and nitroblue teaazolium (NBT), (Moss Inc., Pasadena, 1vlD). Plates 
were allowed to develop at ambient temperature for 10-30 minutes, after which reactions 
were stopped by extensive washing in distilled water. After air drymg, spots were 
counted under a dissecting microscope. B-cell ELISPOT involved the use of 
nitrocellulose plates (Millipore Milliscreen-HA, Millipore, Bedford, MA) that were 
coated overnight at 4 'C with purified recombinant truncated gD at 5.0 pglmL in 
carbonatehicarbonate buffer (pH 9.6). Coated plates were washed three times in sterile 
PBST followed by 3 washes in sterile PBS. Nonspecific binding sites were then blocked 
with complete RPMI 1640 at 37 'C for 1-2 hours. Fresh, unstimulated cells from spleen 
or lymph nodes, prepared as described above, were added in a volume of 100 pL (1 x 
lo7 celldml) to each well. Uncoated but blocked control wells, for nonspecific binding 
of IgG, also received cells from each test sample in triplicate. Plates were incubated at 37 
"C with 5% CO, for 10-12 hours. After the incubation period, all cells were washed out of 
the wells by 2 initial washes with tapwater followed by 6 washes with PBST. 
Biotinylated antimurine IgG, or IgG, antibodies (1/8,000 dilution) were added in a 100 
pL volume of PBST (with 1% FBS) and incubated with mixing for 3-4 hours at ambient 
temperame. After washing in PBST six times, streptavidin-alkaline phosphatase 
(1/1,000 dilution in PBS-T with 1% FBS) was added to each we11 (100 @). After a 60 
minute incubation, plates were washed six times in PBST and 2 times in PBS. Plates 
were developed as described for the cytokine ELISPOT. 
4.2.1 1 Statistical analysis 
Data was entered into a database in the statistical analysis program Instat 
GraphPadTm. Differences in antibody titres among vaccine groups were investigated using 
the nonparametric Mann-Whimey U test. 
4.3 Results 
4.3.1 Immunization with different doses of pSLRSV.SgD. 
In order to identify a suboptimal dose that would subsequently be utilized in 
cytokine modulation experiments a DNA dose titration experiment was conducted. The 
impact of singie dosing versus boosting with pSLRSV.SgD on serum IgG tines, 
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seroconversion efficacy and splenic cytokine profiles was also determined. Female 
C3WHeN mice were immunized im either once (single dose group) or twice (boosted 
group) with either 2, 10 or 50 pg of pSLRSV.SgD. Saline (SAL) and conventional 
vaccine (VSA3 + tgD) groups received boosts 14 days following the initial immunization. 
Mice were euthanised at 2 ,4  and 6 weeks and spleens harvested, pooled and assessed for 
IL-4 or IFN y secretion as measured by ELISPOT. We had previously demonstrated that 
most mice immunized and boosted with 100 pg of pSLRSV.SgD seroconverted at 2 
weeks with peak serum igG titers exceeding 40,000 in some instances (section 3.3 2). 
We also demonstrated previously that mice immunized with pSLRSV.SgD dispiayed 
measurable serum titers 5 1/2 months following boost and that predominant serum 
isotype was IgG,. Despite the predominance of a serum isotype that correlates to a Th2 
type of immune response the 6 month splenic cytokine profile, following restimulation in 
vitro, was almost exclusively E N  y. Upon further examination we were able to 
demonstrate that the predominant senun isotype in mice immunized two times correlates 
more closely to the cytokine profile in the iliac lymph node, which drains the deep tissues 
of the quadriceps muscle mass. 
This dose titration experiment (Tables 4.2 and 4.3) clearly shows that 2 to 4 week 
serum antibody levels in mice immunized with a single dose of pSLRSV.SgD were 
greatly influenced by the dose of DNA. One hundred percent of mice immunized with a 
single 50 pg dose of pSLRSV.SgD seroconverted with mean titers at 2 weeks 
significantly @s 0.5) higher than in mice receiving lower doses. A single 10 pg dose of 
Table 42. Dose Titration of a single dose of pSLRSV.SgD. 
Serum ELISA Titersc Splenic 
vaccine Doseb (no. seropositive miceho. immunized) Cyto kined 
Groupsa $2 Profile (6 week) 
2 weeks 4 weeks 6 weeks E-4 
DNA 
DXA 
DNA 
VS.43 + tgD 
VSA3 + tgD 
VSA3 + tpD 
SAL 
170 * 71 
(1/10) 
5128 * 2944 
(419) 
8640 i 2339 
(1 0/10) 
ILd. 
ad .  
ad.  
n.d 
290 * 142 
(2'5) 
8867 * 8368 
(213) 
9600 441 1 
(515) 
nd. 
nd. 
ad. 
ed. 
-- 
" DNA is plasmid pSLRSV.SgD which encodes a secreted form of BHV- 1 gD 
DNA and VSA3hgD were admhhmed im. or subcutaneously, respectively 
EUSA titers are represented as the mean value of s e m  titers from seropositive mice (s 200 is 
seronegative) with standard error of the mean depicted. Values in parentheses beneath ELISA titers 
represenfs the number of seropositive mice within the total number of mice immlmi;red at day 0. Five mice 
fiom each of the DNA groups were euthanized at 2,4 and 6 weeks for spIenic cytokine determination. 
Values in parentheses at 4 and 6 weeks represent the number of seropositive mice in the remaining mice 
within the group. 
Values represent the mean number of cyokine secreting cells determined from mplicate wells. Standard 
deviations are indicated 
n-d. - not done 
Table 43. Dose Titration of pSLRSV.SgD in Mice after Boosting 
Serum ELISA Titersc Splenic C ytokined 
Vaccinea Doseb (no. seropositive mice/no. immunized) Profile (6 week) 
Groups bd 2 weeks 4 weeks 6 weeks E N  Y IL-4 
DNA 2 117 *22 
(1/15) 
DNA I0 3053 * 335 
(10115) 
DNA 50 4147*1643 
(13/15) 
VSM +t@ -25 146 * 25 
(1;15) 
DNA is plasnid pSLRSV.SgD which encodes a secreted form of BHV- 1 gD 
b DNA and VSA3ngD were administered i-m. or subcutaneously, respectively. -4U mice were boosted 14 
days after the initial immunization. 
ELISA titers are represented as the mean value of serum titers from seropositive mice ( 5  200 is 
seronegative) with standard error of the mean depicted. Values in parentheses beneath ELISA titers 
represents the number of seropositive mice witbin the total number of mice immunized. Each vaccination 
started with 15 mice per group. Five mice from VSA3ltgD groups were euthanid at 2,4 and 6 weeks for 
splenic cytokine evaluation, Five mice from the DNA groups were euthanized at 4 and 6 weeks for splenic 
cytokine determination. 
Values represent the mean number of cytokine secreting cells determined from mpiplicate wells. Standard 
deviations are indicated 
n.d. - not done 
pSLRSV.SgD was suboptimal as seen by poor seroconversion efficiency in immunized 
mice. Mean serum titers, at 2 weeks, of mice immunized with this dose of DNA were 
sigdicantly @s 0.05) lower than mice immunized with 50 pg of DNA However, mean 
titers in seropositive mice were not significantly (ps 0.05) different at 4 or 6 weeks 
between these two groups. Only two mice of 15, receiving a single dose of 2 pg of 
pSLRSV.SgD, showed evidence of seroconversion at 6 weeks post immunization. 
Despite the absence of serum titers in mice receiving 2 ug of vaccine there was clear 
evidence of T-cell priming with low, but sigmficant, levels of IM y and IL-4 production 
in 6 week splenocytes. The predominant T-cell response in all DNA vaccination groups 
appeared to be of the Th 1-type phenotype as indicated by a 2-3 fold higher level of IFN y 
secretion as compared to IL4. Table 4.3 summarizes the kinetics of the antibody 
response and splenic cytokine profiles of C3-N mice boosted 14 days after the initial 
immunization. Mice boosted with 2 ug of pSLRSV.SgD showed a panem similar to mice 
immunized one time only, in that seroconversion efficacy was very low, although titers 
in the few boosted seropositive mice tended to be slightly higher than mice receiving a 
single low dose of pSLRSV.SgD. Mice boosted with 10 ug of pSLRSV.SgD show little 
difference in mean serum antigen-specific antibody titres at 4 and 6 weeks as compared to 
their single dosed seropositive counterparts. Surprisingly the 2 week titers of mice 
boosted at day 14 was significantly @s 0.05) higher that the mice in the single dose 
group. This discrepancy between groups of mice immunized one time with the same dose 
of DNA prepared from the same batch of plasmid was somewhat surprising and we can 
only attribute the differences in early mean serum titers in these 10 pg dose groups on 
variability of the injection technique. Despite the 2 week titer differences in these rwo 
groups of mice the prirmuy diffaence appears to be the enhanced efficacy of 
seroconvenion observed in the boosted group (100%) at 4 weeks as compared to the 
single dose group (40%). Finally, mice boosted with 50 ug of pSLRSVSgD displayed 
mean serum titers that were consistently higher than those observed in mice immunized 
with lower doses of DNA. However, only 4 week titers in mice immunized and boosted 
with 50 ug of pSLRSV.S@ are significantly higher (ps0.05) than mice boosted with 10 
ug of the vaccine. There appears to be no early immunological benefit observed in mice 
immunized once or twice at the optima1 dose of pSLRSV.SgD (50 ug). We included a 
conventional vaccine comprised of affinity column purified recombinant truncated gD 
(tgD) formulated with the adjuvant VSA3. This conventional vaccine formulation has 
been shown to be highly efficacious in cattle and at least two other strains of mice 
(C57BL/6 and Balbk) and typically elicits a predominance of IL-4 in antigen 
restimulated splenocytes (van Drunen Littel-van den Hurk et al., 1984; Baca-Estrada et 
al., 1996). We included this conventional vaccine as a Th2-type positive control group 
for DNA-immunized mice which typically show a Thl-type cytokine profile in antigen 
restimulated splenocytes (section 3.3.4). Despite this we have been plagued by highly 
inconsistent immune response to this vaccine formulation in C3WHeN (H-29 mice. 
Doses between 100 and 1000 ng consistently yielded excellent serum titers, following a 
boost, in C57BU6 (Baca-Estrada et al., 1996). Despite this, Table 4.3 shows evidence 
that C3WHeN mice are poor, or inconsistent, responders to a substantial dose range of 
recombinant tgD formulated in potent adjuvant. However, we assessed splenic cytokine 
profiles in the few seropositive mice immunized and boosted with the highest dose of 
VSAMgD. Although there were some IFN y secreting splenocytes there were 2 fold 
higher numbers of IL4 secreting cells upon in vino restimulation of splenocytes 
harvested from these high dose VSAMgD mice. Although the numbers are not nearly as 
high as observed in other experiments the tendency for this vaccine formulation to drive a 
Th2 type of immune response is consistent. 
4.3.2 Co-administration of pSLRSV.SgD and plasmids encoding cytokines. 
The objective of this experiment was to determine which of eight different murine 
cytokines, encoded within expression plasmids and co-administered with a suboptimal 
(10 pg) of pSLRSV.SgD (Fig. 4.2), would enhance or modulate the immune response. 
Since excessive doses of some of the proinflarnmatory cytokines (IL- 1, IL-6, TNF a) 
might invoke a clinicai response and hinder interpretation of the results a dose of 10 ug of 
pSLRSV.SgD was used. This dose of vaccine was capable of eliciting reasonable titers in 
40-60% of immunized mice. A dose of 10 pg of plasmids encoding cytokines was 
chosen for this preliminary experiment based on the observation that -50% of mice were 
capable of responding to an identical dose of pSLRSV.SgD. Figs 4.3, A, B, and C 
summarize the mean total IgG anti-gD serum titers for immunized mice at 2,4 and 6 
weeks post-immunization. At 2 weeks, mice immunized once with pSLRSV.GM-CSF, 
pSLRSV.IL-4 and pSLRSV.TNF a all show mean serum titers that were significantly @ s 
0.05) higher than control mice immunized with 10 ug of pSLRSV.SgD co-delivered with 
pSLRSV.NuL-B. Table 4.4 shows that at 2 weeks 40% of mice seroconverted when 
Fig. 4.2 Diagrammatic characterization of the plasmid co-administration protocol. Vector 
pSLRSV.SgD, which encodes a secreted version of bovine herpesvirus (BHV)- 1 
glycoprotein D (gD), was mixed with each of eight different murine cytokine cDNAs in 
the context of the pSLRSV expression cassette. All vaccine mixtures were dissolved in 
normal saline in a final volume of 100 pL. The dose was then split and 50 pL injected 
into both quadriceps muscle masses. 

Fig. 4.3 Effect of plasmids encoding cytokines on immune responses to a DNA vaccine. 
Mean ELISA titers for serum IgG in mice immunized once with pSLRSV.SgD and an 
expression cassette encoding one of eight different murine cytokines. Groups of female 
C3WHeN mice (9 or 10/group) were immunized with a suboptimal dose ( 10 pdmouse) 
of pSLRSV.SgD co-administered with 10 pg of expression vectors encoding: IL- 1 a. IL-2. 
IL-4, IL-6, IL- 10, GM-CSF, I M  y or TNF a. Control groups included: mice immunized 
with a mixture of pSLRSV.SgD and pSLRSV.Nu1, as well as. a conventional vaccine 
formulation comprised of VSA3 formulated with a recombinant secreted version of 
BHV-1 gD (500 nghouse). Data presented depicts total IgG in sera harvested at 2 (A), 4 
(B) and 6 (C) weeks. 

. . Table 4.4 Mean serum titers following co-admmstration of plasmids encoding 
cyto kines 
Vaccine' Serum ELSA  ite en^ (no. of seropositive mice/totd no. of mice 
~roups  immunized) 
2 weeks 4 weeks 6 weeks 
pSLRSV . GM- 5370*1437 (9/10) 6880k1392 (10/10) 9280*2049(10110) 
CSF 
a Mice were immmhd as d e s c r i i  in Fig. 4.3. Plasnids encoding cytokines (1 0 pg) were mixed with 10 
pg of pSLRSV.SgD and injected im. in the quadriceps muscles (doses were split between left and right 
quadriceps). Convenuonal vaccine (VSA3hgD) was administered subcutaneously as described in Methods 
(section 1.2.7)and boosted at 14 days. Mice receiving DNA-based vaccines were immunized once only. 
b ELSA titers values were determined by taking the mean of aU mice in each group. Deviations are 
indicated as standard enor of the mean. Values in parentheses represent the number of seropositive mice 
within the total number of mice immunized. 
vaccinated with pSLRSV.SgD + pSLRSVNul-B. Seroconversion efficacy ranged from 
20% @SLRSV.IL- 1 a and VSA31tgD) to 60% @SLRSVIL+ pSLRSV.IL-I 0 and 
pSLRSV.TNFa) depending on the cytokine construct. These data suggest that these 
cytokines @SLRSV.IL-I a, pSLRSVE-4, pSLRSV.IL-10 and pSLRSV.TMa) had little 
impact on seroconversion efficiency when cc+administered with a suboptimal dose of 
pSLRSV.SgD. Conversely, mice immunized with pSLRSV.SgD + pSLRSV-GM-CSF 
showed both the highest mean serum anti-gD IgG titers and seroconversion levels of 90 
% and loo%, at 2 and 4 weeks, respectively. At 4 weeks post-immunization, mean titers 
in all but one vaccine group @SLRSV.TNFa+ pSLRSV.SgD) had increased. Mice 
boosted, at day 14, with VSA3tg.D displayed the highest mean serum IgG titers, 
however, the mean titers in this group are not statistically @ < 0.05) different from mean 
titers observed in mice immunized once with suboptimal doses of pSLRSV.SgD + 
pSLRSV.GM-CSF, pSLRSVJL4 or pSLRSV.IL-6 (Table 4.4). Seroconversion efficacy 
of the VSA3/tgD group (70 %) at 4 weeks resembled that seen in mice immunized with 
pSLRSV.SgD + pSLRSV.IL4 or pSLRSV.IL-6 (50 and 60 %, respectively). Notably, 
100% of mice immunized once, with a suboptimal dose of pSLRSV.SgD + 
pSLRSV.GM-CSF seroconverted by 4 weeks post-immunization. 
Comparisons of DNA-based vaccine + plasmids encoding cytokines with VSA3hg.D 
is of some importance for several reasons. First, a suboptimal single dose of a DNA- 
based vaccine co-adrmnistered with plasmids encoding murine GM-CSF elicited serum 
antibody levels that essentially equalled an optimized dose (for C57BU6 and Balblc) of 
recombinant tgD formulated with a potent adjuvant. Second, seroconversion efficacy 
responses to VSA3tgD varied significantly in C3WHeN mice while co-administration of 
pSLRSV.GM-CSF with 10 pg of pSLRSV.SgD resulted in 100% seroconversion at 4 
weeks. There was a general increase in 4 week senun IgG titers (slight increase in 
pSLl2SV.Sg.D + pSLRSV.IL-2 , pSLRSV.IL4, or pSLRSV.GM-CSF) 1.5 - 2 fold 
increases in pSLRSV.SgD + pSLRSV. IL-I ar and pSLRSV.IL-10 groups, and a 2.5 - 4 
fold increases in pSLRSV.SgD + pSLRSV.Nul, pSLRSVE-6 or pSLRSV.IM y groups. 
Ail vaccine groups, except SgML-4 (10% decrease), showed increases in the number of 
seropositive mice ranging from 10% (SgDIGM-CSF; S g D m  a) to 50% (VSM/tgD). 
Fig. 4.3 C and Table 1.4 summarize mean serum titer IgG titers at 6 weeks post- 
immunization (4 weeks postboost for the VSAMgD vaccine group). Due to a slight 
decrease in the mean serum titers for pSLRSVSgD +pSLRSV.IL-4 and pSLRSV.IL-6 
groups only mice immunized with pSLRSV.SgD + pSLRSV-GM-CSF showed titers that 
were statistically higher @ < 0 -05) than all other groups immunized with DNA-based 
vaccine fomulations. At 6 weeks post-immunization the mean senun IgG titers for mice 
immunized, and boosted, with VSA3hgD were not significantly different from mean 
titers observed in the pSLRSV.SgD + pSLRSV.GM-CSF group. 
4.3.3 Isotype profiles following co-administration of pSLRSV.SgD with plasmids 
encoding cytokines. 
To funher characterize the immune response to plasmids encoding cytokines co- 
administered with a suboptimal dose of pSLRSV.SgD, we assessed the serum levels of 
IgG, and IgG, in mice. Fig. 4.4 shows mean IgG, and IgG, isotype values for 
seropositive mice at 6 weeks post-hmmiation. Typically mice immunized with 
pSLRSV.SgD showed an IgG,: IgG, ratio 2.0 - 2.5: 1 (Fig. 4.5). Isotype data for the 
pSLRSV.SgD + pSLRSV.Nul group were consistent with previous observations (section 
3.3.3). Fig. 4.4 and Table 4.5 summarize the mean isotype values determined from the 6 
Fig. 4.4 Serum IgG isotype profile after immunization with plasrnids encoding antigen 
and cytokines. Mean levels of anti@ IgG, and IgG, antibodies in seropositive 
C3WHeN mice imrntmized intramuscularly once with pSLRSV.SgD co-administered 
with an expression vector encoding one of eight different murine cytokines. Cytokines 
co-administered with pSLRSV.SgD are indicated along the x-axis. The conventional 
(VSA3 + recombinant, secreted form of gD) vaccine group and a control group 
immunized with pSLRSV.Nu1 (Null) + pSLRSV.SgD are also depicted. In all cases , with 
the exception of the VSA3 group, mice received a single, suboptimal dose of plasrnids 
encoding SgD and one of the eight murine cytokines. Immunization doses are as indicated 
in Fig. 4.3. Isotype levels are depicted as optical densities at a 1/100 dilution of 6 week, 
post immunization, sera following a 30 minute development in an lmmunlon 2U ELISA 
plate with the substrate p-nitrophenyl phosphate. 

Table 4.5 Serum isotype profile after co-administration of plasmids encoding 
cytoldnes and a secreted form of BHV-1 gD. 
Vaccine' # Mice Withb Mean Isotype O.D. (1/100)' Ratio of 
Groups Predominance IgG,:IgG, 
of Senun IgG, WL 
S@ + Null 5/6 -5523 * .lo45 2833 * .0899 1.95 
SgD + IL-lcr 
S g D  + IL-2 
S g D  + IL-4 
SgD + IL-6 
SgD + IL-10 
SgD + GM-CSF 
SgD+lFNy 
SgD+TNFu 
VSA3tg.D 
a S g B  pSLRSV.S@, all cytokines are as depicted in Table 4.4 (ie. plasmid encoded). Null refers to the 
Null plasmid pSLRSV.Nul. The conventional vaccine VSA3hgD has been described in Methods (section 
4.2.7) and the dose is indicated in the legend to Fig. 43. Doses and co-admhhmation of plasmids has been 
described in Methods, the legend to Fig. 3.3 and in the foomotes to Table 4.4. 
b Levels of immunoglobulin isotypes were determined by ELIS-4 as described in Methods (section 42.9). 
Data refers to the number of mice showing a predominance, not exclusivity, of serum I @ ,  for all 
seropositive mice at 6 weeks. Predominance was determined by the magnitude of O.D., , values for IgG, 
and IgG, at a 1/ 1 00 dilution. 
Data is represented as the mean of O.D.,, values for IgG, or IgG, in all seropositive mice. 
Fig. 4.5 Serum IgG isotype profile after immunization with plasmids encoding a secreted 
form of BHV- I gD. Relative amounts of IgG, and IgG, in mice immunized with 50 pg 
of pSLRSV.SgD and boosted at 2 weeks. Values are presented as optical densities (405 
nm) following development of ELISA plates in the presence of the substrate p- 
nitrophenyl phosphate. All values were determined at a serum dilution of 1/100 and for 
mice 2 weeks or 4 weeks post boost. Mean values were calculated from optical densities 
determined for 9 (4 weeks) or 10 (6 weeks) individual mice. 

week sera of seropositive mice. Co-adminimation of Th.2-associated cytokines, 
including IL-10, E-6 and IL-4 appeared to enhance the polarization of serum IgG 
isotypes towards IgG,. Surprisingly co-adminisnation of plasnids encoding GM-CSF 
resulted in the most ememe polarization of serum isotypes towards IgG,, largely by 
enhancing the senun level of IgG, without a concurrent increase in IgG,. One hundred 
percent of mice receiving the pSLRSV.SgD + pSLRSV.GM-CSF and pSLRSV.IL-6 
vaccines were predominantly IgG, , while mice immunized with pSLRSV.SgD + 
pSLRSVfIL.4 and pSLRSV.E-10 showed 89% and 80% predominance of IgG,, 
respectively. The one mouse in the pSLRSVSgD + pSLRSV.IL-4 goup which was 
predominantly IgG, displayed a ratio of IgG, : IgG, of 0.464 (data not shown). 
C3WHeN mice immunized with the conventional vaccine VSA3tgD displayed a 
predominance of IgG,, in senun of most mice, 4 weeks post boost. At least two high titer 
mice, in the conventional vaccine group showed substantial amounts of serum IgG, 
(IgG,:IgG, ratios of 1.34 and 0.88)(data not shown). Mice immunized with 
pSLRSV.SgD in conjunction with plasmids encoding IL-2, IFN y or TNF a showed a 
clear trend towards an increase in serum IgG,. In all three cases tbe prevalence of IgG, is 
inconsistent between individual mice within these three groups. Table 4.5 shows mice 
immunized with pSLRSV.SgD + pSLRSV.E-2 or pSLRSV.TNFa showed a clear trend 
towards a predominance of serum IgG,, with mean serum IgG,:IgG, ratios of 1 - 17 and 
0.86 respectively. Sixty-eight percent (4 of 7 seropositive animals) of mice immunized 
with pSLRSV.SgD + pSLRSV.IFN y displayed a predominance of senun IgG, although 
the isowe ratio derived from mean isotype levels for all seropositive animals in this 
vaccine group demonmates an overall predominance of IgG, (Table 4.5). 
4.3.4 High and Low Doses of pSLRSV.IFN y and pSLRSV-GM-CSF co- 
administered with pSLRSV.SgD. 
Results summarked in Figs.l.3 and 4.4, as well as, Tables 4.4 and 4.5 suggested 
that co-administration of a DNA-based vaccine with plasmids encoding murine GM-CSF 
or IFN y warranted further investigation. The dose of plasmids encoding cytokines were 
not optimized in the preliminary experiments therefore the impact of two diff'nt doses 
of these plasmid encoding cytokines, on the ensuing immune response to a fixed dose 
(50 pg) of pSLRSV.SgD, was assessed. Fig. 4.6 A, B and C summarize the mean serum 
IgG titers for all mice immunized with 50 pgs of pSLRSV.SgD co-administered with 10 
or 50 pg of plasmids encoding murine GM-CSF (groups designated GS- 60 and GS- 
loo), IFN y (groups designated IS-60 or IS-1 00) or a control, pSLRSV.Nu1, plasmid 
(groups designated NS-60 or NS-100). Mice were immunized i.m. and boosted at 4 
weeks. 
Two weeks post immunization the seroconversion efficacy is increased regardless of 
the dose of pSLRSV.GM-CSF (Table 4.6 and Fig. 4.6 A). The high dose pSLRSV.GM- 
CSF group (GS- 1 00) appeared, despite 1 00% seroconversion, to suppress the humoral 
response relative to the NS- 100 and IS- 100 groups. High doses (NS- 100) of Nu1 plasmid 
in conjunction with the fixed dose of pSLRSV.SgD also appeared to suppress the 
magnitude of the humoral response (Figs. 4.6 A, B and C). This "suppression" may 
simply reflect competition for cell surface sites of plasmid uptake or may possibly be the 
result of an adjuvant effect intxinsic to bacterially derived plasmid DNA that deviates the 
local lymphoid microenvironment such that a potent Thl response is facilitated (Roman 
et al., 1997). Interestingly, a 10 pg dose of pSLRSV.IFN y (IS-60) appeared to suppress 
humoral responses as compared to NS-60 and GS-60 vaccine groups (Figs. 4.6 A, B and 
C). This dose of IFNy appeared to have little effect on seroconversion efficiency relative 
to NS-60 and GS-60 (Table 4.6). Conversely, co-administration of a high dose (50 pg) of 
plasmids encoding E N  y enhanced mean, gD-specific, serum IgG levels as compared 
to 2 week titers in mice immunized with pSLRSV.SgD and 50 pg doses of null plasmid 
(NS-  100) or plasmids encoding GM-CSF (GS- 100). 
Data obtained from animaIs four weeks after immunization showed that NS-60 and 
GS-60 mean antibody titers were essentially equal and significantly @ s 0 -05) greater than 
mean serum titers in the IS-60 group (Figs. 4.6 B). The advantages conferred by co- 
administration of pSLRSV.GM-CSF observed in Fig. 4.3 A, B, and C were less apparent 
in this titration experiment possibly due to the use of an essentially optimized 50 ug dose 
of pSLRSV.SgD. Mice immunized with pSLRSV.SgD and 10.0 pg of plasmids 
encoding IFN y (IS-60) exhibit diminished mean serum titers at 4 weeks (Fig. 4.6 B). 
This reduction in humoral response in this vaccine group is significantly @s 0.05) lower 
than mean titer values in the corresponding NS-60 and GS-60 vaccine groups. Mean 
senun IgG titers, at 4 weeks, in the NS- 100 and GS- 100 groups are significantly @ s 
0.05) lower than serum titers in the IS-1 00 group. Despite low serum titers in these two 
groups, seroconversion efficacy was 100% at 4 weeks (Table 4.6). 
After boosting our data demonstrated that specific vaccine groups benefited from the 
Fig. 4.6 Effect of co-adrmnistration of plasmids encoding antigen and GM-CSF or DW 
y . Mean serum ELISA titers for mice immunized with a fixed dose of pSLRSVSgD and 
varying doses of expression vectors encoding murine GM-CSF or IFN y. Female 
C3WHeN mice were immunized i.m. with 50 pg of pSLRSV.SgD and 10 or 50 pg of 
pSLRSV-GM-CSF, pSLRSV.IFN y, or Null vector pSLRSV.Nul. Plasmid combinations 
were mixed in 100 pL normal saline and the dose was split between both quadriceps 
muscle masses. Mice were boosted 4 weeks after the initiaE vaccination. Serum from 
vaccinated mice was harvested 2 (A), 4 (B) and 6 (C )  weeks following the initial 
immunization. Total IgG titers are depicted as end point dilution values using 3 standard 
deviations above the mean O.D. (405 m) of prebleed sera as a cutoff. X-axis groups 
represent the following individual vaccine groups: Sal. (normal Saline control), Null 
(control expression vector), NS-60 and NS- I00 (Null vector + pSLRSV.SgD), IS-60 and 
IS- 100 (pSLRSV.IFN y + pSLRSV.SgD) and GS- 60 and GS- 100 (pSLRSV.GM-CSF + 
pSLRS V-SgD). Numbers "60tt and " 1 00" within the group designations indicate final 
amount (in pg) of plasmids injected: in all cases the dose of pSLRSV. SgD was fixed at 
50 pg and doses of 10 or 50 pg of the Nul, or cytokine expressing, plasmids were added. 
Addition of the Nu1 or cytokine plasmid amounts to the fixed dose of pSLRSV.SgD 
generated the final dose values of 60 and 100 pg depicted as pan of the x-axis 
designations. 

Table 4.6 Seroconversion following co-administration of pSLRSV.SgD with 
pSLFGV.GM-CSF or pSLRSV.EN y 
Vaccinea No. of Seropositive Miceb 
Groups 2 weeks 4 weeks 6 weeks 
NS-60 9/10 10/10 10/10 
IS-60 8/10 8/10 7'10 
GS-60 10/10 10/10 10/10 
NS- 100 8/10 10/10 10/10 
1s- 1 00 7/9 ~9 8/9 
GS- 100 10/10 10/10 lO/I 0 
Vaccine group designations are indicated in the legend to Fig. 1.6. 
"dues represent the number of seropositive micwtotal number of immunized animals 
boost (Fig. 4.6). Mice immunized with pSLRSV.SgD + 50.0 pg of pSLRSV.IFN y or 
pSLRSV.GM-CSF showed mean serum IgG titers that were significantly higher @ s 
0.05) than corresponding preboost (4 week) titers. Mean serum titers postboost in the 
NS- 100 vaccine group increased as well, however, this increase was not statistically 
significant @ s 0.05). Interestingly, mice in the GS- 100 group, that showed an apparent 
preboost suppression of antig en-speci fic humoral responses, displayed the highest post 
boost serum IgG titers and were statistically significant @ s 0.05). Co-adminimation of 
10.0 pg of pSLRSV.IFN y appeared to be having a negative impact on the development 
of serum antibody titers, despite boosting, at 6 weeks (Fig. 4.6 C). Finally, vaccine 
groups NSdO and GS-60 showed no apparent enhancement in mean serum titers as 
compared to preboost, 4 week, titers. Table 4.4 shows the number of responders at 4 
weeks to be loo%, in all  experimental groups except the IS-60 and IS-100 vaccine 
groups. Table 4.4 also shows that one mouse in the IS-60 vaccine group appeared to stop 
responding at 6 weeks. These transient responders showed titers just above cutoff level at 
4 weeks (1/400 dilution) and may have been weak responders or simply scored as 
responders at 4 weeks as a result of sample variation during the ELISA plate preparation 
and reading. In any event these mice were not influenced in a positive manner, as 
determined by the absence of gD specific serum titers at 2 weeks post boost. 
4.3.5 Both GM-CSF and IFN y can increase the levels of serum IgG,. 
Co-administration of 10 pg of plasmids encoding FN y and GM-CSF with a 
suboptimal dose (10 pg) dose of pSLRSV-SgD increased serum levels of IgG, and IgG,, 
respectively (Table 4.5). In an effort to explore the potential for these plasmid encoded 
cytokines to deviate the serum immunoglobulin profile we co-administered two different 
doses of these plasmids (10 and 50 pg) with an optimal dose of pSLRSV.SgD (50 pg). 
Figs. 4.7 A and B summarize mean serum isotype levels in mice immunized with 50.0 
pg pSLRSV.SgD co-administered with 10.0 or 50.0 pg of a null piasmid (NS-60, NS- 
IOO), or plasmids encoding murine GM-CSF (GS-60, GS-100) or IFN y (IS-60, IS- 100). 
Mean serum isotype levels of IgG, and IgG, do show that a single dose of 10 or 50 pg 
of pSLRSV-GM-CSF enhanced the amounts of serum IgG, (relative to serum IgG, 
levels) as compared to groups of mice immunized with pSLRSV.SgD + pSLRSV. Nul 
(NS-60 and NS-loo), (Fig. 4.7 A). However, only the 10 pg dose of pSLRSV.GM-CSF 
showed a predominance of IgG, in all 10 mice (Table 4.7). We anticipated, based on 
isotype data presented in Fig. 4.4, and current literature, that mice immunized with 
pSLRSV.SgD + pSLRSV.IFN y would show a tendency towards greater senun levels of 
IgG,. This did occur to some extent (Figs. 4.7 A and B), however, only 5 of 8, and 6 of 8 
seropositive mice displayed a predominance of serum IgG, at 4 and 6 weeks, respectively 
(Table 4.7). Similarly, mice immunized with the 10 pg dose of pSLRSV.IFN y show an 
IgGJgG, ratio of 1 .Z and 1.08 before and after boosting, respectively. Once again the 
isotype switch to IgG, in individual mice immunized with 10 pg of pSLRSV.IE\T y + 
pSLRSV.S@ (50 pg) with 2 of 8 and 4 of 7 seropositive mice showing a predominance 
of  serum IgG, before and after boosting, respectively (Table 4.7). One of the most 
surprising results involved the apparent pre- to post-boost isotype switch in mice 
immunized with 50 pg of pSLRSV.GM-CSF (Figs. 4.7 A and B). The preboost isotype 
profile showed 9 of 10 seropositive mice with a serum predominance of gD specific 
senun IgG,, while postboost sera showed 7 of 10 mice with a predominance of serum 
IgG, . 
4.3.6 Co-administration of pSLRSV-GM-CSF with pSLRSV.SgD upregulates IL-4. 
Co-administration of 10 pg of plasmids encoding GM-CSF with a suboptimal 
dose of pSLRSV.SgD (10 pg) enhanced the kinetics, and efficacy, of seroconversion and 
the magnitude of serum antibody levels (Fig. 4.3 and Table 4.4). We also demonstrated 
that co-administering equal doses of plasmid encoding IFN y and the secreted f o m  of 
BHV-1 gD increased the levels of serum IgG, (Fig 4.4 and Table 4.5). To further 
characterize the immune responses foUowing co-administration of these two plasmid 
Fig. 4.7 Relative amounts of IgG, and IgG, in mice immunized with plasmids encoding 
SgD and cytokines. Groups are as described in Fig. 4.6. Values are presented as optical 
densities (405 nm) following development of ELISA plates in the presence of the 
substrate p-nitrophenyl phosphate. All values were determined at a serum dilution of 
11100 and for mice 4 weeks (Fig. A -preboost) or 6 weeks (Fig. B -postboost) after the 
primary immunization. Mean values were calculated from optical densities determined 
for 7 to 10 individual mice. X-axis groups are as described in Fig. 4.6. 

Table 4.7 Serum IgG, and LgG, levels after co-a- . ation of pSLRSV.SgD with 
pSLRSV.GM-CSF or pSLRSV.IFN y 
Vaccine' #MiceWithb MeanIsotypeOD.(l/lOO)' Ratio of 
Groups Predominance IgG,:IgG, 
of Serum IgG, &GI I& 
NS-60 8/9 .9664 .0294 -6076 i -1027 1.59 
IS40 3/7* -5663 * -0514 5253 i -1332 1.08 
GS-60 W l O  .7049 * 0.229 -3023 * .0462 2.33 
NS- 100 8/10 .9366 * .0324 .6622 * .I237 1.41 
IS- 100 2/8** ,5791 * ,0685 -7930 i .I398 0.73 
GS-100 3/10 -7981 * .0285 .8363 * .I185 0.95 
vaccine group designations are indicated in the legend to Fig. 3.6. 
Levels of immmogiobulin isotypes were determined by ELISA as described in Methods (section 42.9). 
Data refers to the number of mice showing a predominance, not exclusivity, of serum IgG, for all 
seropositive mice at 6 weeks. Predominance was determined by the magnitude of O.D. ,, values for IgG, 
and IgG, at a I/  100 dilution. 
Data is represented as the mean of O.D. ,, values for IgG, or IgG, in all seropositive mice. 
* 4 mice fiom this group showed virtllally identical senrm OD. values for both IgG isotypes 
** 1 mouse from this group showed similar senrm O.D. values for both IgG, and IgG, 
encoded cytokines with pSLRSV.SgD, we assessed antibody isotype and cytokine 
secreting cell numbers within the spleens and draining lymph nodes from immunized 
mice (Tables 4.8 A and B). Because iliac node cell population recovery is limited to 10- 
15 million cells per mouse we were forced to pool samples from several mice in order to 
acquire enough cells for both the cytokine and immunoglobulin isotype ELISPOT 
assay(Tab1es 4.8 A and B). We pooled splenic and iliac lymph node cell populations 
based on serum isotype predominance in an effort to assess if senun isotype correlated to 
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Table 4.8 (A) Cytokine and antibody isotype protiles in mice showing dominance of 
serum IgG,. 
No." Cytokine ELISPOT Isotype 
Vaccine8 
Groups of ELISPOP Mice 
Spleen Iliac Node' Iliac Node 
Saline 30*2 4 2 2  - 79 f 4 0 0 0 
NS-60 8/9 101 * 15 13 *4 86 * 2  32 *12 53 * 16 12 6 
IS-60 3i7 77 * 4 21 i 7  26 * 1 5 i 2  12*8 1 i 0  
GS-60 lOil0 195* 7 103 6 99 * 7 175* 17 2 4 i 3  9 *  1 
NS- 100 8i10 62 * 13 8 ~ 5  61 * 2  9 * 4  33 * 9  9 * 3  
rs- 1 00 2 8  120 * 8 19 * 2 n.d. n.d. 8 i 2  4* 1 
GS- 100 3/10 140*23 78 * 7 153 * 6 I88 * 8 62 * 4 3* 1 
a Vaccine group designations are indicared in the legend to Fig. 4.6. 
b No of mice showing a predominance of IgG, of the total number of seropositive mice (see Table 4.7). 
Values are determined by taking the mean, * the standard deviation, of counts from uipLicare wells 
Values are cdcuiated as in ' 
h the primary draining lymph node of rhe deep tisues if the m u h e  thigh (section 3.3 5). 
n.d- not done because too few cells harvested from the iliac node 
Table 4.8 (B) Cytokine and antibody isotype pro6les in mice showing dominance of 
serum IgG,. 
Vaccine 
Groups 
NS-60 
IS-60 
GS-60 
NS- 1 00 
IS- 100 
GS- 1 00 
No. 
of 
Mice 
Cytokine ELISPOT Isotype ELISPOT 
Spleen Iliac Node Iliac Node 
a Vaccine goup designations are indicated in the legend to Fig. 4.6. 
No of mice showing a predominance of IgG, of the total number of seropositive mice (see Table 4.7). 
Values are determined by taking the mean, * the standard deviation, of counts tiom mplicate wells 
Values are calculated as in ' 
' 1s the primary Iymph node of rhe deep tissues if the murine chi& (section 3.3.5). 
n.d- not done because too few cells harvested from the iliac node 
n/a - cells harvested from iliac node were dead as determined by Trypan blue exclusion 
the IL-4, IFN y ,  IgG, or IgG, ELISPOT pattern within specific lymphoid compartments. 
Co-administration of pSLRSV.GM-CSF leads to a substantial increase in IFN y and IL-4 
secretion in both the spleen and draining lymph node in a dose dependent manner (see 
GS-60 and GS-100 groups in Tables 4.8 A and B). 
Data from pSLRSV.IFN y co-administered with pSLRSV.SgD was difficult to 
interpret, largely due to insufficient numbers of cells from draining Lymph nodes in the 
NS-60 and NS-100 control groups (Table 4.8 B). However, B-cell isotype ELISPOT data 
does suggest that increased numbers of IgG, secreting cells are apparent in mice 
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immunized with pSLRSV.IFN y + pSLRSV.SgD, as compared to NS-60 and NS- 100 
control groups (Table 4.8 B). However, a higher dose of plasmids encoding murine IFK 
y does not enhance the efficiency at which mice develop higher levels of IgG, in sera. 
4.4. Discussion 
Preliminary evidence demonstrated the immune modulatory roles for several plasmid 
encoded cytokines c +administ ered with a previously characterized DNA-based vaccine 
encoding a secreted form of the protective immunopn from bovine herpesvirus- l 
olycoprotein D(Figs. 4.3,4.4,4.6 and 4.7, Tables 4.4,4.5,4.7 and 4.8). Despite the a 
Limited dose range assessed we noted that murine cytokines GM-CSF, IL-4, TNF a, IL-6 
and EN y had measurable modulatory effects on immune responses following i n  
injection of C3WHeN @I-27 mice with plasmids encoding these cytokines co- 
administered with plasmids encoding the secreted form of BHV-1 gD. Within the criteria 
established for assessment of immune modulation, co-administration of plasmids 
encoding IL- 1 a, IL-2 and IL- I0 with plasmids encoding the secreted form of BHV-1 gD, 
appeared to have little positive impact on the immunological outcome following 
immunization. Whether the absence of responses with these three cytokines reflects the 
single, low dose, assessed in the initial experiment (Fig. 4.3 and Table 4.4) requires 
further investigation. Thus, the immune responses to these three cytokines will not be 
discussed at this time. The focus of the discussion will include the possible mechanistic 
avenues associated with observed immunomoduiatory outcomes following co- 
administration of plasmids encoding GM-CSF, IL-4, IL-6, TNFa and m y  . 
Senun anniody and cytokine profiles in C3-N mice following immunization with 
three different doses of pSLRSV.SgD confumed earlier studies which showed that 
animals with measurable senun anti-gD titers displayed a mixed IgG,AgG, isowe, with 
a predominance of IgG,, and y secreting cells in the spleen (section 3.3 .3 ,3 -3.4, 
3.3.6 and Fig. 4.2). Despite the prevalence of EN y in the spleens of immune animals, 
serum levels of IgG, were typically 2 to 3 times greater, on average. than levels of IgG,. 
It was also demonstrated that a single dose of at least 50 pg of pSLRSV.SgD was 
sufficient to eiicit excellent serum IgG titres in 100 % of animals at 4 weeks posr- 
immunization (Table 4.2). We found that a single dose of 10 pg of this plasmid was 
suboptimal in tenns of seroconversion efficacy, although the serum immunoglobulin 
subclass character and splenic cytokine profile was essentially identical to that obsenred 
for animals receiving the higher 50 pg dose (Table 4.2 and 4.3, Fig. 4.4). 
Initial experiments with plasmids encoding cytokines were essentially a prescreen for 
cytokines that might possess an immunomodulatory function. On the understanding that 
seroconversion efficacy, magnitude, and character of serum immunoglobulin profiles, 
were of utmost importance in controlling many infectious viral diseases, we established 
these as criteria for determination of immune modulation by co-administered piasmid 
encoded cytokines. We clearly showed that co-administration of plasmids encoding the 
murim cytokine GM-CSF enhanced early serum antibody magnitude and seroconversion 
efficiency when utilized in the context of suboptimal doses (10 pg) of pSLRSV.SgD 
(Fig. 4.3). Several articles have been published recently describing the immunological 
outcome to DNA-based vaccines co-administered with plasmids encoding GM-CSF and 
in most instances enhancement has been demonstrated (Xiang and Ertl 1995; Syrengelas 
et al., 1996; Conry et al., 1 996a; Geissler et al., 1997; Iwasaki et al., 1997; Kim et al., 
1997). Xiang and Ertl (1 995) first described enhancement of early, post-immunization, 
viral neutralizing tiues and post-boom survival, following challenge, in C3WHe mice 
immunized with plasmids encoding rabies virus G protein co-administered with plasmids 
encoding GM-CSF. They found that the efficacy of protection and the magnitude of 
serum antibody titer correlated directly with the dose of plasmids encoding GM-CSF to a 
maximum of 250 pg. In this particular study, mice were immunized initially with a 
m i m e  of plasmids encoding both G protein and GM-CSF. All animals were 
subsequently boosted at 2 or 3 weeks with plasmids encoding G protein only. Cytokine 
profiles from in virro, antigen stimulated, splenocytes harvested 2 weeks post-boost 
indicated that IL-2, IL-3 , and GM-CSF secretion were upregulated in animals receiving 
plasmids encoding GM-CSF, as compared to animals immunized with plasmids encoding 
G protein alone. In this instance, levels of splenic IL-4 and IFN y were not assessed. 
Iwasaki et. al. (1 997), demonstrated that im. immunization of BALBk (H-Zd) mice with 
a mixture of plasmids expressing a non-immunogenic mutant of influenza nucleoprotein 
(NP) and GM-CSF resulted in significant enhancement of cytolytic activity only after 
boosting. These authors co-administered 100 pg of each plasmid and boosted with both 
plasmids at 3 and 6 weeks. Conversely, Kim et. al. (1997) were not able to demonstrate 
enhancement of CTL activity in BALER mice when plasmid encoded GM-CSF was co- 
administered with plasndd encoding seveml antigens (Env, Gaglpol, Vif and Nef) fkom 
human immmodeficiency virus @W)- I. However, co-adminimtion of plasmids 
encoding GM-CSF with plasmids encoding Env and Gagipol showed enhancement of 
antigen-specific serum immunoglobulin and splenic lymphocyte proliferation following a 
single immunization with 50 pg of each plasmid, or following boosting at day 14. 
Geissler et. ai. (1997) demonstrated that BALB/c mice, pretreated with a 0.9 % 
bupivicaine injection i m ,  receiving a multi-site immmization with 50 pg of plasmids 
encoding GM-CSF and the nonsecreted Hepatitis C virus core protein displayed increased 
seroconversion efficacy with a moderate increase in CTL activity. It should be pointed 
out that Geissler et. al. (1997) utilized an injection protocol that involved boosting with 
plasmid encoded core protein in the opposite leg from which the initial cytokine!antigen 
vaccination occurred. Conry et. al. (1996) demonstrated that immune responses in 
C57BL/6 (H-2b) mice, following ballistic delivery of 2 pg of plasmids encoded a 
carcinoembryonic antigen (CEA) to the skin, was only enhanced by plasmids encoding 
GM-CSF if delivery of this cytokine preceded delivery of CEA to the same site by 
several days. Indeed simultaneous ballistic delivery of these two plasmids failed to 
augment humoral or cell-mediated, CEA specific, immune responses. In this instance 
the authors included a reporter construct as a control plasmid and showed that pre- 
administration of this DNA prior to delivery of CEA resulted in at least 60% of mice 
showing some augmentation of serum antibody responses. Finally, Syrengelas et. al. 
(1 996) demonstrated that plasmids encoding an in-frame genetic fusion of GM-CSF to 
the humanized mouse idiotype determinant of B-cell lymphoma, delivered im. or i.d 
into C3WHeN mice, enhanced early anti-idiotype senun titers. It may also be of s o m  
interest to note that i m  delivery of 100 pg of plasmids encoding this idiotype resulted 
in significantly more saum IgG, in mice than following i.d. immunization. 
It is apparent that GM-CSF plays a significant and varied role in the enhancement 
of immune responses to co-administered DNA-based vaccines. The specific mechanism 
of immune modulation of this cytokines in vivo remains to be established. However, it 
seems reasonable to hypothesize that seroconversion enhancement facilitated by GM-CSF 
is the result of a specific action on resident dendritic cells. It has been demonstrated that 
GM-CSF plays a critical role in recfuiment and maintenance of the ability to Capture and 
process antigen in human and mouse dendritic cells (Heufler et d., 1987; Inaba et al., 
1992; SaIlusto and Lanzavecchia, 1994; Lutz et al., 1996). This cytokine has also been 
demonstrated to upregulate antigen acquisition and presentation functions in bone 
marrow derived macrophages (Fischer et al., 1988). This information, and the ELISPOT 
cytoldne data presented in Tables 4.8 A and B, suppon the hypothesis that secretion of 
GM-CSF by cells harboring plasmids encoding this cytokine are directly responsible for 
the significant enhancement of seroconversion efficacy and indirectly responsible for 
enhancement in the magnitude of mean serum immunoglobulin titers. It would seem 
plausible to predict that the increase in local recruitment of immature, antigen-uptake 
proficient, dendritic cells, and local maintenance of antigen capture fhction, is 
responsible for enhancing the number of responders regardless of variations in animal 
immunoresponsiveness and variability in vaccination technique. An alternative 
explanation, in light of recent evidence that professional antigen presenting cells at the 
injection site are capable of naked DNA uptake (Raz et al., 1994; Condon et al., 1996), is 
that dendritic cells msfected with plasmids encoding GM-CSF may aaffic to the local 
draining lymph node and create a microenvironment conducive to the enhancement of 
antigen-specific T-, and B-cell numbers. 
Enhancement of antigen-specific serum immunoglobulin levels in mice immunized 
with plasmids encoding IL-4, ceadministered with pSLRSV.SgD, without the concurrent 
increase in the number of responders, as observed in mice receiving plasmid encoded 
GM-CSF, supports suggestions that GM-CSF functions directly to enhance vaccine 
efficacy and indirectly, via induction of IL-4 in draining lymph nodes, to enhance the 
magnitude of senun IgG titers. Conversely, although IL-4 has been demonstrated to 
play a role in upregulation and maintenance of the antigen capture function of dendritic 
cells, it seems reasonable to suggest that at the single dose tested (10 pg) this function of 
IL-4 is minimized and that enhancement of serum titer is facilitated by a mechanism 
distinct from that induced by GM-CSF (Fig. 4.3 and Table 4.4), (Sallusto and 
Lanzavecchia, 1994; Lutz et al., 1996). Interleukin- 4 has also been demonstrated to play 
a key role in the immunoglobulin switch to IgG, and IgE (Snapper and Mond, 1993), the 
induction of Th2-type T-cells, inhibition of nascent Th 1 phenotype and deviation of 
short-cultured, antigen-specific, Th 1 T-cells towards a Th2 phenotype (Rocken et al., 
1 996). IL-4 has also been shown to augment B-cell antibody synthesis through 
upregulation of surface IgM and CD40 (Gordon et ai., 1988; Shields et al., 1989), in the 
generation of CTLs and in the recruitment of activated macrophages (Trem et al., 1988; 
Golumbeck et al., 1991; Banchereau, 1991a). Despite early evidence that IL4 can 
enhance the development of antigen-specific CTZs, a recent paper in which BALl3c mice 
were immunized with 50 pg of plasmid encoded IL-4, co-administered with 50 pg of 
plasmid encoded Hepatitis C virus core protein, failed to demonstrate enhancement of T- 
cell mediated wotoxic activiw (Geissler et al., 1997). Although CTL activity was not 
enhanced in this instance, seroconversion efficiency was augmented significantly with a 
slight increase in mean serum IgG titers. Geissler et. al. (1 997) did not assess serum 
immunoglobulin subclass, however, they did determine that the splenic cytokine profile 
from plasmid encoded IL-4 and HCV immunized mice, was characteristic of a Tho 
phenorype upon in vino resthulation. 
It has been demonstrated that the induction of antigen-specific Th2-type cells 
requires simultaneous exposure of uncommitted T-cells to IL-4 and TCR engagement by 
APC MHC Wpeptide complexes (Rocken et al., 1996). Enhancement of mean serum 
titers without a substantial enhancement in levels of serum IgG, (Table 4.5) suggests 
that the dose of IL-4 was sufficient to directly, or indirectly, augment initial B-cell 
interaction with antigen or subsequent interactions with antigen associated with follicuiar 
dendritic cells, but insufficient to facilitate a deviation towards greater levels of T'h2. 
Selective increases in serum IgG, Levels have been demonstrated after 3 i m  injections 
of very high doses (100 pg each) of plasmids encoding lL-4 and subsequent 
immunization with transfemn formulated in aluminum hydroxide (Alum), ( F k  et al., 
1993). Direct action of 1 . 4  on B-celis could occur by several mechanisms: IL-4 derived 
from plasmids taken up and expressed by cells at the injection site, expression within the 
draining lymph node by interstitial dendritic cells msfected in vivo at the injection site 
prior to maturation and mobilization, or by cells within the draining lymph node 
transfected by the wave of plasmid DXA that washes through draining lymphatics and 
lymph nodes immediately following injection (section 3.3.5). It may also be possible 
that redtrnent  of short tern Thl -me Ttells and subsequent exposure to injection site 
microenvironmental IL4 and antigen may lead to deviation towards greater numbers of 
ThZ cells and augmentation of B-cell responses upon movement into draining lymph 
nodes (Rocken et al., 1992). However, in the absence of cytokine ELISPOT data it is 
difficult to ascertain if the enhanced levels of serum IgG, observed in mice immunized 
with plasmids encoding IL4 co-administered with pSLRSV.SgD, is occurring by a 
mechanism other than deviation towards greater numbers of antigen-specific Th2-type 
CD4' T-cells (Davis et al., 1997; Levitsky, 1997). Also, it has been demonstrated that IL- 
4 can significantly enhance proliferative capacity of B-cell receptor (BCR) or CD40 
engaged B-cells and induce lipopolysaccharide (LPS) stimulated B-cells to produce IgG, 
and IgE (Alderson et al., 1987; Defiance et al., 1987; Snapper and Paul, 1987; 
Banchereau et al., 1991b), However, there is some recent controversy as to whether 
antigen-specific B-cell responses are indeed upregulated by IL-4 (Taylor, 1995) . 
Mechanistic details regarding the ability of TNF cr to augment immunity in vivo have 
not been worked out However, there is clear evidence that T -dependent antigen-specific 
B-cell responses are enhanced by co-adminimtion of doses well below the dose range 
demonstrated to cause cachexia and tissue toxicity (Ghiara et al., 1987; Schijns et al., 
1994). htraperitoneal inhion of recombinant TNF a, at doses as low as 1.3 ng/mouse, 
enhanced antigen-specific B-cell responses against sheep red blood cells and rabies virus, 
respectively. Despite evidence in the literature that exposure of cultured dendritic cells to 
recombinant lNF a leads to a 10 fold decrease in presentation of soluble antigen and a 
100 fold decrease in the capacity to present immunoglobulin antigen complexes, we have 
clear evidence that TNF cx can enhance the early humoral response (Fig. 4.3 and Table 
4 4 ,  (Sallusto and Lanzavecchia, 1994). It has been suggested that the dose, as we 
discovered with GM-CSF and EN y, may be a pivotal issue in the outcome of 
experiments where TNF a deviation of T-dependent immune responses are studied. 
Indeed, Sailusto and Lanzavecchia (1 994) hypothesized that too much TNF cr may lead to 
a local or generalized immunosuppressive event as a result of widespread maturation and 
mobilization of peripheral dendritic cell populations. One might predict that smaller 
doses of TM a may enhance mobilization and maturation without an acute compromise 
of antigen presentation. Our data suggests that a relatively low dose of TNF cr modulates 
the immune responses to pSLRSV.SgD in two distinct ways. Co-administration of 
plasmids encoding TNF cc appears to enhance the early kinetics of senun IgG -. response in 
a manner distinct &om that observed in the GM-CSF group, and also deviates the normal 
serum immunoglobulin isotype responses towards greater levels of Ig G, . The observed 
increases in levels of senun IgG, are inconsistent in mice within this group and suggest 
that the dose required to dnve immunoglobulin switch to IgG, is suboptimal, or that 
TNFa must synergize with other cytokines to deviate the immunoglobulin isotype in a 
more efficient manner. This observation is of some importance because to our 
knowledge TNF a has not been correlated to a specific deviation of serum 
immunoglobulin towards I@,. However, administration of TNF a with IL-12 has been 
demonstrated to enhance the levels of Thl-type T-cells in mice (Ahlers et al., 1997). 
Certainly, TNF u has been demonstrated to upregulate IFN y from M( cells (Scharton 
and Scott, 1993), however, it is unknown if this mechanism explains the apparent 
immune deviation observed. It has been demonmted that serum levels of IgG, and IgG? 
were elevated when endogenous NK cells were activated by poly (I:C) (Wilder et al., 
1996), and that only the IgG, increases were NK cell dependent. Recently the adjuvant 
capacity of certain hypomethylated CpG motifs, within bacterially derived DNA, were 
shown to be capable of inducing NK cells to secrete significant amounts of IFN y, 
however, serum isotype data from the nulYpSLRSVSgD control group suggests that 
immunostimulatory sequences within this p lasmid DNA are not responsible for increased 
levels of IgG, observed in the TNF a group. (Klinman et al., 1996). 
TM ct has been shown to be of critical importance in the promotion of the 
follicular dendritic meshwork within developing gexminal centers (Goodnow, 1 997). TTU+ 
a knockout, and TNFR-1" , mice lack lymph nodes, the majority of Peyefs patches, and 
lack follicles within the spleen (Pasparakis e? al., 1996; Kosco-Vilbois et aI., 1997). It is 
hypothesized that CXCR4 and BLRl chemokine receptors serve as important facilitators 
for B-cell enuy into follicular niches which are then induced to produce TNF a 
(Goodnow, 1997). It is possible that plasmids encoding TNF a serve as an exogenous 
source of cytokine to enhance the early kinetics of germinal center development or 
number. 
IL-6 is a multifunctional cytokine that is produced by both lymphoid and 
nonlylnphoid cells and plays a key role in acute phase and immune responses as well as 
haematopoiesis (Hirano et al., 1990). This cytokine is believed to play an important role 
in B-blast development, and to induce synthesis of secretory type IgG. It also appears to 
augment the development of monocytes into mature tissue macrophages. We 
demonanted that co-administration of plasmids encoding IL-6 with pSLRSV.SgD has 
littIe effect on two week mean titers or seroconversion efficiency, however, 4 week mean 
senun titers were essentially equivalent to those observed for IL-4, GM-CSF and 
VSA3/tgD (Fig. 4.3 B and Table 4.4). IL-6 has been demonstrated to augment both 
primary and anamnestic antigen-specific humoral responses, although, it appears that IL-6 
may play a more prominent role in the anamnestic responses (Takatsuki et al., 1988). It 
was demonstrated that macrophages and CD4' T-cells were critical in the immunological 
enhancement observed upon injection of recombinant IL-6. Recently it has been 
suggested that IL-6 may be the initiating signal that deviates the primary immune 
response toward a Th2-type response (Rincon et al., 1997). Despite recent evidence 
suggesting that CD3+CD4+ NKl -1' T-cells are a potential early source of E-4, it has 
been shown that these cells are also capabie of producing IM y (Yoshimoto and Paul, 
1994; Vicario and Zlomik, 1996) which, with IL- 12, has been demonstrated to be 
involved in the deviation of the immune response toward a Th 1 type phenotype 
(Gaj ewski and Fitch, 1988; Scott, 199 1). Although the activation signals for NK 1.1 + T- 
cells have not be definitively identified there is evidence that signalling is mediated 
through surface engagement of the MHC-like molecule CDI on antigen presenting cells 
resulting in upregulation of cytokine secretion from this population of T-cells 
(Yoshomoto et al., 1995). Despite this evidence, Rincon e t  al. (1997) put forth an 
alternative hypothesis for the indirect involvement of IL-6 in the induction of the Th2 
phenotype that involves the polarization of naive CD4' T-cells into effector cells by the 
induction of endogenous IL-4, that originates fkom naive CD4' T-cells, and acts in an 
autocrine or paracrine fashion. Significant levels of IL-6Ra have been identified on 
unstimulated CD4' T-cells and 100 fold increases in T-cell IL-4 &A levels have been 
demonstrated upon antigen stimulation in the presence of exogenous IL-6 or IL-4. A 
second possible explanation for the apparent ability of IL-6 to enhance 4 week antigen- 
specific s e w  titers was determined using IL-6 knockout mice (Kopf er ai., 1994). These 
authors noted that IL-6 deficient mice showed a 5-10 fold reduction of T-cell dependent 
Ab responses against Vesicular Stomatitis virus (VSV). Transgenic mice overexpressing 
E-6 developed a severe plasmacytosis and accompanying increase in polyclonal serum 
I@, . Although IL-6 production in genajnal centers has been demonstrated, it is  own 
whether the apparent augmentation of plasma blast expansion occurs directly or by the 
hypothesized initial expansion of IL-4 producing T-cells suggested by Rincon e t  al. 
(1 997). Whatever the mechanism, the kinetic differences between humoral modulation 
observed in IL-6 co-injected mice and mice receiving GM-CSF, TM a and IL-4 suggest 
a mechanism that is unique to IL-6. 
Interferon y (1M y ) is produced predominantly by T-cells of the Tho, Th 1 and Tc 1- 
type phenotypes, as well as, activated NK cells (Mosmann and Cofkan, 1987; Scharton 
and Scott, 1993). Secretion of IFN y, in conjunction with IL-2 and Lymphotoxin (LT) is 
felt to typify activated T-ceils of the Thl phenotype. This cytokine is multifunctional and 
has been described to: enhance presentation of antigen by inducing upregulation of MHC 
IlII molecules (Steeg et al., 1982), inhibit immune deviation toward the Th2 phenotype 
(Gajewsla and Fitch, 1988), and selectively enhance the immunoglobulin switch to the 
IgG, isotype (Snapper and Paul, 1987). We had previously demonstrated that im. 
injection of plasmids encoding the secreted form of BHV-1 gD resulted in a splenic 
cytokine profile indistinguishable from that observed in mice immunized with membrane 
anchored or cytosolic version of BHV- 1 gD (section 33.1). However, draining lymph 
node cytokine profiles, at 6 weeks post-immunization, showed elevated recall levels of 
IL-4 relative to the authentic and cytosolic versions of gD as well as serum isotype 
profiles that were predominantly, but not exclusively, IgG, (section3.3.6). Conversely, 
mice immunized with plasmids encoding the authentic, membrane-associated BHV-I gD 
and the cytosolic version of gD displayed serum isotype profiles that were predominantly 
IgG, and appeared to be the result of the development of IgG, specific antibody 
secreting cells within the draining lymph node (sections 3.3.3 and 3 -3.6). Co- 
administration of plasmids encoding IFN y with plasmids encoding a secreted form of 
BKV-1 gD @SLRSV.SgD) enhanced mean serum IgG, levels (Fig. 4.4 and Table 4.5). 
However, this response was inconsistent in individual animals. This inconsistency did not 
appear to be a dose related phenomenon and is, perhaps, not surprising in light of 
evidence that has demonstrated that E N  y receptor hockout mice can still produce some 
IgG, and IgG3 ( H u g  et al., 1993). Certainly recent evidence suggests that 
immunoglobulin class switching is a phenomenon that relies on multiple pathways and 
does not rely, exclusively, on cytokine switch factors such as IFN y or IL-4 (Snapper and 
Mond, 1993; Coffman and von der Weid, 1997; Sangster et al., 1997). This hypothesized 
~ o l o g i c a l  red~~.dancy involvement in isotype switching to IgG,, in the face of an 
antigen that promotes IgG, , may explain why some mice failed to display a predominance 
of serum IgG,. 
Finally, we demonstrated that low doses of plasmids encoding IFNy co-administered 
with plasmids encoding the secreted form of BHV- 1 @, mppressed the magnitude of 
mean senun antibody Levels while high does of plasmids encoding this cytokine 
enhanced p r imw and anamnesic humoral responses (Figs. 4.3 and 4.6). Suppression of 
both T-, and B-cell responses in mice immunized with plasmids encoding rabies virus G 
protein co-inoculated with piasmids encoding murine IF&- y have been described (Xiang 
and Ed, 1995). It may be important to note that these authors used the relatively weak 
SV40 early promoter to drive expression of this cytokine and utilized a single dose of 50 
pg of this plasmid. We noted that, with a stronger expression cassette, 10 pg of 
pSLRSV.IFN y suppressed humoral and draining lymph node cytokine responses (Fig. 
4.6 and Table 4.8 A). In an effon to explain depressed immune responses in their model 
Xiang and Ertl(1995), suggested that the upregulation of MHC antigens on the normally 
quiescent population of myocytes would result in increased susceptibility of antigen 
expressing myocytes to antigen-specific cytolysis thereby limiting the amount of antigen 
available for capture, processing and presentation (Hohlfeld and Enpl, 1994). It is also 
plausible that IFN y mediated reduction in antigen uptake by local dendritic cells, 
regardless of enhanced presentation capacity, may result in premature migration of mature 
dendritic cells to the draining lymph nodes prior to optimal uptake of local antigen 
((Kitajima et aI., 1996). 
There is an increasing awareness that the dose of cytokine(s), and cellular 
microenvironmern in which they occur, can play a significant role in modulating immune 
responses (Kishimoto et. aL, 1994; Hughes and Babiuk, 1992; Finkelman and 
Maliszewski, 1 997; Paul and Seder, 1994). While recognizing that this is the case it mug 
be understood that quantifying the expression level of plasmid encoded cytokines in vivo 
is a significant and challenging undertaking beyond the scope of this thesis. However, in 
an attempt to address this issue many researchers involved in DNA-based vaccine 
research are varying the dose of plasmids encoding cytokines in an effort to better 
understand the roles these cytokines can play in vivo. We have demonstrated that the dose 
of co-administered plasmids encoding either GM-CSF or y with plasmids encoding 
a secreted version of BHV-1 gD, can have vastly different effects on the immunological 
outcome. Whether this is due to different levels of expression directly related to 
increased plasmid concentration or due to other factors, such as the quantity of 
immunostimulatory sequences present in the plasmids, is in need of clarification. We 
have demonstrated that GM-CSF affects humoral and/or immunological responsiveness, 
at 2 weeks post immunization, regardless of the dose co-administered. However, it is 
clearly evident that high doses of plasmids encoding GM-CSF, in the absence of 
boosting, can have a suppressive or deviating effect such that the magnitude of the 
humoral response is significantly reduced. Conversely, priming and boosting with high 
doses of plasmids encoding GM-CSF significantly enhanced antigen-specific titers, and 
substantially increased the levels of serum IgG, . Co-administration of plasmids 
encoding GM-CSF strongly upregulated antigen-specific IL4 secretion in both the 
spleen and the draining lymph nodes of immunized mice. This, in part, may explain the 
observed enhancement of saum immunoglobulins and IgG, titers for low doses of 
plasmids encoding GM-CSF. Plasmids encoding murine IFN y co-administered with 
plasmids encoding a secreted version of BHV- 1 gD also displayed dose dependent 
effects. Mice immunized with a low (10 pg) dose of plasmids encoding IFN y displayed 
either suppression of immunity or a polarization towards a Th 1 -type immune phenotype. 
However, mice immunized with a high dose (50 pg) of this construct developed excellent 
pre-boost titers and displayed a 2-fold increase of serum titers following a boost. We also 
demonstrated that ceadministration of low and high doses of plasmids encoding y 
with plasmids encoding the secreted fom of BHV-I gD elevated serum isotype levels of 
IgG, , although the efficacy of this switch was inconsistent on an individual mouse 
basis. Several other observations were made and included: evidence of plasmid uptake 
competition in vivo, immune deviation towards elevated levels of serum IgG, by co- 
administration of plasmids encoding TNF a, evidence that co-administration of 
plasmids encoding IL4, IL-6 as well as TM a enhance mean serum IgG levels with 
differing kinetics. The failure of plasmids encoding IL-2 and IL- 1 a to elicit 
measurable enhancement of responses to mice co-immunized with plasmids encoding a 
secreted form of BHV-1 gD may simply reflect the single dose assessed or the assays 
utilized to determine modulation . 
5.1 Introduction 
One of the prevalent problems faced in vaccine development is the inability to elicit 
active humoral immunity and reproducible cell-mediated immunity in neonatal animals 
born to immune mothers (Harte et al., 1983; Bona and Bot, 1997). Two primary and 
distinct problems exist which hinder the development of protective immunity in neonates. 
The first problem describes the relative immaturity of the neonatal immune system and 
the inability of these animals to mount an effective immune response to the vaccine doses 
normally given to adult animals (Ridge et al., 1996; Sarzotti et al., 1996). In these 
instances, the relevance of mouse models assessing peripheral immune deficiencies in 
neonates is questionable when evidence demonmates substantial differences between 
species in the degree of peripheral immune precociousness. Furthermore, the mechanism 
for observed transient deficient, or polarized, responses to T-dependent antigens may also 
differ greatly between species (Forsthuber et al., 1 996). For example murine neonates 
display a profound reduction in lymphocyte numbers in peripheral lymphoid organs while 
humans and other mammalian neonates display substantial development of peripheral 
lymphoid organs during the neonatal period (Washington et al., 1994; Kimpton et d., 
1995; Ridge et al., 1996). However, human neonates show little CD40 ligand (CD154) 
expression on peripheral T-cells in the immediate neonatal period (Durandy et al., 1995). 
Interaction of this l i p d  with CD40 receptor on interstitial dendritic cells (IDC), B-cells 
and macrophages elicits a critical cosdmulatory signal to T-cells (Stuber et al., 1996). 
Porcine neonates also show a profound peripheral immunodeficiency for up to four weeks 
postnatally (Meager et al., 1978). In light of the variety of mechanisms potentially 
invoked in transient neonatal immunodeficiencies, as well as the degree of deficiency, it 
seems reasonable to identify a time point at which waning maternal antibodies are still 
protective and postnatal immune potential has begun to equal that observed in adults. 
Regardless, the potential for induction for high zone tolerance, or deviation towards a 
Th2 type immunity, in any given species must be taken into account prior to assessment 
of active immune responses to vaccination. 
The second reason for failure of neonatal animals to respond efficiently to 
vaccination is the well documented, but poorly understood phenomenon where maternal 
antiiody inhibits the development of active immunity (Xiang and Ertl, 1992). Although 
maternal antibody is absolutely cxitical for early protection against many neonatal 
pathogens, it leads to a situation where there is an unavoidable window of susceptibility 
to disease following the decline of maternally derived antibody and the development of 
active humoral responses (MacDonaId, 1992). This window of susceptibility occurs 
because the maternally derived passive antibody titer capable of inhibiting the response to 
vaccination is frequently lower than the titer required for protection. Thus young animais 
must "wait'until suppressive passive antibody titers have declined to the point where 
they are no longer able to interfere in the development of an active humoral response to 
vaccination. Thus the "window of susceptibility to disease" is daennined from the time 
the maternal antibody titers wane to nonprotective levels to the point at which 
endogenously produced antibody titers become protective. This window can often amount 
to several weeks and, despite nomograms designed to calculate the point at which 
maternal titers have decayed, calculations can leave many young animals susceptible for 
days or weeks longer than necessary. Multiple immunizations have been utilized, with 
varying degrees of success, to avoid unnecessarily long periods of disease susceptibility. 
However, this approach may be more acceptable, and easier to implement in humans as 
opposed to many food animal species. To summarize, we have a spectrum of ms i en t  
immunodeficiencies in the immediate neonatal period that appear to prevent or actively 
suppress the induction of cell-mediated immune responses to varying degrees depending 
on the species. To compound matters, maternal antibody provided by immune mothers 
specifically inhibits B-cell mediated immunity and indirectly impedes the expansion of a 
nascent population of primed T-cells. These two problems are interrelated but 
mechanistically distinct. However, a number of proposed features unique to 
immunization with DNA-based vaccines suggests this approach has some potential to 
possibly overcome deficiencies characteristic of neonatal animals. 
Genetic immunization, variously termed as nucleic acid, polynucleotide, somatic 
transgene, or DNA-based vaccination was first described 5 years ago (Tang et al., 1992; 
Domelly et al., 1993; Ertl and Xiang, 1 996; Hassett and Lindsay Whitton, 1996; UZmer et 
al., 1996b; Gerloni et al., 1997). This novel method of immunization involves the in vivo 
introduction of plasmid encoded antigens under the control of eukaryotic regulatory 
elements such that cells at the site, and perhaps distal to the site, of plasmid introduction 
become transfected (WOW et al., 1992; Raz et al., 1994). These transiently transfected 
ceils then express antigen that is either directly or indirectly presented to naive T and B- 
cells of the host animal such that antigen-specific humoral and cell-mediated immunity 
results (Ulmer et al., 1996~). Mice immunized with DNA-based vaccines typically mount 
potent CTL responses, frequently accompanied by Th 1 type immune response and often 
with significant serum IgG titers. The mechanism involved in the development of 
immune responses following plasmid immunization is not completely understood. 
However, it is believed that in sztu transfection of dendritic cells and the accompanying 
adjuvant effects of hypomethylated CpG motifs within the plasmid DNA play a 
si@cant, and perhaps, critical role in the efficient development of immunity to these 
novel vaccines (Pemner et al., 1995; Condon et al., 1996; Pisetsky, 1996a; Canon and 
Raz, I 997; Roman et al., 1997). Early work with intramuscular (i-m ) delivery of DNA- 
based vaccines demonstrated that transfected plasmid DNA displayed the abiliv to persist 
exaachromosomally and that the immune response in animals immunized with these 
vaccines was highly durable, sometimes lasting the lifetime of the aaimal without the 
need for fiuther boosting (Wolff et al., 1992; Davis et al., 1996). Once again the 
underlying mechanism for this apparent phenomenon was not understood. However, 
researchers felt that the observed durability may reflect the apparent persistence of 
plasmid DNA within the transfected cells and likelihood for prolonged expression. This 
seemed a reasonable hypothesis given that antigen persistence has been demonstrated to 
be pivotal in ensuring long lasting durable humoral immunity (Bachman et at., 1996). 
However, recent evidence suggests persistence of expression is determined to a large 
extent by the intrinsic immmogenicity of the plasmid encoded antigen and possibly the 
cell type eansfected in sint (Davis et al., 1997). 
In the present study, we investigated the humoral and T helper responses in 6-8 week 
old C3-N and C57BL/6 mice passively immunized with hyperimmune sera or 
antigen-specific monoclonal antiiodies prior to immunization with a single dose of a 
DNA-based vaccine encoding a truncated version of the bovine herpesvirus- 1 (BHV-1) 
olycoprotein D (Tikoo et al., 1993). This truncated version of BHV-1 gD produces an & 
extracellularly secreted glycoprotein lacking the normal hydrophobic transmembrane 
anchor seen in the authentic viral glycoprotein. In choosing this 6-8 week old mouse 
model we eliminated the compounding problem of muine neonatal immunodeficiency 
and the propensi~ to tolerize or deviate responses towards Th2-type immunity. This 
allowed us the opportunity to study the effects of passive antibody titers on the immune 
responses to DNA vaccination, and to gain some insight on the potential for this vaccine 
approach to overcome matern& antibody suppression. 
5.2 Materials and Methods 
5.2.1 Mice. 
Female 5-6 week old C3H/HeNCrLBR and C57BU6 mice were purchased from 
Charles River (Canada). All mice were acclimated for 1-2 weeks prior to vaccination with 
DNA-based or conventional vaccines, 
5 2 -2 Plasmid Constructs- 
All restriction enzymes and DNA modifying enzymes as well as markers and 
plasmids were purchased from Pharmacia or New England Biolabs unless indicated 
otherwise. Expression cassettes utilizing the immediate early promoterienhaacer regions 
from MCMV (Murine Cytomegalovirus) and RSV-LTR (Rous Sarcoma Virus -Long 
Terminal Repeat) were constructed (see section 3.2.1). These regulatory elements were 
placed in the high copy plasmid pSL30 lTm (Invi~ogen Corp., San Diego, CA) to generate 
the expression plasmids pMCEL3Iu.l and pSLRSV.Nu1. Creation of an expression 
cassette expressing a secreted, or auncated, version of BHV-1 gD was described 
previously (Tikoo et al., 1993). Briefly, vector pRSVl.3gDt, which encodes a truncated 
form of gD, was generated by introduction of a unique XhoI site at the S a d  site 
immediately adjacent to the transmembrane domain of pRSV1.3 encoding the full length, 
or authentic, gene for BHV- 1 gD. Following restriction digestion, and end repair, this 
unique Xhoi site was blunt-end ligated to a short linker sequence encoding the unique 
restriction site Nhe I and three stop codons. Expression of this m c a t e d  gene leads to 
secretion of a glycosylated product approximately 62-kDa (Tikoo et al., 1993). Plasmids 
pSLRSV.AgD (AgD = authentic or full length gD) and pSLRSV.SgD (SgD = secreted or 
truncated gD), were created by ligating the 947-bp NdeI fiaginent from pRSV1.3 and 
ligating it into NdeI digested pMCELAgD and pMCEL.SgD (not shown). The NdeI 
fragment from pRSV1.3 contains the RSV-LTR promoter/ enhancer region and a portion 
of the 5' end of the gD gene. Ligation of a 585-bp NdeI-Bgm fragment from pRSV1.3 
ligated into NdeI-Bgm digested pMCEL.NuL generated plasmid pSLRSV.NuL (Tikoo et 
al., 1990; Tikoo et al., 1993). In vino expression of alI constructs was demonstrated by 
immunoprecipitation of truncated gD from media harvested following stable and 
ms ien t  uansfection of L929 (ATCC No. NCTC clone 929) and COS-7 (ATCC No. 
CRL 1 65 1 ) cell lines (data not shown). 
5.2.3 Passive Tmrmlni7.ation. 
Hyperimmune donor mice (C3WHeN) were prepared by i m  immunization with 
100 pg of pSLRSV.S@. Seropositive mice were then boosted on days 14 and 24 with 
recombinant truncated gD (1.0 pg and 1.5 pgmouse, respectively) emulsified in V S A ~ ~ "  
adjuvant (Biostar, Saskatoon, Saskatchewan, Canada), (VSA3ngD). Sera, from 
hyperimmune donor mice, was harvested 10- 14 days following the final boost. 
All donor mouse hyperimmune blood was collected by cardiac puncture of halothane 
anaesthetized mice. Sera were prepared by brief cenaifugation of pooled blood - - and 
transferred to sterile 15 mL centrifbge tubes (Coming Inc., Coming, N.Y.). Recipient 
mice were physically remained and intraperitoneaiiy (i.p.) injected with an appropriate 
amount of hyperimmune antisera to result in passive antibody serum titers in recipient 
mice of between 10,000 and 20,000 ELISA units. A formula to predict recipient mouse 
serum titers prior to passive trader of hyperimme sera was as follows: x = ah x c, 
where a = vol. hyperimmune sera to be injected i.p., b = estimate of extracellular fluid 
volume (approximately 20% of body weight in grams, or approximately 30% of the 
estimated total body water -60% of body weight) and c = the ELISA titer of pooled donor 
sera. AU recipient mouse titers were verified after 24 hours using a gD-specific ELISA. 
5.2.4 Immunization with Plasmid and Conventional Vaccines. 
Inbred 7 week old, female C3H/HeN mice were injected with plasmid DNA 
purified by anion-exchange column (Qagen Inc., Santa Clarita, CA) and dissolved in 
normal saline. All injections of DNA were im while injections of purified antigen 
(authentic or recombinant truncated gD) formulated in either VSA3 (Biostar Inc.) or alum 
(~lhydrogel~", Cedarlane Laboratories Ltd., Hornby, Ontario) were subcutaneous (s.q.) at 
the dorsal midline of the thorax on each mouse. Mice immunized with DNA were 
physically restrained and injected using a 0.5 mL disposable Microjea syringe with a 29 
gauge needle. All mice received doses of plasmid DNA split between the left and right 
quadriceps muscle mass. Mice were not boosted unless indicated otherwise. Nonlethal 
tail bleeds were carried out every 2 weeks until the experiments were terminated. Mice 
were euthanized by an overdose of Halo thaneTm (MTC Pharmaceuticals, Cambridge, 
Ontario). 
5.2.5 ELISA. 
Immunlon 2 microtitre plates (Dynatech Laboratories Inc., Alexandria, VA) were 
coated with purified recombinant truncated gD ( B i o ~  Inc.) at a concentration of 0.050 
pghvell. Antigen was diluted with ELISA Coating buffer (-012 M N+CO,, .038 M 
NaHCQ, pH 9.6 ) and coating was allowed to proceed overnight at 4°C. Plates were 
washed 5 times in phosphate buffered saline (. 137 M NaCl, .003 M KC1 -008 M 
NaJPO,, .001 M NaH2P0,) with 0.05% Tween-20 (PBST) prior to addition of fourfold 
dilutions of mouse sera prepared in PBST with 0.5% gelatin (PBST-g), (Bio-Rad 
Laboratories Ltd., Mississuaga, Ontario). After a 2 hour incubation, plates were washed 
in PBST and an affinity purified biotinylated goat antimouse Ig (Zymed Laboratories Inc., 
San Francisco, CA) diluted to 1/5,000 in PBST-g was added to each plate. After an 
incubation of 60 minutes, p lam were washed extensively and Streptavi din-alkaline 
phosphatase (Gibco, Life Technologies, Burlington, Ontario) diluted to 1!2000, in PBST- 
g, was added to each plate. Following a 60 minute incubation, plates were washed six 
times in PBST. Prior to addition of the substrate the plates were washed two additional 
times in PBS. Development of plates involved the addition of -01 M pnitrophenyl 
phosphate (Sigma Chemical Co., St. Louis, MO) in substrate buffer (0.104 M 
Diethanolamine-Sigma Chemical Co., 0.5 mM IMgCb ). Absorbances were read on a 
Model 3550 Microplate Reader (Bio-Rad Laboratories Ltd.) at 30 minutes and again at 60 
minutes at 405 nM wirh a reference wavelength of 490 nm-. Antibody isotyping ELISAs 
were carried out in a similar fashion except that biotinylated goat antimurine IgG,, IgG, , 
IgG, , IgG, , IgM (Caltag Laboratories, San Francisco, CA) were used at a dilution of 
1/8,000 except for IgM (1/2,000 ). Incubation times with these antibodies was 60 
minutes. Addition of Streptavidin-alkaline phosphatase and development of plates was as 
decribed for total IgG ELISA. 
5.2.6 Spleen and Lymph Node Cell Harvests. 
Mouse splenocytes were prepared by mechanically grinding spleens through a 
sterile nylon mesh into a sterile Peai dish containing 10-20 rnL of RPMI 1640 (Sigma 
Chemical Co.) This material was then pipetted into sterile 15 or 50 rnL tubes and 
allowed to sit, on ice, for 10 minutes. Debris that settled to the bottom was aspirated 
with a sterile Pasteur pipette and discarded. Tubes were centrifuged at 250 x g, in a 
Beckman GPR centrifuge, for 10 minu~es (at 4 "C). Red blood cells were Lysed by 
resuspension of the cell pellet in 1 -0 mUspleen of ammonium chloride lysis buffer (0.1 4 
M NH,CI and 0.01 7 M Tris-HC1, pH 7.2) for 60 seconds. Lysis was terminated by 
addition of 14 mL. of RPMI 1640 at room temperature. Samples were pelleted by 
centrifugation (250 x g) and resuspended in RPMI 1640. Splenocyte numbers were 
assessed by staining with Trypan blue (Gibco, Life Technologies) and counting on a 
haemocytometer. Splenocytes were centrifbged (250 x g) and resuspended at a final 
concentration of 1 x lo7 cefls/mL in RPMI 1640 supplemented with 10% fetal bovine 
serum (FBS) (Sigma Chemical Co.), 100 U/mL of penicillin, and 100 p g / d  of 
streptomycin (Sigma Chemical Co.), 2 mM L-glutamhe (Gibco, Life Technologies, ) 
ImM sodium pyruvate (Gibco, Life Technologies), 10 mM HEPES (Gibco, Life 
Technologies) and 5 x 1 0-' M 2-mercaptoethanol (Sigma Chemical Co. ), (complete 
RPMI- 1640). A modification of a method for harvest of Peyers patch lymphocytes was 
utilized to prepare single cell suspensions ffom lymph nodes (Spalding, 1983) . Briefly, 
iliac lymph nodes were collected into 15 mL tubes containing sterile chilied PBSA . 
Pooled nodes were decanted into a sterile Petri dish and excess PBSA discarded, Nodes 
were diced with a sterile scalpel in a small volume of CMF solution {O. 1 x Hanks 
Balanced Salt Solution (IIBSS), CaZ' MgZ' free; 10 mM Hepes, pH 7.2; 25 mM NaHCO,, 
pH 7.2; and 2% FBS) and then mixed with 10 mL digestion buffer ( 1 x HBSS, 10% 
FBS, 15 mM HEPES, pH 7.2) containing 150 UniWmL of Collagenase (CLS 1, 
Wonhington Biochemical Corporation), and 0.0 1 5 mg/mL DNase I (Phannacia Biotech 
Inc., Baie d'Urfe, Quebec, Canada ). Diced nodes in digestion buffer were transferred to 
silanized 25 -50 mL Ehrlenmeyer flasks containing a sterile Teflon coated stir bar, and 
incubated at 37 "C with stirring for 90 minutes. Samples were harvested into sterile 15 
rnL plastic tubes and allowed to sit for 10 minutes. Large pieces of undigested material 
were returned to the Erhlenmeyer flask and incubated an additional 30-60 minutes with 
5.0 ml of digestion buffer. This material was combined with the initial harvest and cells 
were centrifuged (250 x g) to pellet. Digestion buffer was decanted and the cells were 
resuspended in PBSA (GIBCO-BRL). Cells were counted using a haemocytometer and 
centrifuged (250 x g) one final h e .  Cells were resuspended to a final concentration of 1 
x 10' cells/mL. 
A modified protocol for splenocytes was also used that included an additonal60 
minute digestion of pooled splenocytes with collagenase (150 Units/mL of digestion 
buffer; Sigma Chemical Co.) and DNase I (0.0 15 mghl of digestion buffer, Pharmacia 
Biotech Inc., Baie d 'U~e ,  Quebec, Canada). These digestions were only carried out in 
experiments that included assessment of antigen-specific responses from cells prepared 
from lymph nodes. These digestions were carried out prior to cell counts and 
resuspension. 
5.2.7 ELISPOT. 
A cytokine specific ELISPOT assay was used as described previously (Czerkinsky 
et ai., 1988; Baca-Estrada et al., 1996). Briefly, single cell suspensions isolated from 
spleens, lymph nodes or bone marrow were stimulated in-vino by incubating in complete 
RPMI 1640 at 37 O C  and 5% C 0 2  for 20 h o w  in the presence of recombinant authentic 
gD (0.4 p*). Afrer antigen stimulation, cells were washed twice in complete RPMI 
1640 and diluted to a concentration of 1 x 10' cells/mL of complete RPMI- 1640. 
Nitrocellulose plates (FILT~pla te~~ ,  0.45 pq Polyfiltronics, Inc., Rockland, MA, USA) 
were prepared by coating overnight at 4 O C  with 2 -5 pg/mL of purified andmurine 
interleukin (IL)-4 (Cat. No. 11B11) or 5 pg/mL of purified andmurine interferon CIFN)-y 
(Cat No. R4-6A2) (Pharmingen, San Diego, CA, USA) diluted in carbonatehicarbonate 
buffer ( 45.3 mM NaHC03, 18.2 &I N ~ ~ c o ~ ,  pH 9.6). After coating, unbound antibody 
was washed from the wells thrice with sterile PBST followed by 3 washes with sterile 
PBS . Wells were blocked for 2 hours at 37 "C with complete RPMI 1640. Blocking 
media was decanted and 100 pL of antigen stimulated cell suspensions were added to 
wells in triplicate. After a 20 hour incubation at 37 "C and 5% C 4 ,  plates were washed 2 
times in tapwater and 5 times in PBST to remove cells and nonspecifically bound 
cytokine. One hundred pL of biotinyiated antimurine IL-4 (Cat. No. BVD6-24G2) and 
IFN-y (Cat. No. XMG1.2) (Pharmingen Canada Inc.) monoclonal antibodies (3 yg/mL of 
each in 1% FBS/PBS) were added to appropriate wells and incubated for 4-6 hours at 
ambient temperature on an oscillating mixer. Plates were washed 6 times in PBST and 
100 pL of a 1/1000 dilution of Streptavidin alkaline phosphatase (Bio/Can Scientific, 
Mississauga, Ontario, Canada) in 1% FBS/PBS was added to each well. After a 2 hour 
incubation, at ambient temperature, the plates were washed as before with 2 final washes 
in PBS. Plates were developed by the addition of 50 pL of the substrates, 5-bromo43- 
indolyl phosphate (BCIP), and nitroblue tetrazotium (NBT), (Moss Inc., Pasadena, MD). 
Plates were allowed to develop at ambient temperature for 10-30 minutes, after which 
reactions were stopped by extensive washing in distilled water. After air drying, spots 
were counted under a dissecting microscope. 
B-cell ELISPOT involved the use of nitrocellulose plates (Millipore ~Milliscreen-HA, 
Millipore, Bedford, MA) that were coated overnight at 4 "C with purified recombinant 
truncated gD at 5.0 &mL in carbonatehicarbonate buffer (pH 9.6). Coated plates were 
washed three times in sterile PBST followed by 3 washes in sterile PBS. Nonspecific 
binding sites were then blocked with complete RPMI 1 640 at 3 7 "C for 1-2 hours. Fresh, 
unstimulated cells from spleen or lymph nodes, prepared as described above, were added 
in a volume of 100 jL (1 x lo7 celWmL) to each well. To account for nonspecific 
binding of IgG uncoated, but blocked, control wells also received cells from each tea 
sample in triplicate. Plates were incubated at 37 "C with 5% CO, for 10- 12 hours. After 
the incubation period, all cells were washed out of the wells by 2 initial tapwater washes 
followed by 6 PBST washes. Biotinylated antimurine IgG, or IgG, antibodies (1/8,000 
dilution) were added in a 1 00 5 volume of PBS T (with 1 % FBS) and incubated with 
mixing for 3-4 hours at ambient temperature. After washing in PBST six times, 
streptavidin-alkaline phosphatase (1/1,000 dilution in PBS-T with 1% FBS) was added to 
each well (100 &). After a 60 minute incubation, plates were washed six times in PBST 
and 2 times in PBS. Plates were developed as described for the cytoldne ELISPOT. 
5 - 2 3  Statistical Analysis. 
Data was entered into a database in the statistical analysis program Instat 
GraphPadTm. Differences in antibody titers among vaccine groups were investigated using 
the nonparametric Mann-Whitney U test. 
5.3 Results 
5.3.1 Enhanced 
In a p r e k n a q  
mice immunized with 
development of humoral immunity following DNA immunisation. 
experiment we established that some passively immune C3-N 
a plasmid encoding a secreted form of BHV-1 gD were capable of 
mounting significant levels of humoral immuniry (Lewis et al., 1 997). We expanded 
this study and also assessed if co-administration of plasmid encoded murine GM CSF 
would enhance humoral responses in passively immune mice following DNA 
immmization. Figure 5 .  l D depicts extremely rapid development of active antibody 
titers in most of the immunized mice, despite (perhaps even because of) the presence of 
pre-existing passive polyclonai antisera at the time of immunization. Four week IgG titers 
clearly show 80% of immunized mice seroconverted with a 90% seroconversion rate at 6 
weeks. 
Co-administration of a 25 pg dose of plasmid encoded murine GM-CSF 
(pSLRSV.GM-CSF') with pSLRSV.SgD in female C3-N mice resulted in some 
enhancement of seroconversion efficiency and magnitude of serum antibody responses 
(Fig. 5.1 C vs E). Only one mouse failed to seroconvert in the pSLRSV.SgD plus 
pSLRSV-GM-CSF vaccine group at 2 weeks post-immunization as compared to three 
nonresponders in mice receiving pSLRSV.SgD ocly (Fig. 5.  l E and C, respectively). 
Serum antibody levels were also significantly greater @s 0.05) in the pSLRSV.SgD plus 
pSLRSV.GM-CSF vaccine group as compared to the pSLRSV.SgD group at 4 weeks. A 
2 fold augmentation of splenic IFN y and a 7 fold increase in IL-4 secretion levels 
following immunization with pSLRSV-SgD plus pSLRSV.GM-CSF was also evident 
Fig. 5.2). This data is consistent with earlier experiments which assessed a dose range of 
plasmid encoded GM-CSF on immune responses in mice foilowing co-admini stration 
with an optimized dose of pSLRSV.SgD (unpublished data). Interestingly, co- 
administration of this dose of plasmid encoded GM-CSF with pSLRSV.SgD did not 
enhance seroconversion efficiency or the magnitude of serum IgG levels in passively 
immune mice (Fig 5.1 F). Indeed, inclusion of pSLRSV.GM-CSF appeared to delay the 
onset of active humoral responses and diminished the seroconversion efficiency relative 
to mice immunized with pSLRSV.SgD alone. The suppressive effect of co-administered 
pSLRSV.GM-CSF, in the context of pre-existing passive anti-gD serum titers, is 
consistent with cytokine ELISPOT data presented in Figure 5.2. While the splenic 
cytokine profile was predominantly IL-4, in the presence or absence of passive titers, the 
magnitude of both IL-4 and IFN y in mice receiving pSLRSV.SgD/pSLRSV.GM-CSF 
Fig. 5.1 Effect of passive immunity on induction of active responses by DNA 
immunization. C3WHeN mice immunized with pSLRSV.SgD in the face of passively 
administered hyperimmune sera develop active humoral responses within 2 weeks of 
intramuscular immunization. Hyperimmune sera for passive nansfer to recipient mice (B, 
D, F and G) was prepared as described in Materials and Methods. Hyperimmune serum 
was injected into the intraperitoneal cavity on Day -2. Recipient serum IgG titers were 
read by ELISA on Day - 1. Vaccines VSAYrtgD (A, B), pSLRSV.SgD (C and D) and 
pSLRSV.SgD plus pSLRSV.GM-CSF (E and F) were administered at Day 0 
intramuscularly or subcutaneously (VSA3rtgD). Doses of vaccines were: 200 ng ngD (A 
and B), 50 pg/quadriceps muscle pSLRSV.SgD (C,D& and F) and 12.5 pg/quadriceps 
pSLRSV.GM-CSF (E and F) mixed and co-administered with the pSLKRSV.SgD. All 
experimental groups contained 10 mice except for groups receiving VSA3rtgD (five 
mice/group). Graph G represents geometric mean and standard emor of the mean for I0 
mice receiving hyperimmune sera and no vaccination. Data is represented for individual 
animals. ELISA values are depicted as absorbances (405 nm) at a 1/200 serum dilution. 
Individual mice from vaccine + passive antibody groups were considered seropositive if 
the optical density (O.D. ,& scored a minimum of one standard deviation or better 
above the corresponding value in Graph G. 
Time (Weeks) 
Fig. 5.2 Splenic cytokine profile in passively immune mice immunized with a DNA- 
based vaccine. Splenic cytokine profiles in mice immunized with pSLRSV.SgD is 
similar regardless of the presence of passively administered hyperimmune sera. The mean 
number of cytokine-secreting cells following in vitro restimulation of splenocytes with 
authentic, full-length, gD is depicted. Splenocytes fiom mice illustrated in Fig. 5.1 
including: controls (Hyperimmune serum only) or DNA immunized mice, were harvested 
9 weeks after a single intramuscular immunization. Data groups are depicted as: Decay 
(Control groups receiving hyperimmune serum only), DNA @SLRSV.SgD), DNA + Ab 
(Hyperimmune sera followed by pSLRSV.SgD), DNA + GM-CSF 
@SLRSV.SgD/pSLRSV.GM-CSF) and DNA + GM-CSF + Ab (Hyperimmune sera 
followed by pSLRSV.SgD/pSLRSV.GM-CSF). Mean values for each group were 
determined fiom triplicate wells of pooled splenocytes fiom seropositve, or control, mice. 
Decay DNA DNA DNA DNA 
+ + 
was approximately 4 fold greater than mice immunized with these constructs in the face 
of pre-existing serum titers. Mice immunized once with a suboptirnai dose of the 
conventional vaccine formulation VSA3/rtgD showed little difference in seroconversion 
efficiency or serum IgG levels in the presence or absence of pre-existing titers (Fig. 5.1 A 
and B). 
5.3.2 Effect of U b  on the development of active humoral immunity following 
DNA immunization. 
Since antr'body isotype may influences the development of immune responses 
groups of mice were passively immunized with hyperimmune antisera or anti@ 
monoclonal antibodies of different (IgG, or IgG,) isotypes. The most saiking data 
obtained was clear and significant @r 0.05) evidence that the isotype of the passive 
antibody has a direct impact on the induction of active humoral immunity following 
immunization with a DNA-based vaccine (Fig. 5.3 and 5.4). Figures 5.3 E and G 
illustrate that the pretreatment of C3WHeN mice with MAb PB 136 (IgG,) suppresses the 
efficacy of active humoral immunity while pretreatment with MAb 1G6 (TgGd 
augmented the magnitude and seroconversion efficacy of humoral immunity (Fig. 5.3 F). 
Two weeks after DNA immunization serum IgG ELISA data show that 6 of 8 mice 
developed active titers when the pre-existing passively administered anti-@ antibody 
was a monoclonal of the IgG, isotype (1G6) (Fig. 5.3 F). Conversely, only 1 of 8 mice 
immunized with pSLRSV.SgD in the face of pre-existing titers of PB 136 (IgG,) 
seroconverted during the same time period (Fig. 5.3 E). A mixture of 3 IgG, MAbs 
Fig. 5.3 Effect of monoclonal antibodies on active humoral immunity after DNA 
immunization. Development of active humoral responses, following immunization of 
female C3WHeN mice with pSLRSV.SgD, is affected by the isoytpe of pre-exisitng 
passive titers of monoclonal antibodies. Hyperimmune sera was injected intraperitoneally 
on Day -2 at Low (Ab,,) or High (Ab,) doses. Monoclonal antibodies PB136, 3D9, 2C8 
(IgG,) and lG6 (IgG,) were diluted into normal saline prior to intraperitoneal injection 
on Day -2. Mice were immunized intramuscularly with pSLRSVSgD at 50 pg/quadricep 
once on Day 0. Vaccination with DNA was carried out in the absence of passive titers (B) 
or in the presence of Low (C) or High @) doses of hyperimmune sera. Mice were also 
immunized with pSLRSV.SgD in the presence of passive titers of the Mabs: PB 136 (E), 
lG6 (F) or a combination of PB 136,3D9 and 2C8 (G). Control groups (A) represent 
geometric means and standard deviations for mice receiving High or Low doses of 
hyperimmune sera or MAbs representing IgG, (PB 136) or IgG, (1 G6) isotypes. Data are 
represented as absorbances at 405 nrn for individual mice (except in Control groups), at 
serum dilutions of 1/400. Individual mice from vaccine + passive antibody groups were 
considered seropositive if the optical density (O.D. , & scored a minimum of one 
standard deviation or better above the corresponding value in Graph A. 
Time (Weeks) 
Fig. 5.4 Active humoral immunity develops in passively immune mice following 
immunization with a conventional vaccine. Graphs A (VSA3/rtgD), B (VSA3hgD + 
Ah,) and C (VSA3/rtgD + Ab,) depict conventional vaccine controls for the experiment 
described in Fig. 5. A single dose of 1.0 pdmouse, in VSA3, was administered 
subcutaneously to all mice at Day 0. Data is represented as absorbances at 405 nm for 
individual mice read at serum dilutions of 1/400. Groups depicted in B and C include 
data from each of 8 mice, while the VSAMtgD group (A) included only 5 animals. 
0 2 4 6 8 10 
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shown to recognize different epitopes on BHV-1 gD, showed only 2 of 8 mice 
seroconverring during the fim 8 weeks of the experimental period with only one 
maintaining measurable active titers at 10 weeks (Fig. 5.3 G). 
Immunization of mice with pSLRSV.SgD in the presence of pre-existing High (Fig. 
5.3 D) and Low (Fig. 5.3 C) polyclonal antibody titers showed similarities in 
seroconversion efficacy and magnitude of serum antibody response. The results observed 
with mice immunized in the face of passive polyclonal hyperimmune sera were similar to 
those observed in a separate experiment depicted in Figure 5.1 D. Mean titers for both 
High and Low passive antibody titer groups were statistically @ s 0.05) lower than mean 
titers observed for mice immunized in the face of pre-existing passive anniody titers of 
MAb 1 G6 (isorype IgG,). Seroconversion efficacy appeared similar between Mab 1 G6 
(IgG,), Low dose polyclonal and High dose polyclonal antibody at 4,6 and 8 weeks post- 
immunization. 
Figure 5.4 summarizes data for mice immunized with VSA3/ngD (1 -0 pglmouse) in 
the absence (Fig. 5.4 A) and presence of high (Fig. 5.4 C) and low (Fig. 5.4 B) doses of 
pre-exisring titers of poly clonal antisera. While this relatively high conventional vaccine 
dose is still suboptimal (in the absence of boosting) (Baca-Estrada et al., 1996), there is 
a suggestion that some enhancement of immune response occurred within the high dose 
hyperimmune antibody group and is indicated by a 50% seroconversion rate depicted in 
Figure 5.4 C (VSA3rtgD + A h )  as compared to Figure 5.4 B WSA3htgD +.Ah,,). 
5 -3.3 Mixed Th 1 !Th2 immunity following DNA immmization of passively 
immune C57BU6 mice. 
C3WHeN and C57BU6 mice immunized with pSLRSV.SgD show a 
predominance of IgG, in sera (see section 3.0). However, C3WHeN mice respond 
inconsistently to truncated gD formulated in VSA3 (see sections 3.3.2 and 4.3.1 ). 
Tmrnune responses to VSA3:gD have been described in Cj7BU6 mice (E5aca-Emada et 
al., 1996). To ensure that a proper conventional vaccine control model was utilized we 
decided to assess the issue of passive antibody impact on the induced immune response in 
C57BL/6 mice. In this experiment we utilized a suboptimal dose of 0.1 ug/mouse of 
uuncated gD formulated with the adjuvant VSA3. This dose has been demonstrated to 
elicit poor Bcell responses, even following a boost, but could prime splenic and lymph 
node T-cell responses following subcutaneous immunization. To our surprise this dose 
of VSA3/ngD, in the face of pre-existing levels of passively administered hyperimmune 
sera resulted in 4 of 8 immunized animals developing moderate to high s e m  antibody 
levels (Fig. 5.5 E). This data strongly suggests that that the hyperimmune serum utilized 
to passively immunize 6-7 week old C5 7BY6 mice enhanced, rather than suppressed, the 
development of humoral immunity to the conventional vaccine. Figure 5.6 A 
demonstrates that splenic recall IIN y and IL-4 responses did not differ greatly in the 
presence and absence of pre-existing passive titers of hyperimmune anti-gD antibodies. 
Figure 5.6 B represents cytokine profiles in the iliac nodes and shows significant levels of 
recall IL4 with little of no E N  y in the pool samples from mice immunized with 
VSAYrtgD in the presence of passive hyperimmune antisera. This was somewhat 
Fig. 5.5 Impact of mouse strain on the development of active immunity in passively 
immune mice following DNA immunization. Development of humoral immune 
responses in the face of passive titers of hyperimmune sera appears to be enhanced 
following immunization with pSLRSV.SgD or a conventional vaccine. C57BU6 mice 
were immunized with pSLRSV.SgD (50 puquadricep) (B + C) or VSA3htgD (1 00 
ng/mouse) (D + E) in the presence or absence of passive titers of gD antisera. A single 
dose of hyperimmune antisera was administered to mice (A,C and E) by intraperitoneal 
injection on Day -2. Recipient mouse serum titers were measured by ELISA on Day - 1. 
Vaccines were administered on Day 0, with no subsequent boosts. Senun samples were 
collected at 2 ,4  and 6 weeks post immunization and total serum IgG levels were 
determined by ELISA. Data are depicted for 8 or 10 individual mice within each group 
and represented by absorbances (405 nm) at senun dilutions of 11160. Individual mice 
From vaccine + passive antibody groups were considered seropositive if the optical 
density (O.D. ,,A scored a minimum of one standard deviation or better above the 
corresponding value in Graph A. 
Time (Weeks) Time (Weeks) 
Fig. 5.6 Effect of passive immunity on cytokine and antibody secretion profiles 
following DNA immunization. Splenic and iliac lymph node cytokine and antibody 
isotype profiles are similar regardless of the passive titer status at the time of 
immunization with pSLRSV.SgD. Pooled cells were prepared fiom spleens and 
retroperitoneal iliac lymph nodes harvested at 7 weeks post immunization h-om 
seropositive CSTBU6 mice. Figures A (Spleen) and B (Iliac node) depict IL-4 and IFN y 
secreting celldl O6 cells following 20 hours restirnulation, in v i m ,  with authentic full 
length gD. Cytokine and B-cell isotype ELISPOT (C) results are expressed as the mean of 
triplicate wells fiom pooled cells from 10 (Control passive hyperirnunne-Decay-group), 9 
(pSLRSV.SgD), 7 (pSLRSV.SgD + Ab), 5 (VSA3htgD) and 4 (VSA3rtgD + Ab) mice 
from each group. 
- 
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surprising because the iliac lymph node does not drain the subcutaneous immunization 
site utilized for the VSA3rtgD vaccine as indicated by the relative absence of IL-4 or EX 
y secretion from lymph node cell pool collected from untreated mice immunized with 
VSrUlrtgD (Fig. 5.6 B). This i n f o d o n  suggests that pre-existing passively 
admininered antiserum was responsible for a fundamental difference in antigen 
disaibution following immunization. However, it is &own why T-cell responses 
would have o c m e d  within this nondraining lymph node compartment and not Bcell 
responses (Fig. 5.6 C). 
Not surprisingly, C57BU6 mice immunized one time with 100 pg pSLRSV.SgD, in 
the presence or absence of passive serum titers to BHV-I gD, generated humoral 
immune response of greater magnitude and consistency than mice immunized with the 
suboptimal dose of VSA3rtgD (Fig. 5.5 B and C). Splenic cytoldne profiles were 
consistent with previous experiments in that recall levels of IFN y exceeded those of IL- 
4 (Figure 5.6 A). Draining lymph node cytokine profiles showed a ratio of IFNy:IL-4 
that approached 1 : 1 and was distinct from the splenic cytokine profile in this regard. This 
diminished level of IFN y relative to iliac node IL-4 levels, was likely responsible, in 
large part, for the predominance in serum IgG, in mice immunized with plasmid encoding 
the truncated version of BHV-1 gD (Figure 5.7). 
Fi,me 5.7 summarizes the serum antibody isotype in seropositive mice following 
imrunization with pSLRSV.SgD in the absence and presence of passively administered 
antisera. This figure illustrates that the mouse strain had a greater impact on serum IgG 
isotype profile than pre-existing passive titers (C57BU6 mice in Groups 8 and 9) 
Fig. 5.7 Influence of mouse strain on serum isotype profiles. Serum isotype ELISA 
profiles are affected by mouse strain and not the presence of passive titers of polyclonal 
or monoclonal antisera. Pooled seropositive sera from mice depicted separate 
experiments depicted in Figures 5.3 (Groups 1 and 2), 5.5 (Groups 3-7) and 5.7 (Groups 8 
and 9) were assessed for serum IgG isotype by isoytping ELISA. Groups 1 and 2 
represent female C3WHeN mice immunized with pSLRSV.SgD and pSLRSV.SgD + 
Passive hyperimmune sera, repsectively. Groups 3-7 represent data from female 
C3WHeN mice immunized with pSLRSV.SgD, pSLRSV.SgD + Low dose hyperimmune 
sera, pSLRSV.SgD + High dose hyperimmune sera, pSLRSV.SgD + Mab PB 136 (IgG,), 
and pSLRSV.SgD + Mab 1G6 (IgG,), respectively. Groups 8 and 9 represent serum 
ELISA isotype data From female C57BL/6 mice immunized with pSLRSV.SgD and 
pSLRSV.SgD + hyperimmune sera. Ail serum samples were collected from mice at 6 
weeks postimmunization. Data is represented by absorbances (405 nrn) ar a serum 
dilutions of 1/ 160. 
n n n n  
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However, serum IgG, consistently predominated in all vaccine groups with some 
suggestion that IgG, levels were elevated in mice treated with high doses of 
hyperimmune sera or MAb 1 G6 (IgG,). 
5.4 Discussion 
In this study we evaluated the ability of pSLRSV.SgD, a DNA-based vaccine 
encoding a secreted version of BHV-1 gD, to elicit active immunity in passively immune 
C3H/HeN or C57BU6 mice. Potent active humoral immunity was evident within 2-4 
weeks of immunization regardless of the passive immune status of injected mice. Indeed, 
in this particularly model, there was clear evidence that the presence of passive 
antibodies appeared to augment the development of the active immune response to 
pSLRSVSgD, as well as, a subunit vaccine formulation. 
At least two recent articles describe use of DNA-based vaccines to circumvent 
maternal antibody suppression (Monteil et al., 1996; Hassett et al., 1997). Monteil et. al. 
(1 996) utilized day old piglets f?om immune and nonirnmune dams and demonstrated that 
following i n  injection with 400 ug of plasmid encoding pseudorabies virus glycoprotein 
D, piglets from immune dams did not develop serum antibodies or demonstrate any 
evidence of priming. Furthennore piglets from nonimmune dams developed moderate 
serum antibody titers only following a boost at 6 weeks postparnun 
Hassett et. al. (1997) immunized murine neonates &om immune and nonimmune 
dams i.m with 50 jtg of plasmids encoding the nucleoprotein (NP) from LCMV 
(Zymphochoriomeningitis virus). These authors showed that, following sublethal 
challenge, approximately 50% of neonates from immune and nonimmuue dams 
developed MHC-restricted, Np-specific CTLs more rapidly than unprimed animals. 
Funher, approximately 95% of these immune neonates showed reductions in splenic 
viral titers following challenge. These authors argued that maternal antibodies did not 
interfere with the development of CTL responses possibly due to the fact that L C W - h i  
is an intracellular protein that would not come into direct contact with serum antibody. 
These authors did not determine if humoral immunity was induced in this model because 
LCMV-specific CTL have been demonstrated to be adequate and sufficient to confer 
protection against viral challenge. These studies are compelling because they 
demonstrated that companmentalization of the antigen may serve to circumvent some of 
the problems associated with maternal antibody suppression of immunity. However, this 
approach would be restricted to pathogens that can be reliably and completely - - cleared 
with CTL responses only (Zinkemagel, 1996). Unforhmately these authors did not 
include a conventional vaccine control, such as modified live LCMV or NP formulated 
with adjuvants such as ISCOMs or Liposornes known to facilitate potent C'IZ responses 
(Cox and Coulter, 1997). In Light of the suboptimal efficacy described for mice following 
immunization with plasmid encoded LCMV-NP this comparison is critical before any 
claims of efficacy of DNA-based vaccines can be made. Several other publications 
describe the impact of DNA-based vaccines on neonatal immune responses (Bot et al., 
1996; Mor et al., 1996; Wang et al., 1997). While two of these publications describe the 
successful development of T-cell responses in neonatal mice neither addressed the 
influence of maternal antibody on the development of active humoral i m m ~ ~ @  or rhe 
mechanism whereby passive antibody suppresses active B-cell responses to antigen. 
The mechanism for in vivo B-cell failure to respond to Ag in the presence of 
antigen-specific maternal or passive antibody in neonates is unknown. However, recent 
evidence suggests that simultaneous signalling through the B-cell receptor (BCR) and the 
Fcy RIIBl receptor on naive B-cells results in a negative signal delivered to the potential 
antigen-specific B-cells that prevents not only secretion of antigen-specific IgM but also 
inhibits the maturation of these B-cells into IgG secreting plasma cells and presumably 
inhibits the development of a memory B-cell population (Phillips and Parker, 1983). 
Several recent articles demonstrate that co-ligation of these two receptors on naive/pre B- 
cells results in phosphorylation of Tyrosine'Og of the 13 a.a. immunoreceptor tyrosine- 
based inhibition motif VIM) found within the cytoplasmic domain of receptor 
Fcy RIIB 1 (Mum et al., 1994; Ravetch, 1997). This phosphorylation event initiates an 
inhibitory cascade that commences with recruitment of one of several candidate 
phosphatases (SHIP andlor PTPl C) that modulate inhiiition of cellular calcium influx or 
mobilization of inmcellular calcium stores required for BCR mediated signalling 
@'Ambrosia et al., 1995; 0x10 et al., 1996). B-cells in mice express only the low affinity 
Fcy RIIB 1. Interestingly, Fc y RTIB 1 receptor knockout mice show 
hyperimmunoglobulinemia in response to both T-cell dependent and T-cell independent 
antigens (Takai et al., 1996). Thus, it appears that Bcell FcyRIIBl coiigation with BCR 
may mediate a feedback inhiiition which prevents excessive expansion of B-cell 
responses to a given antigen as long as senun IgG antibody levels remain high (Tew et 
d., 1997). 
Ow initial premise was that expression of plasmid encoded antigen from in vivo 
transfected ceiis would persist beyond the point where senun antibodies, in passively 
immune mice, waned to noninhi'bitory levels. In addition , DNA-based vaccines may 
induce the development of active humoral responses prior to waning passive titers and 
increase the Likelihood of eliciting potent celi-mediated immunity. Recent evidence 
suggests that the efficacy of DNA-based vaccines may stem From the proximity of 
antigen presenting ceik (bearing injected plasmid sequences encoding antigen) and/or 
antigen expression to naive T and B-cell populations (Steinman et al., 1997; Tew et al., 
1997). This proximity is suggested by several recent articles implying that local and 
possibly lymph node resident dendritic cells may be of pivotal importance in the effcient 
development of ensuing immune responses (Pemer et al., 1995; Condon et al., 1996; 
Manickan et al., 1997; Roman et al., 1997). If this is indeed the case, then trafficking to 
draining lymph nodes would allow direct presenration of antigen to naive T and B-cells 
without sigmficant exposure to pre-existing antibody. 
The rapid development of active humoral immunity described by our data suggests 
that longevity of antigen expression following DNA immunization is not an issue in this 
model. Figures 5.1 D, 5.3 C and D, and 5.5 C clearly demonstrate that C3WHeN mice 
immunized with plasmid pSLRSV.SgD develop active humoral immunity regardless of 
the presence of high or low doses of passive hyperimmune sera. There are a number 
possible explanations for this occurrence other than the discussed advantages of in vivo 
transfected dendritic cells and proximity to naive T and B-cells within the draining 
lymphoid tissues. For example, it has been demonstrated that passive titers of IgM do not 
suppress the development of active B-cell responses, indeed, this isotype has been 
demonstrated to enhance the developing humoral immune responses relative to vaccine 
controls (Henry and leme, 1 968). A more comprehensive, albeit evolving, understanding 
of the inhibitory signalling occuning in B-cells allows one to hypothesize that 1gM:Ag 
complexes prevent inhibitory B-cell signalling by interfering with the ability to co-ligate 
FcyRIIBl and BCR receptors. It has been demonstrated that syngeneic idiotype 
presentation in the context of IgM is highly immunogenic while presentation of the same 
idiotype in the context of Ig isotypes, IgG,, IgG, and IgG, leads to antigen-specific 
tolerance (Reitan and Hannestad, 1995). Indeed it appears likely that complement fixation 
by the polymeric IgM is directly involved in the ensuing humoral response (Heyman ex 
al., 1988). Indeed mutation of serinea within the third constant domain of IgM ablates 
the complement fixation capacity and corresponds to a significant reduction in the ability 
of IgMAg complexes to facilitate thymus-dependent humoral immune responses 
(Shulman et al., 1986; Heyman et al., 1988). The specific mechanism by which IgM 
drives the development of T-dependent B-cell responses appears to involve direction of 
the Ag:IgM:C3d (iC3d) complexes to CD21 receptors on FDC and B-cells (up to the 
centrocyte stage) for subsequent presentation to primed CD4' T-cells. CD21 and C3 
hockout mice, as well as a complement deficient breed of dogs, have been demonstrated 
to be defective in the ability to mount normal humoral immune responses to infection or 
vaccination with T-dependent antigens (O'Neil et al., 1988; Carroll and Fischer, 1997). 
Furthermore, pretreatment of mice with MAbs directed against CR2 or a soluble 
CR2:IgGl chimeric molecule resuln in suppression of antibody responses to a T- 
dependent antigen (Hebell et al., 199 1). Indeed it has been demonstrated recently that 
C3d polymer fusions to hen egg white lysozyme enhanced serum antibody responses by 
1 00 to 1 0000 fold (Dempsey et al., 1 996). Thus it appears that substantial evidence exists 
that describes a fundamental role of complement component C3 in the induction of T- 
dependent B-cell responses. 
Despite the evidence for the potential roles of IgM and complement in 
circumvention of passive antibody mediated B-cell suppression we feel that conmbution 
of passive IgM to the development of active humoral immunity is minimal. For example, 
although there were low titers of IgM in donor sera utilized in these experiments, a 3-5 
hour serum halflife for this isotype would effectively ensure only minute amounts of 
antigen-specific passive IgM would be present at the time of immunization (Vieira and 
Rajewsky, 1988). However, Figure 5.3 F suggests that antibody isotype IgG, may 
provide some potential for facilitating circumvention of suppressive pre-existing passive 
titers. Certainly there is evidence suggesting that IgG, possesses a much greater capacity 
to fix complement than IgG, (Klaus et ai., 1979; Ishizaka et al., 1995). However, there 
is in vivo data, based on an idiotype switch variant model, which demonstrates that IgG,, 
IgG,, and IgG,, failed to enhance the immunogenicity of the presented idiotype (Reitan 
and Hamestad, 1995). This work suggests it may not be the complement fixation capacity 
of IgG, that is responsible for the augmented humoral immunity observed in Figure 5.3 
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It has also been suggested that affinity differences in passive antibodies may have a 
significant impact on the immune outcome following immunization (Keller et al., 1991). 
While a plausible mechanism for how differences in passive antibody affinity can 
determine outcome to immunization is udmown, it has been documented that high 
affinity monoclonal antibodies tend to suppress the development of humoral immunity 
while lower affinity monoclonals have little or no effect (Keller et ai., 199 1). However, it 
should also be noted that this information was acquired using only monoclonal antibodies 
of the IgG, isotype and showed at least one high affinity monoclonal that failed to 
suppress the development of humoral immunity. Affinity differences between IgG! and 
IgG, antibodies described in Figures 5.3 E,F and G may also play a role in modulating 
the immune response. 
Ultimately the apparent inability of low affinity MAb to suppress B-cell responses 
may involve a natural antibody or BCR facilitated displacement of antigen bound, low 
affinity MAb. This displacement would effectively eliminate the Fcy RIIB 1 -BCR 
coiigation signal necessary for inhibitory B-cell activation. Regardless, the polyclonality 
of matemally derived antibodies, in the context of maternal immunization regimes of 
pathogen exposure, make affinity contribution to inhibition or enhancement of responses 
to neonatal vaccination difficult to explain. A more plausible explanation, although 
relatively unexplored, involves desmied Fc affinity differences for the high affinity 
Fcy RI (CD 64) receptor present on blood borne professional antigen presenting cells 
(Tew et al., 1997). Fc receptor distribution is well documented, and there is some 
evidence that targeting to the high affinity receptors on nonphagocytic (maturing) 
dendritic-like cells by monomeric Ab:Ag complexes can circumvent the "normal" B-cell 
downregulation upon exposure to Ag:Ab complexes (Ravetch and Kinet, 199 1; Van de 
Winkel and Capei, 1993; Fanger et al., 1996; Ravetch, 1997; Tew et al., 1997). There is 
also evidence suggesting that the affinity of FcyRI for IgG, and IgG, is much greater 
than for IgG, or IgG, (Van de Winkel and Capel 1993). These affinity differences might 
explain the ability of - W b  1G6 (IgG,) to enhance humoral immunity while l a b s  
PB 136, 3D9 and 2C, (IgG,) do not. 
We also investigated whether co-administration of a plasmid encoding murine GM- 
CSF with pSLPSLRSV-LTKSgD would augment humoral responses in the face of pre- 
existing dters of passive polyclonal antibody. Somewhat surprisingly, inclusion of 
plasmid GM-CSF appeared to inhibit, rather than enhance, the humoral immune response 
(Fig. 5.1 F) since GM-CSF has been demonstrated to perpetuate antigen uptake and 
processing capacity of epidermal Langerhans cells (Heufler et al., 1987; Momssey et al., 
1987; Sallusto and Lanzavecchia, 1994). This capacity has been suggested to play a direct 
role in the observed augmentation of seroconversion efficacy and both cell-mediated and 
humoral immunity in mice immunized with plasmid encoded antigen and co-administered 
GM-CSF (Xiang and Ed, 1995; Conry et ai., 1996a; Geissler et al., 1997; Kim et al., 
1997; Lewis et al., 1997). We previously demonstrated that piasmid encoded GM-CSF 
augments seroconversion efficacy and the magnitude of serum antibody levels 
significantly when co-administered with suboptimal. and to a lesser extent, optimal doses 
of pSLRSV.SgD (see sections 4.3.2 and 4.3.4). The failure of GM-CSF to augment B- 
cell immunity in this case suggests that maintenance of peripheral dendritic cell antigen 
uptake and processing capacity does not play a significant role in the ability of these 
animals to mount potent, rapid B-cell immunity despite the presence of passive titers. 
Other issues to consider when using DNA-based vaccines in neonates include: 
separation of intrinsic adjuvanticity of the plasmid DNA from immunological 
recognition of B-cell epitopes, naivete of the neonatal immune system and safety. 
Considerable evidence has arisen recently regarding the potential contribution of 
hypomethylated CpG motifs, adjacent sequences and distant poly G sequences in the 
recognition, uptake and adjuvanticity of bacterially derived DNA (Pisetsky, 1996a). 
Although the mechanism for recognition of immunostimulatory sequences (ISS's) has not 
been determined, it bas been shown that absence or presence of these ISS's can result in 
reduction or enbancement of immune responses, respectively (Sato et al., 1996; Roman et 
al., 1997). It has also been demonstrated recently that these ISS's are responsible for 
induction of cytoldnes (EN a, P, IL-12,I.L-18) responsible for d i r e c ~ g  the ensuing 
immune response towards a Thl type of response (Roman et al., 1997). There is currently 
Linle evidence regarding the longevity of the innate responses to ISS's , however, we have 
observed substantial elevations in IL-4 and EN y in draining lymph nodes, bone marrow 
and spleen 7 days following injection of a Null plasmid (unpublished data). Regardless, 
the adjuvant effects of hypomethylated plasmid DNA may have waned at the time that 
antigen-specific BCR on naive B-cells are able to "see" plasmid encoded antigen in the 
absence of coligation of FcyRIIBl. This problem is potentially compounded in species 
where the neonatal immunological naivete requires low doses of vaccine to avoid 
inducing a tolerance or profound immune deviation . It is possible that this problem of 
temporal separation of adjwancy &om antigen recognition by B-cells can be eliminated 
by co-administering plasmid encoded immunodeviating cytokines such as IL- 1 8 or IL- 12, 
however, considerable work must be done before advocating use of plasmid encoded 
cytokines in neonates. It may be possible that ballistic delivery may provide an 
mechanism whereby the issue of segregation of plasmid adjuvancy effects from 
productive B-cell recognition of antigen is avoided. However, the method of DNA 
vaccine delivery must be considered in the context of specific pathogens and the 
character of the n o d  protective immune response (Mosmann and Sad, 1996; 
Zinkernagel, 1996). We must not ignore the benefits of Th 1 -like T-cell responses and 
CTL activity and characteristic ability of DNA vaccines to elicit either or both of these 
types of immunity. It has been demonstrated that potent CTL responses against measles 
virus haemagglutinin and fusion proteins can occur despite a profound suppression of B- 
cell responses by preexisting passive titers (Gallem et al., 1995) . Ultimately, T-cell 
responses may provide an avenue of effective irnrnunization that is more achievable than 
the elicitation of B-cell responses in the face of suppressive maternal titers. These 
responses would, at the very least, decrease the time of disease susceptibility by 
providing a primed population of helper T-cells at the time of boosting. 
There are a variety of experimental approaches that may increase the immune 
responses in the presence of passive antibody titers to an even greater levels than 
described in this article. Many of these involve the creation of molecular chimeras 
comprised of antigen and moieties that either prevent signalling through the B-cell 
Fc y RIIB l or provide additional positive signalling that could, hypothetically, override 
negative signals delivered through co-ligation of the BCR and Fcy RIIB 1 receptors. 
Prevention of signalling through co-ligation of BCR and FcyRIIB1 is best described by 
fusions of complement fixing antiiodies such as IgM or IgG, in mice or direct fusion of 
complement component C3d or iC3b to the antigen in question (Dempsey et al., 1996). 
Although the specific receptor for IgM has not been identified it has been demonmed 
that engagement of this antibody by antigen can enhance humoral responses in the face of 
passive titers of IgG (Reitan and Hannesrad, 1995). We, of course, have demonmated in 
this article the potential for the complement fixing IgG, to circumvent the suppressive 
effects of passive I,@, however, the specific mechanism remains unknown. Induction of a 
positive signal that may override negative signalhg might also be accomplished by the 
creation of a molecular fusion of CD40 ligand (CD154) to antigen or inclusion of this 
sequence within the same plasmid encoding the antigen. CD40 engagement has been 
demonstrated to be the critical, necessary and sufficient cestirnulatory signal to drive 
naive B-cells to secrete IgM and initiate maturation towards isotype switched plasma 
cells or memory B-cells (Gray et al., 1994; Han et al., 1995). 
In summary, our data suggests that mice immunized once with a plasmid encoding 
a secreted fonn of BHV-I gD were able to mount both humoral and cell-mediated 
immune responses in the face of pre-existing passive antibodies. How ever, the apparent 
enhancement of humoral responses, following immunization with a suboptimal dose of a 
conventional vaccine, suggests that a factor (or factors) within the passive sera 
administered to recipient mice may be responsible for the observed humoral immunity in 
this model. It is also possible that the strain of mouse, adjuvant VSA3 and/or dose of 
recombinant truncated gD can play pivotal roles in the enhanced seroconversion 
described for C57BW6 mice. Despite this problem these data provide diretion for firmre 
experimentation addressing the potential of DNA-based vaccines in the presence of 
passive antibody. 
When I began this project, no single publication describing immune responses to 
DNA-based vaccines existed in scientifx literature. There were several published 
accounts describing uptake and expression of naked plasmid DNA encoding reporter 
oenes, by myocytes following i m  injection into muscle tissue (Wolff et al., 1990; Wolff a 
et al., 199 1 ). There was also some exciting preliminary data, initiated at VIDO, that 
demonstrated the potential for delivery of plasmid encoded antigens to elicit significant 
levels of immunity in mice and cattle. Since the commencement of this project, well over 
400 hundred scientitic articles have been published, in refereed journals, describing 
aspects of this most recent immunological phenomenon. 
In this thesis I extended the initial work by Dr. Graham Cox, who demonstrated that 
immunization of mice and cattle with plasmids encoding bovine herpesvirus (BEN> 1 
giycoproteins B, C and D resulted in significant levels of humoral immunity and 
indications that cell-mediated immunity was also elicited (Cox et al., 1993). I also 
assessed the ability of plasmids encoding eight different muxine cytokines (IL- 1 a, IL-2, 
IL-4, Ed, IL-10, GM-CSF, m y  , TNFa) to augment or modulate immune responses to 
c*administered plasmids encoding a secreted f o m  of BHV-1 gD. In addition, immune 
responses were characterized in passively immune mice following immunization with 
plasmids encoding a secreted form of BW-1. 
The fim objective of this thesis was to create several efficient expression plasmids 
encoding membrane anchored, secreted or cytosolic versions of BHV-I @, and establish 
that these constructs generated proteins that occurred in the appropriate cell 
compartments. The 111 length cDNA for BHV- 1 gD (membrane anchored) had 
previously been cloned, sequenced and placed in an expression cassette (Tikoo et al., 
1990). A secreted version of gD had also been described previously (Tikoo et al., 1993). 
A cytosolic version of BHV-1 gD was generated by deleting the signal peptide from the 
cDNA encoding the secreted version of gD, and ail three cDNAs were subcloned with 
gene regulatory elements, into a high copy number plasmid backbone. This allowed 
maximal yield, following amplification in DH-5 a bacterial hosts, and eliminated 
concerns o w  plasmid batch differences within single experiments. Following transient 
transfection of COS-7 cells with each the plasmids we established that each version of g D  
occurred primarily within the cell compamnent for which the cDNAs had been designed 
(Fig. 3.3). 
Creation of membrane anchored, cytosolic and secreted forms of the same protein 
allowed the investigation of immune responses to plasmid encoded antigens and allowed 
assessment of how the cell compament in which antigens occurred could affect the 
subsequent immune character following i.m immunization. Female C3WHeN mice all 
developed substantial levels of serum antibodies and splenic qtokine profiles showing a 
prevalence of EN y (Fig. 3.4,3.5,3 -6 an 3.10). Although EN y plays a significant role in 
the isotype switch to IgG, only mice immunized with cell-associated versions of gD 
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(cytosolic and membrane anchored) displayed a predominance of serum IgG, (Figs. 3.7, 
3.8,3.9). Mice immunized with plasmids encoding the secreted form of gD displayed a 
predominance of serum IgG, which appeared to be a result of the influence of higher 
levels of IL-4 production in the draining lymph node of immune mice (Figs. 3.7, 3.8,3.9 
and 3.13). Thus it appeared that the cell compartment in which the antigen primarily 
occurred was able to modulate both humoral and cellmediated immune responses. 
In an effort to extend studies on immune modulation, plasmids encoding the 
secreted version of gD were co-administered with plasmids encoding a variety of murine 
cytokines previously shown to augment or deviate immune responses. Conventional 
molecular techniques were utilized to subclone cDNAs for IL-2 and GM-CSF into the 
same plasmid driving expression of the secreted version of gD (Material and Methods, 
4.2.4). RT-PCR, in conjunction with site specific mutagenesis, of the total RNA or 
mRNA preparations from a variety of cell sources was utilized to generate IL- 1 a , IL-4, 
L-6, L-10, IFNy and T M a ,  cDNAs which were subcloned into the same piasmid 
utilized to express the secreted versio~ of gD (Materials and Methods, 4.2.4). Following 
restriction analysis, partial dideoxy sequencing and functional bioassay confirmation of 
cytokine identity, a preliminary experiment was carried out using a suboptimal dose of 
plasmids encoding the secreted version of BHV- 1 g .  co-administered with an equal dose 
of each of the plasmids encoding the cytokines (Fig. 4.3). Data from this experiment 
demonstrated that co-administration of plasmids encoding GM-CSF enhanced mean 
serum titers and the seroconversion efficacy of immunized mice (Table 4.4). Plasmids 
encoding murine TNF a, IL-4 and IL-6 also enhanced the magnitude of senm IgG 
levels but with unique kinetics (Fig. 4.3 and Table 4.4). Co-administration of plasmids 
encoding EN y and TNF a increased the levels of serum IgG, in some, but not all, 
immunized mice Fig. 4.4 and Table 4.5). In a follow-up experiment an optimal, fixed, 
dose of plasmid expressing BHV-1 SgD was co-adrmnistered with a two different doses 
of plasmids encoding GM-CSF or IM y (Fig. 4.6). Moderate doses of GM-CSF 
reproducibty enhanced early mean titers. High doses of GM-CSF resulted in a 
suppression of humoral responses, however, boosting with high doses of this cytokine 
resulted in an extremely potent memory response resulting in very high s e w  titers and a 
surprising increase in the levels of serum IgG, (Fig. 4.7 and Table 4.7). Assessment of 
cytokine secretion, within draining lymph nodes and the spleen, showed that co- 
administration of plasmids encoding GM-CSF induced significant increases in IL-4 
secretion after boosting (Tables 4.8 A and B). Co-administration of plasmids encoding 
IFN y resulted in the reduction of antibody responses, at moderate doses, that persisted 
regardless of boosting (Fig. 4.6). Conversely, mice immunized with high doses of this 
cytokine showed enhanced mean serum antibody levels and benefited from boosting (Fig. 
4.6). Mice immunized with both moderate and high doses of plasmids encoding IFN y 
displayed elevations in mean serum IgG, (Fig. 4.7 and Table 4.7). 
The final objective of this thesis was to investigate the potential for DNA vaccines to 
overcome suppression of active humoral immunity (specifically B-cell mediated 
immunity) caused by preexisting passive titers of antigen-specific antibody (Muta et ai., 
1994). Certain unique features of DNA-based vaccines such as longevity of expression 
(Wolff et al., 1992) and the ability to transfed peripheral, and possibly secondary 
lymphoid resident, antigen presenting cells (Raz et al., 1994; Condon et al., 1996) 
suggested that this vaccination approach may be more effective than conventional 
methods of immunization. Immunization of 7-8 week old female C3WHeN or C57BU6 
mice, in the face of varying levels of passive titers of anti-@ antibodies resulted in 
seroconversion of mice within 2-4 weeks of immunization (Figs. 5.1 D, 5.3 C and D, and 
5.5 C). Subsequent experiments employing monoclonal antibodies of the IgG, or IgG, 
isotype suggested that the rapid and profound development of active antibody titers in the 
presence of pre-existing high titers of passive polyclonai antisera may have occurred 
because of IgG, levels within the polyclond antisera (Fig. 5.3 E,F and G). Literature 
indirectly supports this observation with evidence that passive titers of IgM can enhance 
the development of active antibody responses and that complement fixation is a necessary 
feature of this humoral immunity (Henryandleme, 1968; Heyman et al., 1988; 
ReitmandHannestad, 1995). 
The data provided in this thesis, and uncovered during the course of these studies, 
has provided important information on the impact of antigen form, co-administered 
plasmid encoded cytokines, and passive antibodies on the immune responses following 
immunization with plasmids encoding various forms of BHV-1 gD. Data provided and 
presented during the course of this work has, as often occurs with scientific 
investigations, raised many more questions and laid the groundwork for future 
investigations. Ongoing, and future directions, for studies include: 
(i) Obviously, the importance of plasmid based vaccines in mouse models is significant 
as an early indicator of the potential for success and information regarding the immune 
character, however, the full utility of this vaccine technology can only be realized by 
testing in the appropriate target species. For example, serum antibody levels are poor in 
cattle following i.m delivery to the gluteal muscle mass, however, i-d. delivery to the 
skin of the ear greatly enhances this response (Cox et al., 1993; van Drunen Littel-van 
den Hurk et al., 1998). Furthermore, as observed in the mouse, the cellular compartment 
in the which the antigen occurs can have a profound impact on the immunological 
outcome following immunization of cattle. 
(ii) Although the data presented in this thesis discusses immune responses following im 
immunization with DNA-based vaccines, literature and studies carried out by Drs. Ralph 
Braun and Sylvia van Drunen Littel-van den Hurk have demonstrated the advantages of 
i.d. delivery of plasmids encoding antigens by injection and ballistic protocols @ram et 
al., 1997; van Drunen Littel-van den Hurk et al., 1998). These data have led many 
scientists to investigate the mechanisms of immunity to DNA vaccines and the specific, 
and critical, cell types involved in presentation of plasmid encoded antigens to naive T- 
and B-cells within secondary lymphoid tissues . Preliminary evidence regarding the 
conm%ution of myocytes tmnsfected with plasmids encoding antigens following im. 
immunization is controversial. While the question of direct involvement in immune 
priming by transfected myocytes has been resolved, questions revolving around the 
contribution of these antigen depots to the post prime development and maintenance of 
immune responses is very much at issue (Ulmer et al., 1996c; Feltquate et al., 1997). It 
has been inferred in this thesis that injection site transfection of cells is of critical 
immunological importance and that direct transfection of cells within draining lymph 
nodes immediately following introduction of DNA occurs ineffectively and contributes 
lirtle to immunity (Figs. 3.1.1,3.1.2 and 3.1.3). Scientists continue to address the question 
of immune mechanism following delivery of DNA-based vaccines by each of the several 
methods available to introduce naked DNA vaccines into animals. 
(iii) Preliminary work presented in this thesis contributed, in part, to the establishment of 
research projects at VIDO that address the mechanism by which GM-CSF and IL-4 
augment immune responses to co-delivered antigen. The impact of these two cytokines, 
delivered i.d. in a sheep model, on the afferent lymphatic cell population character and 
dynamics, as well as, draining lymph node histological architecture and 
immunocytochemical profile are currently being assessed. Similarly, some initial work 
uncovered during the course of my studies, suggested the possibility that a surprising 
level of intrinsic adjuvanticity was associated with Null plasmids utilized in this thesis 
(data not presented in this thesis). The subsequent appearance of articles in refereed 
journals describing immune stirnulatory sequences comprised of hypomethylated CpG 
motifs within bacterially derive deoxyribonucleic acids, laid the groundwork for ongoing 
studies, at VIDO, of these sequences in a sheep model (Krieg et al., 1995: Pisetsky, 
1996a; Klinman et al., 1997; Roman et al., 1997). 
(iv) Data presented in this thesis suggested that extracellular forms of antigens enhanced 
the early kinetics and magnitude of humoral immunity to BHV-1 gD (Table 3.2). 
Subsequent srudies in cattle supponed this work to some extent and indicated that cattle 
responded more efficiently to plasmids encoding a secreted form of BHV-I gD following 
id. immunization (van h e n  Littel-van den Hurk et al., 1998). This information was 
utilized to set the direction for the development of a DNA-based vaccine encoding a 
protective antigen (VP7) from the bovine rotavirus. VP7 normally encodes a protein with 
an endoplasmic localizing signal sequence that prevents secretion of this protein until it 
has associated with several other components (VP4 and VP6) of the viral capsid (Shaw et 
al., 1996). Creation of plasma membrane anchored and secreted forms of VP7, by Dr. S. 
Swadhat, have resulted in enhanced expression of these proteins as demonstrated by h 
vizro transfection of COS 7 cells. Despite the absence of detectable immune responses to 
these novel constructs, experience with gD, cytokine augmentation of immunity, and 
literature, have allowed the identification a variety of logical approaches to solve the 
problem of antigenicity from this unique viral protein. 
(v) It is well documented that young animals from immune mothers are protected, in 
part, from infectious diseases by the passive transfer of maternal antibodies through 
colostrum and the placenta (species dependent)(MacDonald, 1992; Xiang and Ertl, 1992). 
We felt that some unique features of DNA-based vaccines justified a preliminary 
investigation into the potential to circumvent the suppressive effects of passively acquired 
antibodies on development of active immunity following imrmmization. Extension of 
data presented in this thesis is currently being assessed in mouse models and target 
species. Fume direction should include: assessment of immunity following 
immunization at different times following acquisition of passive titers, studies regarding 
the potential for chimeric antigens to avoid co-ligation of Bcell receptors and FcyRIIB 1 
receptors (IgM:Ag chimen) or redirection of antigen towards non B-cell Fc receptors, 
such as the high affinity FcyRI receptor on dendritic cells (antLCD64 Fab:Ag fusions). It 
may also be practical to ignore attempts to elicit B-cell responses in the face of passive 
titers and to focus on cell-mediated immunity in these young animals. Certainly, DNA- 
based vaccines possess a unique capacity to drive potent CD4+ and CD8+ T-cell 
responses following immunization of animals. 
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